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SUMMARY 
 
Disturbance of neuronal metabolism has implications for a 
number of neurological and psychiatric conditions, and enhanced 
knowledge of this is important in developing new methods for treating 
such disorders. The present research was undertaken to aid 
understanding of diseases related to disturbance in glutamate and    
γ-amino butyric acid (GABA) metabolism.  
 Two different types of neuronal cell cultures were used in these 
studies; one containing GABAergic neurons of cerebral neocortical 
origin and one containing cerebellar neurons. The latter consists 
primarily of glutamatergic granule neurons in addition to ~6 % 
GABAergic neurons and a small number of astrocytes. Metabolism was 
studied by 13C magnetic resonance spectroscopy (MRS) and mass 
spectrometry (MS) after adding 13C-labeled precursors                  
([1-13C]glucose, [U-13C]glutamate or [U-13C]glutamine) to the 
medium of these cultures. High performance liquid chromatography 
(HPLC) was used to quantify different amino acids in cell extracts and 
medium. The amount of protein in the cultures was determined to 
assess cell damage. 
 In the cerebellar neuronal cultures, GABA was present in 
surprisingly large amounts compared to neocortical GABAergic 
cultures. 13C MRS experiments showed that GABA was actively 
synthesized throughout the culture period by the subpopulation of 
glutamate decarboxylase (GAD) positive (GABAergic) neurons and 
subsequently distributed to the other cells in the culture, i.e. to the 
granule neurons. The function of GABA in these glutamatergic neurons 
still remains uncertain; however, roles as neurotrophic and 
neuroprotective agent as well as substrate for energy production have 
been suggested. 
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As shown previously, both glutamate and glutamine were 
shown to be excellent precursors for intermediary metabolism in 
cerebellar neurons. However, it was concluded that glutamate was 
preferred over glutamine, suggesting that these neurons rely more on 
reuptake of released glutamate than of supply of glutamine from 
astrocytes for glutamate homeostasis. This is not surprising when 
considering the cerebellar structure, with few astrocytes compared to 
neurons and a relatively large distance between astrocyte and 
synapse.   
Exposure of cerebellar cultures to 50 μM kainic acid (KA), a 
potent glutamate agonist, which is known to eliminate vesicular 
release of GABA in these cultures, only marginally affected glutamate 
and GABA metabolism, whereas increasing the KA concentration to 
0.5 mM led to a reduction of both GABA and glutamate metabolism 
compared to unexposed cultures. It was previously believed that 
treatment with 50 μM KA eliminated the GABAergic neurons in 
cerebellar cultures, and KA has therefore been added in order to 
obtain essentially pure glutamatergic granule cell cultures. Although 
KA treatment abolishes vesicular GABA release, the GABA 
synthesizing cells are not eliminated by this treatment and still 
produce GABA in substantial amounts.  
Results from the present studies can only be understood in 
terms of inter- and intracellular compartmentation of metabolism. The 
main focus of metabolic compartmentation studies has been on the 
two compartments made up by neurons and astrocytes. One pathway 
previously believed to take place in the astrocytic but not in the 
neuronal compartment, is the pyruvate recycling pathway for 
complete tricarboxylic acid (TCA) cycle oxidation of glutamate. 
Despite this, in one of the present studies, such recycling was clearly 
present in both astrocytic and neuronal cultures from cerebellum. 
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1 INTRODUCTION 
 
1.1 Medical Aspects of Neuronal Metabolism 
 
Normal energy metabolism in the brain has several unusual 
features compared to other organs, and disturbance of this 
metabolism is considered important in many brain disorders (Balázs et 
al., 2006). One of the features of normal brain function is the high 
metabolic rate; in fact, the brain is one of the most metabolically 
active organs in mammals, illustrated by the fact that despite 
constituting modest 2 % of the total body mass, the brain accounts 
for an astounding 20 % of the resting body’s oxygen consumption 
(McKenna et al., 2006a). This oxygen is almost exclusively used for 
oxidation of glucose (Sokoloff, 1960), the main energy source of the 
brain. Under extraordinary conditions, like prolonged starvation, the 
mature brain can adapt to using ketone bodies produced in the liver 
from fat to cover some of the energy needs (Stryer, 1995b). 
Nevertheless, the brain is not very flexible when it comes to energy 
substrates compared to other organs and is critically dependent on 
aerobic metabolism of glucose (Dugan and Kim-Han, 2006; 
McKenna et al., 2006a). Another feature is the limited intrinsic 
energy stores of the brain. Although some glycogen can be stored, 
mainly in astrocytes (Pfeiffer-Guglielmi et al., 2003; McKenna et al., 
2006a), the brain has no significant energy reserve. It has been 
estimated that if glycogen was the only source of fuel, it would be 
consumed in a few minutes (McKenna et al., 2006a). Thus, the brain 
is dependent on a constant supply of glucose and oxygen via the 
blood.  
The dependence of a constant blood supply carrying glucose 
and oxygen makes the brain particularly vulnerable to ischemic injury 
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(Dugan and Kim-Han, 2006). This is most often seen as a disruption 
of blood supply to a part of the brain caused by a thromboembolic 
occlusion of an intracranial artery, commonly known as a stroke 
(Smith, 2004). This is the most common neurological disorder in 
terms of both morbidity and mortality (De Girolami et al., 1999). 
When the blood flow, and thereby the energy supply, to the brain is 
impaired, ATP levels decreases, which in turn affects the active ion 
pumps, such as the Na+/K+ ATPase. The ion gradients over the cell 
membrane, and thus the membrane potential will be disrupted, and 
the neurons are depolarized (Smith, 2004; Balázs et al., 2006; Dugan 
and Kim-Han, 2006). This causes a cascade of events ultimately 
leading to cell death. With the reduction of cerebral blood flow in 
ischemia, the extracellular glutamate concentration is substantially 
elevated (Smith, 2004). This leads to excessive activation of 
excitatory amino acid receptors, in particular glutamate receptors, 
causing cell death, a mechanism referred to as excitotoxicity (Olney, 
1978).  
A role for excitotoxicity has been implicated in the etiology of 
many neurodegenerative diseases, including Alzheimer’s disease, 
Parkinson’s disease and amyotrophic lateral sclerosis (ALS) (Mattson, 
2003; Balázs et al., 2006). Excessive or prolonged activation of 
specific glutamate receptors results in a rise in intracellular Ca2+ 
concentration, triggering a cascade of intracellular events culminating 
in neurodegeneration. Different types of neurons have different 
vulnerability to excitotoxicity, depending on their receptors, Ca2+ 
permeability and ability to handle an increase in intracellular Ca2+ 
(Balázs et al., 2006). The glutamatergic N-methyl-D-aspartate 
(NMDA) receptors are the primary receptors activating excitotoxicity 
because of their high permeability to Ca2+, although other glutamate 
receptors can initiate excitotoxicity by allowing excessive Ca2+ entry. 
Studies have shown that cytoplasmic Ca2+ is insufficient to cause 
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neuronal death in itself, and that mitochondrial Ca2+ accumulation is 
essential for excitotoxic cell death (Stout et al., 1998; Nicholls et al., 
2003). Ca2+ causes mitochondria to generate reactive oxygen species, 
and this oxidative damage can initiate cell death. Diseases such as 
Alzheimer’s disease, Parkinson’s disease and ALS are accompanied by 
increased oxidative stress, and in these patients, neurons are more 
susceptible to excitotoxic death (Balázs et al., 2006). Thus, 
excitotoxicity contributes to oxidative stress, which in turn reduces 
the threshold for excitotoxicity, leaving cells more vulnerable to 
injury. This is one of the reasons why excitotoxicity contributes to 
many neurodegenerative diseases. Knowledge of regulation of 
glutamate receptors in Alzheimer’s disease, Parkinson’s disease and 
ALS have resulted in clinically efficacious drugs and new therapeutic 
medications are continually being developed (Mattson, 2003).  
Another common neurological disorder is epilepsy, 
characterized by recurrent, spontaneously occurring seizures with 
symptoms caused by abnormal excessive or hypersynchronous 
neuronal activity in the brain (Blume et al., 2001; Fisher et al., 2005). 
The epileptic seizure is a pathophysiological process characterized by 
a synchronous activation of a large group of neurons in the brain. This 
may be caused by a disturbance in the fine-tuned balance between 
excitatory glutamatergic and inhibitory GABAergic neurotransmission, 
a theory supported by the fact that inhibition of γ-amino butyric acid 
(GABA) synthesis and administration of GABA antagonists and 
glutamate agonists induce seizures (Bradford, 1995; Hosford, 1995). 
Studies of glutamate and GABA contents in epileptogenic brain tissue 
have shown contradictory results. An increased level of glutamate 
compared to GABA in superfusates and microdialysates from 
hyperactive focal tissue was presented by Bradford, (1995), whereas 
Aasly et al. (1999) showed an increased GABA concentration in brain 
tissue from epilepsy surgery. This indicates that a high concentration 
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of GABA in tissue not necessarily provides protection against seizures. 
Activation of glutamate receptors is essential for seizure activity and 
mediates excitotoxic neuronal damage and death (Balázs et al., 
2006). Antiepileptic drugs such as phenobarbital, phenytoin and 
carbamazepine work by suppressing excitability by different 
mechanisms.  
Glutamate and glutamate receptors also appear to have a role 
in several non-degenerative neurological and psychiatric disorders. 
One example is schizophrenia, a psychiatric disorder characterized 
by psychosis, impaired perception or expression of reality (positive 
symptoms) and by significant social dysfunction (negative symptoms) 
(Morrison and Murray, 2005). For decades, theories and treatment of 
schizophrenia have focused on dopaminergic neurons. However, in 
recent years it has been suggested that glutamatergic neuro-
transmission is also involved in the pathophysiology of this disease 
(Carlsson et al., 2001; Carlsson et al., 2004; Balázs et al., 2006; 
Kondziella et al., 2006). Numerous in vivo and ex vivo studies have 
shown disturbances of glutamate signaling in schizophrenia patients 
(for review, see de Bartolomeis et al., 2005). This supports the 
glutamate hypofunction theory, which focuses on the NMDA receptors. 
Pharmacological inhibition of these receptors leads to a state with 
positive and negative symptoms resembling those of schizophrenia 
(Rujescu et al., 2006). Levels of glutamine have been shown to be 
altered in patients experiencing their first episode of schizophrenia 
(Theberge et al., 2002), whereas in postmortem brain biopsies of 
schizophrenic patients, a reduction of glutamine synthetase (GS), the 
enzyme catalyzing the formation of glutamine from glutamate, was 
reported (Burbaeva et al., 2003). The recent advances in knowledge 
on glutamate involvement in schizophrenia pathophysiology pave the 
way for new pharmacological strategies in treating schizophrenia (de 
Bartolomeis et al., 2005; Balázs et al., 2006).        
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In order to understand the pathophysiological mechanisms, a 
premise for the development of pharmacological treatment of these 
diseases, basic research on neuronal metabolism is of importance. 
 
 
1.2 The Cells of the Brain 
 
The functional unit responsible for transmitting and processing 
information in the nervous system is the neuron (De Girolami et al., 
1999; Augustine, 2004). These are cells anatomically and functionally 
specialized for transmission of electrical and chemical signals. 
However, in the cerebrum the neurons are greatly outnumbered by 
the other main cell type of the brain, the glia (Nedergaard et al., 
2003). During phylogenetic development, the glia to neuron ratio has 
increased at the same time as the cerebrum and especially the 
cerebral cortex has expanded in size (Karlen and Krubitzer, 2006). 
The human brain has the largest neocortical surface relative to brain 
size and the highest glia to neuron ratio of all land mammals, which 
can suggest that glial cells play important roles in higher cognitive 
functions (Nedergaard et al., 2003). In contrast to the cerebrum, the 
cerebellum is one of the most evolutionary primitive brain regions. In 
the cerebellum, the neurons greatly outnumber the glial cells 
(Andersen et al., 1992). This is because of the numerous 
glutamatergic granule cells, in fact this single cell type is by far the 
most numerous neuronal cell type in the brain. It has been calculated 
that the human cerebellum consists of approximately 105 x 109 
granule cells (Andersen et al., 1992), whereas the number of neurons 
in the neocortex is approximately 20 x 109 (Pakkenberg and 
Gundersen, 1997; Gredal et al., 2000).     
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1.2.1 Neurons and Neurotransmission (Augustine, 2004) 
The intracellular signal of the neuron is an electric impulse 
caused by ion movement across the cell membrane. This action 
potential propagates from its point of initiation at the cell body and 
runs down the axon to the nerve ending, where the neuron forms 
synapses with other cells, either neurons or effector cells (muscle- or 
glandular cells). In the nerve ending the electrical signal is 
transformed to a chemical signal consisting of neurotransmitters, 
which lead the signal to the next cell.  
Chemical transmission between neurons involves synthesis, 
storage, release, receptor binding, and inactivation (including 
uptake or reuptake) of the transmitter substance. The 
neurotransmitter is first formed and stored in vesicles where it is 
protected from enzymatic degradation. When the neuronal cell 
membrane is depolarized by an action potential, the vesicles release 
the transmitter to the synaptic cleft. The transmitter molecules diffuse 
passively in the synaptic cleft between the two cells and bind to 
receptors typically on the postsynaptic cell. Receptor binding leads to 
a change in the cell membrane’s permeability to one or more ions, 
and the membrane potential of the postsynaptic cell can temporarily 
be changed. An excitatory impulse will cause membrane 
depolarization and decrease the membrane potential, whereas an 
inhibitory impulse will lead to membrane hyperpolarization and 
increase the membrane potential. The direction of the change in 
membrane potential is determined by the neurotransmitter and the 
receptor it binds to. Since most neurons are innervated by thousands 
of synapses, the postsynaptic effects of each active synapse can be 
added together in space and time, and determine whether the 
postsynaptic neuron will generate a new action potential or not. 
Excitatory impulses are mainly transferred through the 
neurotransmitter glutamate. Binding of glutamate to receptors on 
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the postsynaptic neuron brings it closer to the threshold for triggering 
of an action potential. Inhibitory impulses are mainly caused by the 
neurotransmitter GABA. Under influence of GABA, the postsynaptic 
neuron will be brought further away from the action potential 
threshold, and thus GABA works against the formation of an action 
potential. 
There are two main types of receptors, ionotropic, ligand-
gated ion channels, and metabotropic receptors. On the ionotropic 
receptors, the binding site is located on the ion channel itself, and 
these receptors therefore transfer fast postsynaptic signals. The 
metabotropic receptors have an indirect connection between binding 
site and ion channel through second messengers. These receptors 
have a modulating effect by increasing or decreasing the probability 
for an action potential to be triggered by the sum of postsynaptic 
signals. In addition to receptors on the postsynaptic neuron, there are 
autoreceptors responding to the neurotransmitter released from the 
neuron itself and modulating release or synthesis.  
After receptor binding the transmitter is inactivated, either 
actively (through enzymatic degradation (e.g. acetylcholine), reuptake 
into the presynaptic neuron or uptake in glia) or passively (by 
diffusion).  
Chemical neurotransmission thus involves five steps; 
synthesis, storage, release, receptor binding and inactivation, each a 
potential target for pharmacological modulation. 
 
1.2.2 Glia 
 Historically, glial cells were considered a type of passive 
connective tissue, which provided structural support to the neurons, 
which were considered to be the only true functional cells of the brain. 
Today, glial cells are recognized as partners to neurons in virtually 
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every function of the brain, and as participants in the pathophysiology 
of the dysfunctional or diseased brain (Nedergaard et al., 2003).  
There are three main types of glial cells in the brain; 
microglia, oligodendrocytes and astrocytes (the last two are 
sometimes referred to as macroglia). Microglia are derived from 
macrophages and serve a phagocytic function in the brain. 
Oligodendrocytes produce myelin in the central nervous system 
(CNS). Myelin consists of multiple layers of oligodendrocyte 
membranes wrapped concentrically around one or more axons, acting 
like insulation allowing the action potentials to be conducted at high 
speed. The astrocytes’ main task is regulation of the chemical 
environment of the brain. These glial cells have endfeet surrounding 
the blood vessels in the brain. The astrocytes interact with the 
vasculature to form a gliovascular network, which has been subject 
for intense research activity the past decade (Nedergaard et al., 
2003). It has been suggested that astrocytes influence the integrity of 
the blood-brain barrier consisting of the endothelial cells connected 
with tight junctions (Ransom et al., 2003). This barrier keeps many 
substances from entering the brain, and is one of the ways the brain 
is protected against potentially harmful substances. Astrocytes also 
envelop synapses in the CNS, preventing neuroactive transmitters 
from moving freely in the brain, and play an important role in 
inactivation of these and other substances through efficient uptake 
and conversion into other substances. These glial cells also play a 
significant role in supplying neurons with a number of metabolites and 
precursors for amino acid neurotransmitters. This is described in the 
following section.  
 
1.2.3 Neuronal-Glial Interaction and Compartmentation 
 In this thesis, metabolism is studied in vitro in cell cultures 
consisting of mainly one cell type (Hertz et al., 1985). By analyzing 
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the metabolites in different cell types separately, useful information 
can be provided. However, it is important to acknowledge that the in 
vivo situation is different from in vitro. Brain tissue is a metabolically 
heterogeneous system including two distinct compartments consisting 
of neurons and glia (van den Berg et al., 1969; Berl and Clarke, 1983; 
McKenna et al., 2006a). There is an extensive exchange of 
metabolites between the two cell types, and this is essential for 
normal brain function.  
 A component of the compartmentation is that astrocytes 
contain a different set of enzymes than neurons. They can 
therefore supply neurons with substrates the neurons themselves are 
unable to synthesize. Pyruvate carboxylase (PC) is for example 
present only in glia (Yu et al., 1983; Shank et al., 1985), and this 
enables these cells to convert pyruvate to oxaloacetate (OAA), which 
is part of the tricarboxylic acid (TCA) cycle. Neurons are depending on 
a flux of precursors for TCA cycle intermediates from astrocytes. 
Without this the TCA cycle in neurons would be drained of carbon 
atoms because neurons have no net synthesis of TCA intermediates, 
and by releasing the neurotransmitters glutamate and GABA carbon 
atoms derived from the cycle are lost.  
Another astrocyte specific enzyme is glutamine synthetase 
(GS), and thus glutamine is only produced in astrocytes (Norenberg 
and Martinez-Hernandez, 1979), but is exported to a great extent to 
neurons, where it is an important precursor for amino acids, such as 
glutamate and GABA (Schousboe et al., 1977; Sonnewald et al., 
1993; Schousboe, 2003; McKenna et al., 2006a). This constitutes the 
basis for the “glutamate-glutamine-GABA cycle” (Berl and Clarke, 
1969; van den Berg and Garfinkel, 1971; Benjamin and Quastel, 
1975; Berl and Clarke, 1983; for review see Bak et al., 2006), which 
is discussed later, and in detail in paper 3.    
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1.3 Transport and Metabolism of Glucose, Glutamate and GABA 
 
1.3.1 Glucose 
 As mentioned, the brain is one of the most metabolically active 
organs in mammals, and glucose is the brain’s main energy source 
(McKenna et al., 2006a). Delivery of glucose from the blood to the 
brain requires transport across the blood-brain barrier. This is 
facilitated by glucose transporter proteins (GLUTs). Three of these 
proteins have been established as cell specific transporters in 
mammalian brain (Vannucci et al., 1997). Firstly, two isoforms of 
GLUT1, the 55 kDa and 45 kDa isoforms, which are primarily detected 
in endothelial cells of the blood-brain barrier and in astrocytes, 
respectively (Maher et al., 1994; Maher, 1995). Secondly, GLUT3, 
which is a neuronal glucose transporter and lastly GLUT5, which is 
exclusively expressed in microglia of the human and rat brain (Payne 
et al., 1997). 
 Inside the cells, glucose (C6H12O6) is eventually converted to 
carbon dioxide (CO2) and water (H2O) in three phases, this oxidation 
generates energy in the form of ATP (Stryer, 1995c; McKenna et al., 
2006a). In glycolysis, occurring in the cytoplasm of the cell, glucose 
is divided into two C3-fragments in the form of pyruvate. The latter 
can be converted to lactate, alanine or acetyl coenzyme A (acetyl 
CoA), which can be processed in the TCA cycle. This cycle takes place 
in mitochondria, and produces reducing equivalents for oxidative 
phosphorylation. In addition to energy production, the TCA cycle also 
supplies carbon skeletons for the synthesis of metabolites such as 
glutamate and GABA. The last phase of metabolism, the one 
generating the most ATP, occurs in the inner membrane of the 
mitochondria and is called the electron transport chain. In this 
aerobic catabolism of one glucose molecule in the brain a total of 36 
molecules of ATP are produced (Stryer, 1995c). 
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1.3.2 Glutamate 
Glutamate is an excitatory amino acid mediating fast 
excitatory synapse responses in the CNS (Storm-Mathisen et al., 
1983; Fonnum, 1984). It is widespread in all of the CNS and the brain 
contains large amounts, about 5-15 mmol per kg wet weight, 
depending on the region (Schousboe, 1981). In addition to being the 
most important excitatory neurotransmitter, glutamate has an 
important metabolic function.  
Glutamate does not cross the blood-brain barrier, and is thus 
produced from glucose within the brain itself (Gruetter et al., 1994; 
McKenna et al., 2006a). There are mainly two mechanisms for 
synthesis of glutamate. The amino acid can be formed from the TCA 
cycle intermediate α-ketoglutarate by transamination (catalyzed by 
one of the aminotransferases, most commonly aspartate 
aminotransferase (ASAT) or alanine aminotransferase (ALAT)) or 
reductive amidation (catalyzed by glutamate dehydrogenase (GDH)). 
The other mechanism of glutamate synthesis is conversion from 
glutamine synthesized in glial cells and exported to neurons where it 
enters mitochondria, where the enzyme phosphate activated 
glutaminase (PAG) catalyzes the reaction (Kvamme et al., 2000; 
Kvamme et al., 2001). Regulation of the transmitter pool of glutamate 
and the availability of this pool is based on an elaborate interaction 
between neurons and glia.  
After synthesis, glutamate is stored in synaptic vesicles in high 
concentrations and released to the synapse after increase in 
intracellular calcium following depolarization of the nerve ending. The 
release is modulated by a metabotropic auto-receptor on the 
presynaptic neuron. The concentration of glutamate in the synapse 
can rise from 2-5 µM before release to as much as 50-100 µM after 
depolarization.      
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There are both ionotropic and metabotropic glutamate 
receptors. The ionotropic glutamate receptors located on the 
postsynaptic neuron are divided into three classes; the NMDA 
receptor, the AMPA receptor and the KA receptor. These subtypes 
are named after the first synthetic agonists, which bound strongly and 
relatively specific to them, N-methyl-D-aspartate, α-amino-3-
hydroxy-5-methyl-isoxazole-4-propionic acid, and kainic acid, 
respectively. Binding of glutamate to one of these receptors can lead 
to depolarization of the membrane of the postsynaptic neuron.  
In papers 1 and 4, cell cultures were exposed to the potent 
glutamate agonist kainic acid (KA), binding to the KA and AMPA 
classes of ionotropic receptors (Lerma, 1998). KA injection has been 
used as an epilepsy model and the effects of KA have previously been 
studied both in animals and cell cultures, increasing the knowledge of 
the epileptogenesis (Ben-Ari and Cossart, 2000). Animals injected 
with KA (systemic or intracerebral) have seizures resembling complex 
partial epileptic seizures (Ben-Ari, 1985; Sperk, 1994; Bradford, 
1995; Muller et al., 2000; Qu et al., 2003). The synchronized neuronal 
hyperactivity starts in the CA3-region of the hippocampus and spreads 
to other limbic structures. The seizures are followed by cell loss 
comparable to the cell loss seen in patients with temporal lobe 
epilepsy (Nadler, 1981). Some time after the injection (weeks to 
months), the animals develop spontaneous epileptic seizures, thus 
they develop epilepsy (Ben-Ari, 1985; Leite et al., 2002).  
In cell cultures, KA has shown effects on survival of neurons; 
however, these effects are not fully understood (Balázs et al., 1990; 
Kato et al., 1991; Jensen et al., 1999; Drian et al., 2001). The 
complexity is illustrated by KA having a trophic effect with increased 
survival of cerebellar neurons in culture at low doses, whereas high 
doses are toxic to these cells (Balázs et al., 1990). Studies have also 
shown that KA has different, even opposite, effects on neurons in 
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different developmental stages (Frandsen and Schousboe, 1990; 
Drian et al., 2001;). In papers 1 and 4, KA effects on cell survival and 
metabolism in neuronal cultures were studied. 
The receptors are, as previously mentioned, named after their 
synthetic agonists. It is of great value that also glutamate receptor 
antagonists are known. This makes selective inhibition of receptors 
possible. In papers 3, 4 and 5, cell cultures were incubated in medium 
containing [U-13C]glutamate in order to study glutamate metabolism. 
In these experiments glutamate receptor antagonists DNQX (6,7 
dinitroquinoxaline-2,3(1H,4H)-dione, an AMPA/kainate-selective 
glutamate receptor antagonist), and D-AP5 (D-2-amino-5-
phosphonopentanoic acid, which inhibits the NMDA receptor), were 
added to the incubation medium of the cell cultures to avoid toxic 
effects of glutamate during incubation (Frandsen et al., 1989). 
As mentioned, a high glutamate concentration has neurotoxic 
effects, and it is of critical importance to keep the extracellular 
glutamate concentrations low. Glutamate receptors are widespread, 
and can be found on most of the cellular elements (dendrites, nerve 
endings, neuronal cell bodies as well as glial cells) in the brain. After 
release glutamate can diffuse out of the synaptic cleft and interact 
with glutamate receptors in other locations than the postsynapse, and 
it is therefore important to remove the transmitter from the cleft after 
release. This is mainly done by uptake through sodium dependent 
glutamate transporters in the cell membranes of astrocytes 
surrounding the synapse (for review, see Danbolt, 2001). Five distinct 
high affinity subtypes of glutamate (excitatory amino acid) 
transporters are at present identified; EAAT1 (GLAST), EAAT2 (GLT), 
EAAT3 (EAAC), EAAT4 and EAAT5. EAAT1 and EAAT2 are responsible 
for most of the glutamate uptake, and until recently they were 
believed to be found exclusively on astroglia. However, Danbolt et al. 
(2006) reported that in hippocampal slices, about 15 % of EAAT2 was 
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distributed in nerve terminals and axons, and that neuronal glutamate 
reuptake through these was quantitatively significant. EAAT3 is 
present in several types of neurons as well as in glia, particularly in 
oligodendrocytes (Conti et al., 1998). EAAT4 is expressed mainly in 
the purkinje cells of the cerebellum, while EAAT5 is found in the retina 
(Arriza et al., 1997).  
Glutamate taken up by astrocytes can be metabolized to 
glutamine by the above mentioned astrocyte specific enzyme 
glutamine synthetase (GS). Glutamine can then be released from the 
astrocytes and taken up in the nerve ending of the glutamatergic 
neuron, where it once again is converted to glutamate by the enzyme 
PAG. Thus, a recycling of the neurotransmitter called the glutamate-
glutamine cycle based on neuronal-glial interaction occurs (see 
above). This cycle is the main subject of paper 3 and is illustrated in 
Figure 1.1. 
 
FIGURE 1.1 Glutamate is formed from α-ketoglutarate in the TCA cycle and from 
glutamine synthesized in astrocytes. After release to the synaptic cleft, glutamate is 
taken up in astroglia and converted to glutamine, which can be exported back to 
neurons, where it can be converted to glutamate again. This glutamine-glutamate cycle 
thus involves both neurons and glia.  
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Glutamate can also be converted to α-ketoglutarate, which can 
be further processed in the TCA cycle for production of energy or 
intermediate metabolites in both astrocytes and neurons. 
 
1.3.3 GABA       
GABA is, like glutamate, an amino acid neurotransmitter, but 
whilst glutamate is excitatory, GABA is the most abundant inhibitory 
neurotransmitter in the brain (Storm-Mathisen, 1974; Storm-Mathisen 
et al., 1983). GABA is mainly formed by decarboxylation of glutamate, 
a process catalyzed by the enzyme glutamate decarboxylase 
(GAD), which exists in two isoforms, GAD65 and GAD67. GAD65 appears 
to be targeted to membranes and axonal regions including nerve 
endings, and has been hypothesized to preferentially synthesize GABA 
for vesicular release (Waagepetersen et al., 1999; Waagepetersen et 
al., 2001), whereas GAD67 is more widely distributed throughout the 
cell. GAD has been detected in various GABAergic neurons, but also in 
glutamatergic hippocampal granule cells (Schwarzer and Sperk, 1995; 
Gutierrez and Heinemann, 2006). However, the role of GABA in these 
cells is yet to be understood. The study of GABA in glutamatergic 
cerebellar neurons is discussed in papers 1, 2, 3 and 4. 
It should be noted that there are other possible pathways of 
GABA synthesis. It can be formed from putrescine in two ways; by 
oxidative deamination catalyzed via diamine oxidase and by 
transformation into monoacetylputrescine which then undergoes 
deamination via monoamine oxidase. However, this GABA synthesis 
pathway has been shown to be insignificant in the brain (Seiler, 
1980). Also in paper 2, it was shown that GABA in cerebellar neuronal 
cultures was not synthesized by this pathway.  
 When the presynaptic GABAergic neuron is depolarized, GABA 
is released from vesicles to the synaptic cleft by exocytosis 
(Augustine, 2004). The transmitter molecules cross the cleft by 
Glutamate and GABA: Major Players in Neuronal Metabolism 
 
 16 
 
passive diffusion and are bound to receptors on the postsynaptic 
neuron. The most important postsynaptic GABA receptor is the 
GABAA-receptor, an ionotropic receptor where the GABA binding 
sites are located on the alpha subunits. When GABA is bound to the 
receptor, Cl- ions flow into the cell, and the postsynaptic membrane is 
hyperpolarized (Augustine, 2004). The GABAA receptor is a target for 
a number of pharmacological agents, for example benzodiazepines 
and various anesthetics. Auto regulation of GABAergic neurons is 
mainly mediated through metabotropic GABAB receptors in the 
presynaptic cell membrane. A third receptor, the presynaptic 
ionotropic GABAC receptor is also described. 
 The effect of GABA is rapidly terminated by reuptake of the 
transmitter into the presynaptic neuron and to a lesser degree uptake 
by surrounding astrocytes (Schousboe, 1981; Borden, 1996; 
Schousboe, 2003) via GABA transporters (GAT). Four subtypes of 
transporters have so far been identified; GAT-1, primarily present on 
GABAergic neurons and to a lesser extent in astrocyte membranes, 
GAT-2, GAT-3 and the low affinity subtype BGT-1. The antiepileptic 
agent tiagabine inhibits GAT-1 (Borden, 1996), and thus increases the 
GABA concentration in the synaptic cleft, making more GABA available 
to the receptors. GABA taken up in the nerve terminal can be stored 
in vesicles and used again. Another option for intracellular GABA is 
conversion via GABA aminotransferase (GABA-T) to succinic 
semialdehyde, which is subsequently oxidized to succinate in the 
GABA shunt (Balázs et al., 1970). GABA-T can be inhibited by γ-vinyl-
GABA (GVG) and aminooxyacetic acid (AOAA) (Wu and Roberts, 1974; 
Lippert et al., 1977). AOAA can also inhibit GAD and a number of 
transaminases when present in high concentration (Wu and Roberts, 
1974). In paper 2, GVG and AOAA were added to the medium of 
cerebellar neuronal cultures.  
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Succinate formed from GABA can be utilized for energy 
production or formation of intermediate metabolites in the TCA cycle, 
for example α-ketoglutarate which can be converted to glutamate and 
glutamine (the latter only in astrocytes). Glutamine can be transferred 
from the astrocyte back to the neuron, where it can be converted to 
glutamate in the mitochondria via the enzyme PAG. Glutamate can 
also be converted to α-ketoglutarate and thus enter the TCA cycle of 
the neuron or be transformed into GABA again by the enzyme GAD. 
Figure 1.2 shows the GABA recycling, and its involvement of both 
neurons and astrocytes (Sonnewald et al., 1993). 
 
 
FIGURE 1.2 GABA is produced in neurons from glutamate, which either comes from α-
ketoglutarate in the TCA cycle or from glutamine transferred from astroglia. After 
release to the synaptic cleft, GABA is taken up in neurons and glia via transporter 
proteins. Inside the neuron, the transmitter can be stored in vesicles and be re-used, or 
succinate from GABA can be metabolized in the TCA cycle of both neurons and 
astrocytes.  
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2 OBJECTIVES 
  
Disturbance of neuronal metabolism has implications for a 
number of neurological and psychiatric conditions, and enhanced 
knowledge of this will hopefully lead to new methods for treating such 
disorders. The present research was undertaken to aid understanding 
of diseases related to disturbance in glutamate and GABA metabolism. 
 
The specific questions addressed were the following:  
 
Glutamate and glutamine 
• It is known that glutamate and glutamine serve as substrates 
for intermediary metabolism in cerebellar neurons. Is there a 
substrate preference between these two amino acids? 
• Is glutamate and glutamine metabolism in cerebellar neurons 
affected by long-term exposure to KA? 
• The pyruvate recycling pathway has been shown to operate in 
astrocytes. Is it also active in cultured neurons from 
cerebellum? 
 
GABA   
• Is GABA present in cerebellar neuronal cultures, and if so, how 
is the concentration compared to that in neocortical neuronal 
cultures?  
• If GABA is present in these neurons, how does it get there; is it 
taken up from serum in the medium or is it synthesized by the 
cerebellar neurons (GABAergic and/or glutamatergic)?  
• If it is synthesized, what is the mechanism and time course 
throughout the culturing period for this synthesis? 
• Does long-term KA exposure affect GABA synthesis in these 
cultures?  
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3 METHODS 
 
3.1 Neuronal Cell Cultures 
 
 Cell cultures represent an important in vitro method in 
neurobiology, and primary cultures of neurons from cerebral cortex 
and cerebellum from mice are frequently used as models for studying 
basic physiological mechanisms as well as pathological conditions and 
pharmacological intervention (Schousboe et al., 1985). Primary 
cultures are prepared by taking cells directly from an organism, in 
contrast to cultures from cell lines which originate from one individual 
cell or a group of cells, often from tumors. The advantage of primary 
cultures is that they consist of “normal” diploid cells and thus their 
properties and metabolism more closely resembles that of the 
corresponding cells in vivo than do cell lines (Hertz et al., 1985). 
 In order to obtain viable cells, timing is crucial. Tissue must be 
at the developmental stage which favors cultivation of the preferred 
cell type. For neuronal cultures, the tissue must be at a proliferating 
or early post-mitotic stage (Hertz et al., 1985). The reason for this is 
that older neurons with established axons and dendrites will be more 
vulnerable to mechanical damage during the culture preparation. 
Different CNS cells are ready for cultivation at different ontogenetic 
stages. In mice, neurogenesis is nearly completed at the time of birth, 
with a few exceptions, one of them being interneurons in cerebellar 
cortex. Granule neurons are such cerebellar interneurons which 
develop approximately from day two until 15 after birth. The 
cerebellar neuronal cultures, consisting of about 90 % glutamatergic 
granule neurons, are therefore prepared from tissue taken from 
seven-day-old mice (Messer, 1977; Schousboe et al., 1989). A 
photomicrograph of cerebellar neurons in culture is shown in Figure 
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3.1. Neuronal cultures from cerebral cortex consisting mainly of 
GABAergic interneurons, are established with tissue from 15-day-old 
mouse fetuses (Drejer et al., 1987; Hertz et al., 1989). 
  
 
FIGURE 3.1 Photomicrograph of cerebellar neurons cultured for seven days. The 
majority of the cells are glutamatergic granule neurons characterized by their small size 
and the presence of granules in the cell body. The bar represents 0.100 mm. 
 
In the present studies, cerebellar neuronal cultures are used in 
all papers, whereas neocortical cultures in addition are used in paper 
1. The cultures are prepared by dissecting out the brain region of 
interest, i.e. cerebral cortex or cerebellum. The tissue then undergoes 
a multiple step purification, first it is finely cut with a razorblade. 
Subsequently the tissue is trypsinized followed by trituration in a 
DNase solution containing a trypsin inhibitor from soybeans. The steps 
of chemical and mechanical division result in single cells in 
suspension, which is transferred to a Dulbecco’s minimum essential 
medium (DMEM). The medium contains 31 mM glucose and 10 % 
Glutamate and GABA: Major Players in Neuronal Metabolism 
 
 23 
 
(v/v) fetal calf serum (FCS), which has been through heat inactivation 
of the complement system. The cell suspension is seeded in poly-D-
lysine coated Petri dishes after adjustment of cell density based on 
cell counting. Poly-D-lysine has an electrostatic attraction of 
negatively charged cell membranes, which gives high affinity for 
neurons and makes it easier for these cells to attach to the dishes. 
The cultures are incubated at 37 °C in 95 % atmospheric air with 5 % 
CO2.   
The presence of glia in neuronal cultures is unfortunate 
because these cells will proliferate and thus displace the neurons. In 
order to reduce the content of non-neuronal cells in the culture, the 
cytotoxic chemical cytosine arabinoside is added to the culture 
medium 24-48 hours after preparation. The proliferation of dividing 
cells like glia will be inhibited by this treatment, whereas neurons are 
at a post-mitotic stage and not dividing at this point in time, and will 
therefore not be affected (Hertz et al., 1985). Despite the cytotoxic 
treatment, some glial cells are present in the neuronal cultures. 
Approximately 5 % of the cells in the cerebellar neuronal cultures are 
glial cells (Messer, 1977). 
 In the present studies the cell cultures were exposed to 
different chemical substances and extracted after various days in vitro 
as described in the papers. In the extraction procedure, the cultures 
are divided into three fractions; medium, cell extract and protein. 
Different parameters were analyzed in medium and cell extract, and 
the protein amount was quantified as described later. 
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3.2 Identification of Metabolites and Metabolic Pathways by MRS 
 
3.2.1 MRS in Neurobiological Research 
 Magnetic resonance spectroscopy (MRS) is a method that can 
be used to detect metabolites and map metabolic pathways in cells. It 
has a number of advantages in studies of cell metabolism. The atomic 
nuclei most frequently used in metabolic MR research are 1H, 31P and 
13C (for review, see Bachelard and Badar-Goffer, 1993). 
 1H and 31P have a high natural abundance, and are often used 
for studying differences in concentration of biological compounds 
under different metabolic conditions. In contrast to these nuclei, 13C 
has a natural abundance of only 1.1 %. This makes detection difficult, 
and 13C MRS is of limited use in studies of endogenous metabolites 
unless the compounds occur in large amounts. The low natural 
abundance of 13C can, however, be used as an advantage in the study 
of metabolic pathways (Cerdan and Seelig, 1990; Bachelard and 
Badar-Goffer, 1993; Sonnewald et al., 1994). 13C-labeled precursors 
can be added to cell cultures or be injected into animals or humans, 
and MRS can be used to detect and quantify 13C atoms and their 
position in different metabolites are detected and quantified. Thus, 
metabolic pathways can be monitored with little background 
interference from endogenous metabolites. As a result, 13C MRS is an 
important tool in analyzing brain metabolism and the metabolic 
trafficking between different cellular compartments.      
 
3.2.2 Basic MR Theory (Derome, 1987; Hornak, 1997) 
 The background for magnetic resonance spectroscopy is the 
phenomenon of nuclear magnetic resonance. MR was first discovered 
in 1946 by Felix Bloch and Edward Purcell, and for this work they were 
jointly awarded the Nobel price in physics in 1952 (Hornak, 1996). 
The phenomenon is based on the nuclear magnetic momentum of the 
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atom, and the nuclear resonance arises when the nuclei of certain 
atoms are situated in a static magnetic field and in addition are 
exposed to an oscillating magnetic field.  
 Only those nuclei which possess the quality called “spin” can 
experience this phenomenon. Individual unpaired electrons, protons 
and neutrons possess spins of ½. This means that spin can have 
values that are multiples of ½, and spin can be positive or negative. 
Two or more particles with spin in opposite direction can neutralize 
the observable effect of the spin, and these particles will not be 
detectable by MRS. The nucleus of the 12C-atom (which constitutes 
most of the natural carbon) has a spin of 0, and cannot be detected, 
whereas the nucleus of the 13C-atom contains six protons and seven 
neutrons, and has a net spin of ½.   
 Nuclei with spin behave like small magnets, which point in 
different directions. If an externally applied magnetic field is imposed, 
the nuclei will orientate themselves with respect to the direction of the 
field to minimize their energy and point in one of two possible 
directions, either in the same direction as the magnetic field, which is 
the lower energy position (E1) or opposite to the magnetic field 
(antiparallel), which is a position of higher energy (E2). The nuclei will 
precess around its own axis with a certain frequency called the Larmor 
frequency.  
In addition to the static magnetic field (B0), an oscillating 
magnetic field (B1) in the form of electromagnetic waves (radio 
waves) is applied perpendicular to B0. This adds energy to the system, 
and makes some of the nuclei in the low energy position change to 
the high energy position, as illustrated in Figure 3.2. This excitation 
can only happen if the frequency of the radio waves matches the 
energy difference, ΔE, between the two energy levels. The energy 
difference and thus the resonance frequency, is different for different 
nuclei, there can only be resonance for one type of nucleus at the 
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time. 13C has a resonance frequency of 10.71 MHz per Tesla, where 
Tesla (T) denotes the strength of the magnetic field. 
 
 
FIGURE 3.2 In a static magnetic field, B0, the 13C nuclei will behave like small magnets, 
illustrated by arrows. They will orientate themselves in a position with low energy, E1, 
or in a position with high energy, E2. The difference between the two energy levels is 
ΔE. When energy in the form of radio waves is added, B1, some of the spins will be 
excited and change direction to the high energy position, as shown on the right. 
 
 When the oscillating magnetic field B1 is turned off, the system 
is in a high energetic, unstable state. The system will return to the 
equilibrium state in a process called spin relaxation, where the excited 
spins are restored to their low energy position. In this process electric 
current is generated in a detection coil as a signal called the Free 
Induction Decay (FID). The procedure of applying electromagnetic 
waves with the right frequency is repeated numerous times, and the 
FID signals are stored in a computer. The FID spectra are acquired in 
the time domain and cannot be analyzed directly. Through the 
mathematical operation known as the Fourier transformation, the FID 
spectra are therefore converted into MR spectra in the frequency 
domain. Under the right circumstances the area under each peak in 
the MR spectra is directly proportional to the number of nuclei, and 
thus to the concentration of the different compounds. In the present 
experiments, lyophilized cell extracts were redissolved in D2O 
containing 0.10% ethylene glycol as an internal standard. The MR 
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B0 
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analyses were done using different instruments; details are given in 
papers 1 and 5.           
       
3.2.3 13C MRS (Derome, 1987; Hornak, 1997) 
 The resonance frequency of the 13C nucleus is determined by 
the strength of the magnetic field, as described previously (10.71 MHz 
per Tesla). In addition, the structure of the molecule containing the 
13C-atom and the atoms surrounding the 13C influence the resonance 
frequency. This means that there are slightly different Larmor 
frequencies for the same nuclear type in different positions within a 
molecule. The reason for this is that the electrons also work as 
magnets which affect the nuclei. The electrons in the chemical bonds 
give rise to magnetic fields which can locally modify the external 
magnetic field. The carbon nucleus will for example have a higher 
affinity for the electrons than the hydrogen nucleus in a C-H bond. 
The carbon nucleus is referred to as shielded, and the resonance 
frequency of the 13C nucleus is decreased. In a C=O bond, the 
situation is opposite, the oxygen nucleus has the highest electron 
affinity, the 13C nucleus becomes unshielded and the Larmor 
frequency is increased. The fact that different carbon atoms will have 
a slightly different frequency because of their chemical environment is 
called chemical shift. This makes it possible to distinguish between 
different metabolites and also different nuclei within each metabolite 
as they appear in specific locations in the spectrum. This can be seen 
in Figure 3.3, showing an MR spectrum of cell extracts from cerebellar 
neuronal cultures incubated in medium containing [U-13C]glutamate. 
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FIGURE 3.3 A 13C NMR spectrum of cell extracts from cerebellar neuronal cultures 
incubated in medium containing [U-13C]glutamate, for details see paper 5. Peak 
assignments: (1) malate C-2, (2) ethylene glycol (internal standard), (3) glutamate C-
2, (4) aspartate C-2, (5) malate C-3, (6) aspartate C-3, (7) glutamate C-4, (8) 
glutamate C-4 in glutathione, (9) glutamine C-4, (10) glutamate C-3, (11) glutamine C-
3. 
  
Looking at the MR spectrum in Figure 3.3 it can be seen that 
the peaks have different configurations, most of them are multiplets 
consisting of more than one peak with different heights. This is 
because magnetic nuclei also are influenced by surrounding magnetic 
nuclei. This can be a nucleus of the same (homonuclear coupling) or a 
different kind (heteronuclear coupling). If a 13C atom only has 12C 
neighboring atoms, it is observed as a single peak (a singlet) in the 
spectrum. However, if it has one or two 13C neighboring atoms, it will 
be represented as a doublet, a triplet or a doublet of doublets. The 
splitting occurs because the labeled neighbors will influence the first 
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13C atom, changing the spin-spin coupling constant (J) or the 
frequency separation, between the different peaks in a multiplet. This 
is illustrated in Figure 3.4 taken from paper 5 of a part of an 13C MR 
spectrum from cell extracts of cerebellar neurons after incubation with 
[U-13C]glutamate, for details see paper 5.  
 
FIGURE 3.4 Part of a 13C MR spectrum of cell extracts from cerebellar neuronal cultures 
incubated in medium containing [U-13C]glutamate, for details see paper 5. The 
aspartate C-3 multiplet and the isotopomers responsible for the configuration of the 
peaks are shown. The effect of homonuclear 13C-13C coupling can be seen by the 
difference in coupling constants (given in Hz). ● represents 13C and ○ represents 12C 
atoms. No information can be obtained about labeling in the C-1 position indicated by 
broken gray lines. 
 
13C nuclei will also be affected by neighboring protons 
(heteronuclear coupling), because these nuclei posses spin. This leads 
to splitting of the peaks in an MR spectrum. To avoid this splitting, the 
protons are exposed to radio waves around their Larmor frequency, so 
that the same number of protons are in the low (E1) as in the high 
(E2) energy position, and by this operation the spectra become proton 
decoupled. When energy is added to the system to decouple the 
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protons, ΔE for the 13C nucleus increases and some of the carbon 
peaks (those representing 13C atoms bound to protons) in the 
spectrum appear artificially large. This is called the nuclear 
Overhauser effect (nOe), and when quantifying the peaks, the values 
must be adjusted for this effect.       
 By adding 13C labeled precursors such as [1-13C]glucose, [U-
13C]glutamate or [U-13C]glutamine to neuronal cell cultures, the cells 
will incorporate the 13C-compounds in their metabolism. Using 13C 
MRS, the different metabolites in which 13C has been incorporated can 
be identified and quantified. In addition the method can be used to 
distinguish between 13C-labeling in different positions in the 
metabolites.  
 
 
3.3 Mass Spectrometry 
 
3.3.1 Detection of 13C Labeling in Metabolites by MS  
 Mass spectrometry (MS) coupled to a separation method can 
also be used to obtain information about 13C labeling in different 
metabolites (Biemann, 1962). The advantage of using MS is that it is 
far more sensitive than MRS. In cell extracts from cerebellar neurons 
incubated for two hours with [U-13C]glutamate or [U-13C]glutamine it 
was possible to detect labeling in glutamate, glutamine, GABA and 
aspartate in addition to the TCA intermediates malate, succinate, 
fumarate and citrate. When six of the same cell extract samples were 
pooled together and analyzed by 13C MRS, only labeling in glutamate, 
glutamate incorporated into glutathione, glutamine, aspartate, and 
occasionally malate was seen (Figure 3.3). On the other hand, the 
disadvantage of MS compared to MRS is that it only gives the percent 
distribution of different masses (M (the mass of the parent ion), M+1 
(the mass of the parent ion plus 1 unit of molecular weight (Dalton) 
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corresponding to one atom of 13C), M+2, M+3, etc.) of the metabolite 
isotopomers, whereas the position of the 13C atoms within the 
molecule is not detected by this method as it is by MRS.    
 
3.3.2 Basic GC/MS Theory (McMaster and McMaster, 1998) 
Mass spectrometry is often used in combination with gas 
chromatography (GC/MS). In experiments described in papers 3, 4 
and 5, cell extract samples were lyophilized, redissolved in 10 mM 
HCl, adjusted to pH<2 and dried under atmospheric air. The amino 
acids were extracted into an organic phase of ethanol and benzene 
and dried again under atmospheric air before derivatization with 
MTBSTFA (N-methyl-N-(tert-butyldimethylsilyl)-trifluoroacetamide) + 
1% t-BDMS-Cl (tert-butyldimethylchlorosilane) as described by 
Mawhinney et al. (1986). The cell extract sample is then injected into 
the injection port of the GC, where it is immediately vaporized and 
carried to the column by the carrier gas. It is important that the 
carrier gas is inert and does not react with the sample or column, and 
for this reason helium was used in the present studies. The column 
used was a capillary column coated with silica (Varian WCOT fused 
silica 25 m x 0.25 mm ID coating CP-Sil 5CB-MS). The various 
components in the cell extract sample travel through the column at 
different speeds based on their chemical and physical characteristics 
(mass, shape, interaction with column surface, etc.), and they are 
separated. Each component ideally produces a specific peak which 
appears in the chromatogram after a characteristic retention time.      
After separation of the different metabolites in the cell extracts 
by GC, MS is used to separate molecules of the same metabolite with 
different masses (M, M+1, M+2, etc.), i.e. different isotopomers of 
each metabolite. The gas carrying the separated metabolites is let into 
the ionization chamber where a beam of electrons is accelerated with 
a high voltage. The molecules in the sample are shattered into ionized 
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fragments upon collision with the high voltage electrons. The charged 
fragments are electrically focused into an intense ion beam which 
enters the quadrupole analyzer. The electrically charged poles of the 
quadrupole create an electromagnetic field, and the ion beam is 
forced into a corkscrew, three-dimensional sine wave. Across the 
quadrupole rods a combined field of direct current and an oscillating 
radio frequency signal is applied. This interrupts the paths of all ions 
except for those with one specific mass to charge ratio. A mass 
spectrum is obtained by scanning through the mass range of interest 
over time. When using the instrument’s SCAN mode, the whole mass 
range is scanned. However, when knowing which masses to look for, 
the instrument is set to scan over a very small mass range, the 
selected ion monitoring (SIM) mode. The narrower the mass range 
the more specific the SIM assay. The method used in the present 
studies was developed using the SCAN mode for analyzing standard 
solutions of individual compounds to determine the retention time and 
the masses of interest for the compounds. When this was done, a SIM 
method was set up with retention time windows in which the 
instrument was set to scan over a few masses in order to enhance 
sensitivity. After being selected in the quadrupole, the charged 
particles travel in a curved path towards the detector, and on the way 
the charge is amplified through collisions with the detector surface.   
The computer linked to the GC/MS instrument gives a plot of 
relative abundance against the mass to charge ratio value of the ions. 
An example of two gas chromatograms and mass spectra is shown in 
Figure 3.5. The peaks are integrated and the percentage of mono-, 
double-, triple labeling etc. in a compound is calculated after 
correction for natural abundance determined in a standard solution of 
unlabeled compounds. However, as mentioned earlier, this method 
does not differentiate between isotopomers containing the same 
number of 13C atoms in different positions. 
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FIGURE 3.5 Parts of gas chromatograms (top) and mass spectra (bottom) from a 
standard solution of unlabeled compounds (left) and a sample of cell extract from 
cerebellar neuronal cultures incubated for two hours in medium containing 0.25 mM [U-
13C]glutamate, for details see paper 3. The chromatograms show the malate, aspartate 
and glutamate peaks, and the mass spectra show masses M (unlabeled) to M+5 
(uniformly labeled) for glutamate. 
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3.4 13C Labeling Patterns 
 
Understanding the labeling patterns from 13C labeled 
precursors involves knowledge about cell metabolism. This can be 
found in a biochemistry textbook, for example the one written by 
Stryer (1995a) 
 
3.4.1 Labeling from [1-13C]glucose 
 In papers 1 and 2, neuronal cell cultures prepared for MRS 
analysis were cultured in medium containing [1-13C]glucose for the 
whole culture period. Glucose is the most important substrate for 
neuronal metabolism, and the metabolites made from this labeled 
glucose, will contain 13C and thus be detectable by 13C MRS. In order 
to interpret the MR-spectra and understand the results obtained from 
these spectra, it is necessary to know the relevant metabolic 
conversions of [1-13C]glucose. This is illustrated in Figure 3.6. 
 
FIGURE 3.6 Metabolism of [1-13C]glucose in neurons. ● represents 13C and ○ represents 
12C atoms. PDH is the enzyme pyruvate dehydrogenase which catalyzes the reaction 
from pyruvate to acetyl-CoA. *Unlabeled pyruvate will have the same conversions as [3-
13C]pyruvate, but the products will not be detectable by 13C MRS. 
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Through glycolysis, [1-13C]glucose is converted to two 
pyruvate molecules. One of them will contain a 13C-atom in the third 
position ([3-13C]pyruvate), whereas the other one will contain only 
12C-atoms (the natural abundance of 13C of 1.1 % is not taken into 
consideration). [3-13C]pyruvate can be converted to [3-13C]lactate or 
[3-13C]alanine. Alternatively, [3-13C]pyruvate may enter the 
tricarboxylic acid cycle via pyruvate dehydrogenase (PDH) as [2-
13C]acetyl-CoA. In the TCA cycle, [2-13C]acetyl-CoA is combined with 
oxaloacetate (OAA) and converted through several steps to α-
ketoglutarate with 13C-labeling in the C-4 position, which may leave 
the TCA cycle and form [4-13C]glutamate, which in turn can be 
converted to [2-13C]GABA. 
If α-[4-13C]ketoglutarate does not leave the cycle, it will (after 
several steps) appear as [2-13C]oxaloacetate (OAA) or [3-
13C]oxaloacetate (because succinate, one of the intermediate 
compounds between α-ketoglutarate and OAA in the TCA cycle, is a 
symmetrical molecule). 13C-labeled OAA can be converted to [2-
13C]aspartate or [3-13C]aspartate by transamination, or condense with 
a new acetyl-CoA-molecule, labeled or unlabeled with 13C (from 
labeled or unlabeled pyruvate), and make a second turn in the TCA 
cycle. If 13C-labeled OAA reacts with unlabeled acetyl-CoA, the 
resulting labeling (after several steps) in glutamate and GABA is [2-
13C]- and [3-13C]glutamate and [3-13C]- and [4-13C]GABA. If 13C-
labeled OAA reacts with [2-13C]acetyl-CoA, [2,4-13C]- and [3,4-
13C]glutamate and [2,4-13C]- and [2,3-13C]GABA are formed. The 
labeling [1-13C]glucose in glutamate and GABA after one and two 
turns in the TCA cycle is shown in Figure 3.7.  
After more turns in the TCA cycle and reactions between 
molecules with and without 13C-atoms in different positions, the 
possibilities are many for 13C-labeling of the different metabolites, and 
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the picture becomes more complicated than shown in Figures 3.6 and 
3.7. 
 
 
FIGURE 3.7 Labeling of 13C in glutamate and GABA from [1-13C]glucose in the first and 
second turn of the TCA cycle. ● represents 13C and ○ represents 12C atoms. 
  
3.4.2 Labeling from [U-13C]glutamate and [U-13C]glutamine  
 In papers 3, 4 and 5, neuronal cell cultures from cerebellum 
were incubated in medium containing [U-13C]glutamate or [U-
13C]glutamine. When taken up by the neurons, the latter can be 
converted into the former, and from here on the labeling patterns are 
the same for the two precursors. [U-13C]glutamate can together with 
cysteine and glycine form the tripeptide glutathione (GSH). The 
labeled glutamate incorporated in glutathione can be identified by 13C 
MRS; its peaks will appear in a different location in the spectrum than 
free glutamate (Figure 3.3). Another possibility for [U-13C]glutamate 
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is conversion into [U-13C]GABA catalyzed by the enzyme GAD. [U-
13C]GABA could not be detected in cell extracts by MRS after two 
hours incubation in medium containing [U-13C]glutamate. However, 
using MS, the M+4 isotopomer of GABA (representing [U-13C]GABA) 
was detected. A third option for [U-13C]glutamate is the formation of 
α-[U-13C]ketoglutarate, which is metabolized in the TCA cycle. After 
several steps in the TCA cycle, labeled α-ketoglutarate is turned into 
[U-13C]oxaloacetate, which can condense with unlabeled acetyl CoA to 
form [3,4,5,6-13C]citrate. The resulting glutamate isotopomer (after 
several steps) is [1,2,3-13C]glutamate formed from α-[1,2,3-
13C]ketoglutarate. This first turn for [U-13C]glutamate in the TCA cycle 
is shown in Figure 3.8.  
 
FIGURE 3.8 Metabolism of [U-13C]glutamate in neurons. ● represents 13C and ○ 
represents 12C atoms. Glutathione is a tripeptide, and the black box is representing 
labeled glutamate, while cysteine and glycine are amino acids without 13C labeling, 
represented by white boxes.  
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 If α-[1,2,3-13C]ketoglutarate does not leave the TCA cycle as 
[1,2,3-13C]glutamate, but continues its voyage in the cycle, 13C 
labeling is distributed amongst the TCA cycle intermediates as 
presented in Figure 3.9.    
 
FIGURE 3.9 Schematic representation of possible isotopomers of metabolites arising 
from [U-13C]glutamate or [U-13C]glutamine via the three first turns in the TCA cycle in 
neurons: ● represents 13C and ○ represents 12C atoms. For clarity, the labeling of 
fumarate, malate, OAA and isocitrate is left out; the three first compounds are labeled 
in the same manner as succinate and the latter as citrate, although the numbering of 
the C atoms differs. GLU: glutamate; αKG: α-ketoglutarate; SUC-CoA: succinyl-CoA; 
SUC: succinate; FUM: fumarate; MAL: malate; OAA: oxaloacetate; CIT: citrate; 
ISOCIT: isocitrate.  
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From labeled intermediates of the first TCA cycle turn, [U-
13C]aspartate and [U-13C]lactate can be formed, the former from 
transamination of [U-13C]OAA and the latter derived from [U-13C]OAA 
or [U-13C]malate. The presence of [U-13C]lactate implies that also [U-
13C]pyruvate is present in the cells, and as mentioned, this compound 
can enter the TCA cycle through acetyl CoA. Pyruvate derived from 
TCA cycle intermediates re-entering the cycle as acetyl CoA 
constitutes the pyruvate recycling pathway. In paper 5, it was shown 
that this recycling, previously believed to be astrocyte specific in cell 
cultures (Håberg et al., 1998; Waagepetersen et al., 2002), also take 
place in cerebellar neurons. In this case acetyl CoA is 13C labeled, and 
this gives rise to particular labeling patterns in metabolites derived 
from the TCA cycle. The labeled isotopomers in glutamate and 
aspartate resulting from TCA cycle activity involving labeled and 
unlabeled acetyl CoA are shown in paper 5.  
 After more turns in the TCA cycle and entry of unlabeled or 
labeled acetyl CoA condensing with different isotopomers of OAA, the 
possibilities are many for 13C-labeling of the different metabolites, and 
the picture becomes more complicated than shown in the illustrations.  
 
 
3.5 Identification and Quantification of Amino Acids by HPLC 
  
High Performance Liquid Chromatography (HPLC) is a type of 
chromatography which in the present studies was used to quantify 
different amino acids in cell extracts and medium. The amino acids 
were pre-column derivatized with o-phthaldialdehyde and 
subsequently separated on a ZORBAX SB-C18 (4.6 × 250 mm, 5 µm) 
column from Agilent using a phosphate buffer (50 mM, pH = 5.9) and 
a solution of methanol (98.75 %) and tetrahydrofuran (1.25 %) as 
eluents (Geddes and Wood, 1984). A gradient of the two eluents was 
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used to obtain a faster and more optimal separation. The separated 
amino acids were detected with fluorescence and quantified by 
comparison to a standard curve derived from standard solutions of 
amino acids run after every twelve samples. An example of an HPLC 
chromatogram is presented in Figure 3.10. 
 
 
FIGURE 3.10 An HPLC chromatogram showing peaks representing glutathione and 
different amino acids in solution eluted at different retention times, the x axis shows 
time in minutes, and the y axis shows fluorescence intensity.  
 
 
3.6 Protein Quantification 
 
The amount of protein in the cell cultures was determined using 
the Pierce BCA protein assay. Bicinchoninic acid (BCA) is a water-soluble 
sodium salt and a sensitive, stable and specific reagent for the copper ion 
Cu+. When samples containing protein are treated with BCA protein 
assay reagent, protein reduces Cu2+ to Cu+ in an alkaline solution, and a 
purple colored product is then formed by the interaction between two 
BCA-molecules and one copper ion (Smith et al., 1985). This product is 
water soluble and exercises strong absorbance at 570 nm. The amount of 
protein is determined by measuring absorbance on a spectrophotometer 
and comparing to standard samples made from bovine serum albumin. 
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4 SUMMARY OF PAPERS 
 
Paper 1 
Neocortical and cerebellar neurons were cultured in medium 
containing [1-13C]glucose for seven days to evaluate neuronal metabolism.  
In the cerebellar cultures consisting mainly of glutamatergic granule 
cells, a surprisingly extensive content and 13C labeling of GABA was 
seen. The intracellular amount of GABA in these cultures was 20 ± 4 
nmol/mg protein compared to 32 ± 2 nmol/mg protein in cultures of 
neocortical neurons (predominantly GABAergic). GABA labeling was similar 
in the two types of cultures.  
The cerebellar neurons contained only 6 % glutamate 
decarboxylase (GAD)-positive neurons as shown using immunolabeling 
of GAD67, whereas a dense network of neurons in the neocortical cultures 
stained positively for GAD67.  
Exposure of the cerebellar cultures to 50 µM KA, which is known to 
eliminate vesicular release of GABA, only marginally affected GABA labeling 
and cellular content and had no effect on the number of GAD67 positive 
neurons in the cerebellar cultures. However, KA exposure eliminated a 
massive punctate immunostaining observed in control cultures. It can 
be postulated that this staining represents GAD close to vesicles, and that 
this synthesis is eliminated by 50 µM KA. Increasing the KA concentration to 
0.5 mM in the culture medium for seven days led to a reduction of GABA 
labeling and content compared to cerebellar cultures not exposed to KA.  
Although it is likely that this large capacity for GABA synthesis 
resides in the relatively few GAD-positive neurons, it seems unlikely that 
they could contain the large GABA content in the cultures. Therefore it must 
be concluded that the newly synthesized GABA is redistributed among 
the majority of the cells in these cultures, i.e. the glutamatergic 
neurons. The function of GABA in these neurons is yet to be understood. 
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Paper 2 
The time course of glutamate and GABA synthesis and 
degradation in cerebellar neuronal cultures (maintained in vitro for 1-13 
days) was investigated in this study. Moreover, the enzymes involved in 
GABA synthesis in these cultures were probed pharmacologically.  
The intracellular amount of GABA increased the first five days 
before decreasing, whereas glutamate was constant until day six and 
thereafter decreased. Furthermore, GABA content in the medium 
increased with time in culture, indicating release from cells in a non-
depolarization dependent manner. Formation of labeled GABA after 
incubation with either [1-13C]glucose or [U-13C]glutamine demonstrated 
GABA synthesis during the first three days in vitro, and synthesis after one 
week was shown by labeling from [U-13C]glutamine added on day seven. 
Thus, there was a continuous GABA synthesis and degradation 
throughout the culture period in cerebellar neuronal cultures. 
Adding aminooxyacetic acid (AOAA, 10 μM), an inhibitor of 
transaminases and other pyridoxalphosphate dependent enzymes including 
GABA-T, to the culture medium caused an increase in intracellular GABA and 
a decrease in glutamate. The specific GABA-T inhibitor γ-vinyl GABA also 
increased GABA, but had no effect on glutamate content. In the presence of 
10 µM AOAA, GABA labeling from [U-13C]glutamine was not affected, ruling 
out the putrescine pathway for GABA synthesis. Increasing the AOAA 
concentration to 0.5 mM led to a decrease in GABA, presumably due to a 
partial inhibition of GAD. In order to block both GAD and the transaminases 
completely, 5 mM AOAA was used, this abolished GABA labeling. The results 
indicate that GABA synthesis in cerebellar cultures is catalyzed by 
GAD and takes place in the subpopulation of GAD positive cells. In 
the presence of 5 mM AOAA glutamate and protein content in the cultures 
was reduced, most likely through inhibition of transaminases involved in 
glutamate synthesis as well as those involved in the malate-aspartate 
shuttle resulting in impaired oxidative metabolism of glucose. 
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Paper 3 
In this study the role of the glutamate-glutamine cycle in cultures 
of cerebellar neurons was evaluated.  
Cells were incubated in medium containing [U-13C]glutamate or [U-
13C]glutamine in the presence and absence of unlabeled glutamine and 
glutamate, respectively. Both [U-13C]glutamate and [U-13C]glutamine 
were shown to be excellent precursors for synthesis of neuroactive 
amino acids and TCA cycle intermediates. Labeling from [U-13C]glutamate 
was higher than from [U-13C]glutamine in all metabolites measured. The 
presence of [U-13C]glutamate plus unlabeled glutamine in the experimental 
medium led to labeling very similar to that from [U-13C]glutamate alone. 
However, incubation in medium containing [U-13C]glutamine in the presence 
of unlabeled glutamate almost abolished labeling of metabolites. Thus, 
glutamate was the preferred substrate for intermediary metabolism in 
cerebellar neurons. It can be concluded that the cerebellar neurons rely 
more on reuptake of glutamate than supply of glutamine from 
astrocytes for glutamate homeostasis. This is not surprising when 
considering the cerebellar structure, with few astrocytes compared to 
neurons and a relatively large distance between astrocyte and synapse.   
Label distribution indicating TCA cycle activity showed more 
prominent cycling from [U-13C]glutamine than from [U-13C]glutamate, 
showing compartmentation of metabolism.  
Labeling of succinate from [U-13C]glutamate or [U-13C]glutamine 
was lower than of the other TCA cycle intermediates. This could be caused 
by the unlabeled carbon skeleton of GABA (synthesized in GAD positive 
neurons during the culture period and distributed throughout the culture) 
entering the TCA cycle in granule cells as succinate. Thus, a possible 
function of GABA in glutamatergic neurons is as a substrate for energy 
production, the results indicate an active role of the GABA shunt in these 
cultures.  
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Paper 4 
The long-term effects of the glutamate agonist kainic acid (KA) on 
glutamate and glutamine metabolism in cerebellar neurons were investigated 
in this study. Neurons were cultured in medium containing 0.05 or 0.50 mM 
KA for seven days and subsequently incubated in medium containing [U-
13C]glutamate or [U-13C]glutamine. 
The protein amount and number of cells was greatly reduced in 
cultures exposed to 0.50 mM compared to those exposed to 0.05 mM KA. 
Glutamine consumption was not affected by KA concentration, 
whereas high KA led to decreased glutamate consumption. This 
confirmed the role of KA as an inhibitor of glutamate transport reported 
earlier.  
Neurons cultured with 0.50 mM KA and incubated with [U-
13C]glutamate contained decreased amounts of glutamate, aspartate and 
GABA compared to those cultured with 0.05 mM KA. Incubation of cells 
exposed to 0.50 mM KA with [U-13C]glutamine led to an increased amount of 
glutamate compared to cells exposed to 0.05 mM KA, whereas the 
intracellular amounts of aspartate and GABA was unaffected by KA 
concentration. 
Furthermore, mitochondrial metabolism of α-[U-13C]keto-
glutarate derived from [U-13C]glutamate and [U-13C]glutamine was 
significantly reduced by 0.50 mM KA.  
Intracellular compartmentation was illustrated by the fact that 
TCA cycling of the carbon skeleton from [U-13C]glutamine was more 
pronounced than that from [U-13C]glutamate. Moreover, cycling of the carbon 
skeleton from [U-13C]glutamate subsequently used to form GABA was affected 
by KA, whereas cycling of the carbon skeleton from [U-13C]glutamine was not, 
showing compartmentation of the GABAergic cellular population. Finally, 
intercellular compartmentation was evident because the carbon skeleton 
from [U-13C]glutamate had a higher turnover in the GABAergic than in the 
glutamatergic compartment which constitute these cultures. 
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Paper 5 
In this study the pyruvate recycling pathway for complete 
oxidation of glutamate was investigated in cultures of astrocytes and 
neurons* from cerebellum. The two types of cultures were incubated in 
medium containing [U-13C]glutamate. Previous cell culture studies have 
reported pyruvate recycling taking place in astrocytes, but it has not been 
detected in neurons.  
Using mass spectrometry, the M+4 mass in glutamate and glutamine 
and M+3 in aspartate are the only isotopomer masses resulting from TCA 
cycle activity involving pyruvate recycling that can be distinguished from 
those derived from TCA cycling using unlabeled acetyl CoA. Atom percent 
excess of M+4 in glutamate was similar for astrocytes and neuron-
enriched cultures. However, the latter showed more recycling in glutamine 
(synthesized in the small fraction of astrocytes) than the pure astrocyte 
cultures, whereas the reverse was the case for aspartate. In fact, the atom 
percent excess of the isotopomer representing pyruvate recycling in 
glutamine was slightly but significantly higher than that in glutamate in the 
neuron-enriched cultures.  
In order to verify pyruvate recycling in neurons, cell extracts were 
analyzed using 13C MRS, and recycling was clearly detectable in 
glutamate and aspartate. The reason why such recycling in neurons was 
detected now, but not earlier could be the enhanced sensitivity of the cryo 
MR probe used in the present experiment.  
It can be concluded that pyruvate recycling is taking place in neurons 
as well as in astrocytes. 
 
 
 
*Because these cultures have been shown to contain a small number of astrocytes in 
addition to the neurons, they are referred to as “neuron-enriched” in this publication. It 
should be noted that they are identical to the cultures called granule cell cultures and 
cerebellar neuronal cultures in other parts of this thesis and in other publications. 
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5 DISCUSSION 
 
GABA in cerebellar neuronal cultures 
 Cell cultures are excellent model systems for the study of 
specific aspects of cellular function. Neuronal cultures have been used 
to obtain information about regional differences in the brain, and the 
neurotransmitter phenotype has been of great interest. Two types of 
neuronal cultures have been used in these studies in our laboratory; 
neocortical and cerebellar.  
 The GABAergic nature of neocortical neuronal cultures has 
been shown in various studies (Yu et al., 1984; Drejer et al., 1987; 
Belhage et al., 1993; Waagepetersen et al., 2001). Upon 
depolarization of the cell membrane, these cells release GABA in a 
Ca2+-dependent fashion. GABA labeling from 13C labeled glucose has 
been reported in cortical neuronal cultures (Sonnewald et al., 1991; 
Sonnewald et al., 1993; Waagepetersen et al., 1998). In addition to 
GABA, these cultures contain substantial amounts of glutamate, which 
is not surprising because glutamate is the direct precursor of GABA 
and also takes part in cell metabolism. 
 On the other hand, neuronal cultures prepared from 
dissociated cerebella of seven-day-old rats and mice have been shown 
to express both GABAergic and glutamatergic characteristics, due to 
the fact that they primarily consist of cerebellar glutamatergic granule 
cells with a minor contribution of GABAergic stellate and basket 
neurons (Thangnipon et al., 1983; Schousboe et al., 1989). Upon 
depolarization of the cell membrane, these cells show vesicular 
release of both glutamate and GABA (Pearce et al., 1981; Drejer et 
al., 1982; Palaiologos et al., 1988; Palaiologos et al., 1989; Belhage 
et al., 1992; Damgaard et al., 1996). Different explanations for the 
presence of GABA and GABA release in these cultures have been 
suggested.  
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One suggestion has been that GABA is synthesized and 
released by the small number of GABAergic neurons in these cultures 
(Damgaard et al., 1996). This is in concurrence with the “one neuron 
one neurotransmitter” hypothesis. The same hypothesis makes it 
difficult to accept the presence of GABA (thought to be a 
neurotransmitter only) in glutamatergic cells. However, there have 
been reports of the presence of GABA in glutamatergic neurons both 
in vivo and in vitro (Sandler and Smith, 1991; White et al., 1994; 
Schwarzer and Sperk, 1995; Lehmann et al., 1996; Jaffe and 
Figueroa, 2001; Sperk et al., 2003; Gutierrez and Heinemann, 2006). 
Jaffe and Figueroa (2001) reported GABA release from granule cells in 
the olfactory bulb, and showed that this partly was due to reversing of 
GABA transporters. Lehmann et al. (1996) showed 
immunocytochemical localization of GABA immunoreactivity in dentate 
granule cells, both in control rats and in rats, in which epilepsy had 
been induced through kindling. Sandler and Smith (1991) 
demonstrated coexistence of GABA and glutamate in mossy fiber 
terminals of the primate hippocampus, whereas White et al. (1994) 
found the same in striatal projection neurons in rats. An explanation 
for this has been that GABA is taken up from the surrounding (in vivo) 
or from serum in the medium (in vitro) by these glutamatergic 
neurons. 
Stating that GABA is present in neuronal cultures from the 
cerebellum, leads to the question of whether GABA is actively 
synthesized in these cultures. This was investigated in paper 1, where 
[1-13C]glucose was present in the culture medium for the entire 
incubation period (seven days). 13C MRS analyses showed an 
extensive GABA labeling from [1-13C]glucose which proves that GABA 
is actively synthesized by the cells from glucose via glycolysis and TCA 
cycle. The amount and labeling of GABA in neuronal cerebellar 
cultures were surprisingly high compared to cultures of neocortical 
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neurons, which almost entirely consist of GABAergic neurons (Hertz et 
al., 1985).  
In order to find out more about GABA synthesis in cerebellar 
neuronal cultures, GAD immunostaining was done by a collaborating 
research group. Results from this are also presented in paper 1. 
Immunostaining showed that approximately 6 % of neurons in the 
cerebellar cultures exhibit GAD-like immunostaining, and there was 
pronounced punctuate staining in the cell processes of these cells. 
This is in compliance with the earlier mentioned studies reporting a 
minor contribution of GABAergic stellate and basket neurons in these 
cultures (Thangnipon et al., 1983; Schousboe et al., 1989).    
Various studies have shown that by exposing cerebellar 
neuronal cultures to 50 µM KA, vesicular release of GABA is eliminated 
(Drejer and Schousboe, 1989; Simmons and Dutton, 1992; Damgaard 
et al., 1996). KA treatment has thus been thought to eradicate the 
GABAergic neurons and has been used in order to obtain pure 
glutamatergic granule cell cultures (Drejer and Schousboe, 1989). The 
belief that KA eliminates GABAergic neurons in the cerebellar cultures 
has been supported by the fact that GABAergic neurons in neocortical 
cultures are vulnerable to KA toxicity at low concentrations as 
assessed by measurement of lactate dehydrogenase leakage 
(Frandsen and Schousboe, 1990).  
In paper 1, addition of 50 µM KA to the cell culture medium 
essentially eliminated the punctate immunostaining most likely 
corresponding to GABA-containing vesicles, whereas the number of 
GAD67-positive cells remained unchanged. GABA labeling and cellular 
content of GABA was only marginally affected. This indicates that KA 
treatment does not eliminate the GABAergic neurons in cerebellar 
cultures, as previously believed, but rather alters the GABAergic 
neurons so that their vesicular GABA release is terminated.  
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It can be discussed whether the GABAergic neurons in 
cerebellar cultures can account for all the GABA present in these 
cultures. Calculations based on previously published data suggest that 
the 6 % GABAergic cells are not sufficient to contain all the GABA 
detected in the cell extract from these cultures (see paper 1). The 
granule cells most likely also contain a share of the detected GABA, 
the size of this share and the function of GABA in these glutamatergic 
cells is unknown. A discussion of GABA function in granule cells is 
found in papers 1 and 2. In paper 3 it was proposed that the GABA 
distributed from GABAergic to glutamatergic neurons enters the TCA 
cycle as succinate and is used for energy metabolism. This was 
suggested because a dilution of labeling was seen in succinate 
compared to the other TCA intermediates after incubation with [U-
13C]glutamate or [U-13C]glutamine. 
Another question arises when GABA synthesis in cerebellar 
neuronal cultures is established; what is the time course of GABA 
synthesis in these cultures? MRS studies have shown that short time 
incubation with [U-13C]glutamate and [1-13C]glucose leads to labeling 
of GABA in cortical neurons (Westergaard et al., 1995; 
Waagepetersen et al., 1998). Using similar incubation conditions with 
both [U-13C]glutamate and [U-13C]glucose for cerebellar neurons did 
not lead to MRS detectable labeling of GABA (Qu et al., 2000; 
Waagepetersen et al., 2000). However, using mass spectrometry, a 
more sensitive method, labeled GABA was detected in the cerebellar 
neurons after incubation with [U-13C]glutamate (Qu et al., 2000). 
Labeling of GABA from [U-13C]glutamate and [U-13C]glutamine was 
also detected by MS in papers 3, 4 and 5. In paper 1, the cultures 
were given labeled glucose not only for a short time, but for the entire 
culturing period. This led to significant GABA labeling in both 
neocortical and cerebellar cultures. Thus, it is clear that GABA is 
present, but, since labeling after short exposure is very small (Qu et 
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al., 2000), it appears that there is a much slower turnover of GABA in 
cerebellar neurons compared to cortical GABAergic neurons.  
Investigations of the time course of GABA formation and 
degradation in cerebellar neuronal cultures is presented in paper 2, in 
which cultures were extracted after 1-13 days in vitro and amounts of 
GABA and glutamate in cell extracts and media were quantified by 
HPLC. The experiments showed that the amount of GABA increased 
the first five days before decreasing. Protein increased until day four, 
whereas glutamate was constant until day six and thereafter 
decreased. The study demonstrated GABA synthesis in the cultures 
since the amount of GABA more than doubled during the first five 
days in culture. This was accompanied by an increase in the amount 
of protein. It should be noted that the number of neurons does not 
increase after the brain tissue is removed from the animals, on the 
contrary approximately 50% die (Westergaard et al., 1991). Thus, the 
increase in protein reflects cell growth and possibly differentiation. 
After day five the amount of GABA decreased slightly until the end of 
the culture period (day 13). The prominent increase of GABA during 
the first week in culture may reflect its functional importance during 
differentiation (Belhage et al., 1998; Waagepetersen et al., 1999). 
Experiments using [U-13C]glutamine and [1-13C]glucose presented in 
the same paper showed that there was a continuous GABA synthesis 
and degradation throughout the culture period in cerebellar neuronal 
cultures.  
In paper 2, pharmacological agents were used in order to 
identify the enzymes involved in GABA synthesis in the cerebellar 
neuronal cultures. The presence of the specific GABA-T inhibitor γ-
vinyl-GABA (GVG) in the medium led to an increase in intracellular 
GABA content compared to untreated cultures. This was also seen in 
cultures where aminooxyacetic acid (AOAA) was added. In low 
concentrations (10 µM), AOAA has been shown to block GABA-T, and 
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thus inhibit the conversion of GABA to succinic semialdehyde and 
subsequently succinate (Wallach, 1961; Schousboe et al., 1974). Cell 
cultures exposed to AOAA were therefore expected to have higher 
GABA concentrations than control cultures analogous to the effect of 
GVG. The experiments showed that this indeed was the case, an 
increase in GABA concentration was observed in the AOAA group 
compared to the control group. In addition, exposure of cerebellar 
neuronal cultures to 10 µM AOAA led to an increase in glutamate 
content compared to untreated control cultures. This is because this 
concentration of AOAA also inhibits other transaminases besides 
GABA-T, among them transaminases responsible for glutamate 
synthesis (Kihara and Kubo, 1989). Transaminases are also involved 
in the malate aspartate shuttle, and synthesis of glutamate has been 
shown to be dependent of the function of this shuttle in cerebellar 
neuronal cultures (Palaiologos et al., 1988). The fact that GABA was 
increased in the presence of AOAA, rules out that the putrescine 
pathway is responsible for GABA synthesis in these cultures, because 
this pathway also involves transamination (Seiler, 1980). GABA 
synthesis in these cultures is thus likely to be catalyzed by GAD. This 
was supported by using 5 mM AOAA on some cultures in paper 2, a 
concentration that blocks both GAD and transaminases completely 
(Wu and Roberts, 1974; Kihara and Kubo, 1989), and that abolished 
GABA labeling from [U-13C]glutamine completely. 
 In conclusion, the present studies have shown that GABA is 
present and is actively synthesized during the entire culture period in 
cerebellar neuronal cultures. The enzyme GAD which catalyzes the 
conversion of glutamate to GABA is most likely responsible for the 
GABA synthesis and this takes place in the ~6 % GAD positive cells in 
the cultures. GABA content and labeling from [1-13C]glucose is not 
affected by the presence of 50 µM KA in the culture medium, even 
though vesicular GABA release is eliminated by this treatment. After 
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synthesis, GABA is released to the medium in a non-depolarization 
dependent manner, and is probably taken up by the granule neurons 
constituting the majority of the neurons in these cultures. The 
function of GABA in these glutamatergic neurons still remains 
uncertain; however roles of neurotrophic and neuroprotective agent 
as well as substrate for energy production have been suggested. 
 
Compartmentation of metabolism 
The brain is a highly heterogeneous organ on various levels. 
Macroscopically this can be seen as a difference between different 
parts of the brain, as for example between the cerebrum and the 
cerebellum. Moving closer, the brain regions can be divided into gray 
and white matter, and these subdivisions can be further separated 
into the type of cellular elements constituting them; mainly neurons 
and glia. As mentioned in the introduction, there are subdivisions of 
these cell types as well. Thus, it is to be expected that brain 
metabolism is compartmentalized, and this has indeed been shown in 
several studies from the beginning of the 1960s, first by Berl, Clarke, 
Lajtha and Waelsch (for review, see Hertz, 2004). They injected 
radioactively labeled glutamate intracisternally, and observed that a 
small pool of this glutamate was rapidly used to synthesize glutamine. 
This “small compartment has been shown to be made up by glia, most 
likely predominantly or exclusively astrocytes. The neurons have been 
shown to be unable to synthesize glutamine and constitute the “large 
compartment” (Berl and Clarke, 1983; Hertz, 2004; McKenna et al., 
2006a). The main focus in studies of brain compartmentation has thus 
been on the two compartments made up by neurons and astrocytes.  
In the first study of brain compartmentation when injecting 
radioactive glutamate (Berl et al., 1961 as cited in Hertz, 2004) the 
labeling of glutamine was higher than that of the precursor glutamate. 
This was because the activity of the glutamine-forming glutamate 
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pool, into which the precursor selectively entered, was “diluted” by 
unlabeled glutamate from other pools (Hertz, 2004). The same was 
the case with other precursors (Waelsch et al., 1964; Berl and 
Frigyesi, 1969). However, glucose injections did not cause more 
labeling of product (glutamine) than precursor (glutamate), 
suggesting that it entered both compartments equally well (Hertz, 
2004). A few years later, van den Berg and Garfinkel (1971) did 
simulation studies of metabolite flow and inter-compartmental 
trafficking of compounds. GABA was shown to be formed in one 
compartment and predominantly degraded in another, thus there was 
a flow of GABA between compartments. This was balanced by a 
glutamine flow going in the other direction (van den Berg and 
Garfinkel, 1971). An analogous glutamate-glutamine cycle was 
suggested by Benjamin and Quastel (1975). 
In all the papers in this thesis, evidence of compartmentation 
of metabolism has been seen. This may seem surprising since cell 
cultures consisting of predominantly one cell type have been used. 
However, the cerebellar neuronal culture model system has been 
shown to be well suited for studying metabolic compartmentation. 
Firstly because of the resemblance to the in vivo situation both in 
respect to glutamate and glutamine metabolizing enzymes (Drejer et 
al., 1985). Secondly, the cultures show similarities to the in vivo 
situation due to expression of both GABAergic as well as glutamatergic 
characteristics (Pearce et al., 1981; Hertz et al., 1985; Hertz and 
Schousboe, 1987; Drejer and Schousboe, 1989; Kovacs et al., 2003). 
The glutamatergic granule cells dominate quantitatively in the 
cultures, just as in the cerebellum in vivo (Drejer and Schousboe, 
1989; Andersen et al., 1992). In addition, the cultures contain about 
6 % GABAergic stellate and basket neurons, and a small number of 
glial cells (Messer, 1977; Drejer et al., 1985; Damgaard et al., 1996, 
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paper 1). Thus, cellular compartmentation of metabolism can readily 
be studied in these cultures.  
In paper 1, cerebellar neurons were cultured in medium 
containing [1-13C]glucose. From the first turn in the TCA cycle, [4-
13C]glutamate and [2-13C]GABA can be formed as shown in Figure 3.6. 
In calculating the cycling ratio of the two amino acids, the ratio of the 
product GABA was higher than that of glutamate (results not shown in 
the paper). This is a classical example of compartmentation analogous 
to that seen by (Berl et al., 1961). The same type of 
compartmentation was seen in paper 5 by the atom percent excess of 
the isotopomer derived from recycling in glutamine being higher than 
that in glutamate in the neuronal cultures.  
In paper 2, it was shown that GABA synthesis in cerebellar 
neuronal cultures takes place in a compartment constituted by the 
subpopulation of GAD positive GABAergic neurons present in these 
cultures. In paper 4, a further compartmentation of the GABAergic 
compartment was reported. This was evident from the fact that 
cycling of the carbon skeleton from [U-13C]glutamate subsequently 
used to form GABA was affected by KA, whereas cycling of the carbon 
skeleton from [U-13C]glutamine was not. Since the cerebellar cultures 
consist of two types of GABAergic neurons, stellate and basket 
neurons, it is not surprising that the GABAergic compartment shows 
further compartmentation.    
The compartmentation of metabolism discussed so far has 
been due to differential metabolism in different cell types; glia and 
neurons, glutamatergic and GABAergic neurons, and also subtypes of 
GABAergic neurons. This intercellular compartmentation is partly due 
to the fact that different cell types contain different enzymes. 
Although most enzymes involved in cell metabolism are present in all 
cell types, some are cell specific. Examples are the presence of GAD in 
the GABAergic, but not the glutamatergic neurons in the cerebellar 
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cultures (paper 1) and that of GS and PC in astrocytes, but not in 
neurons (Norenberg and Martinez-Hernandez, 1979; Yu et al., 1983; 
Shank et al., 1985). The latter two enzymes enable astrocytes to 
convert glutamate to glutamine and pyruvate to OAA, whereas 
neurons are unable to make these conversions. Another metabolic 
pathway believed to be astrocyte specific is the pyruvate recycling 
pathway for complete oxidation of glutamate in the TCA cycle (Håberg 
et al., 1998; Waagepetersen et al., 2002). However, experiments 
presented in paper 5 proved this belief wrong by showing pyruvate 
recycling in cultured cerebellar neurons.   
Compartmentation has also been shown in monocultures 
consisting of one type of cells (Westergaard et al., 1995; 
Waagepetersen et al., 1998; Waagepetersen et al., 2006). This can be 
due to differential intracellular distribution of enzymes between 
cytosol and mitochondria as proposed in paper 1 to explain the 
differential effect of KA on labeling in alanine and lactate. Moreover, 
intracellular compartmentation of processes that occur exclusively in 
or on mitochondria, such as conversion of glutamine to glutamate by 
the enzyme PAG located in the inner mitochondrial membrane 
(Kvamme et al., 2000; Kvamme et al., 2001) have also been 
reported. This is called mitochondrial heterogeneity, and is 
presumably caused by differential distribution of enzymes in different 
mitochondria (McKenna et al., 2000; McKenna et al., 2006b). This 
was seen from results presented in papers 3 and 4 since TCA cycling 
of the carbon skeleton from [U-13C]glutamine was more pronounced 
than that from [U-13C]glutamate. This is in accordance with 
intracellular compartmentation previously reported in cultured cortical 
neurons, where TCA cycle metabolism of the carbon skeleton 
subsequently used in formation of GABA was higher from [U-
13C]glutamine than from [U-13C]glutamate (Westergaard et al., 1995). 
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From the minute scale of metabolic compartmentation between 
different cell types, different organelles (cytosol and mitochondria) 
inside one cell type and between different organelles (mitochondria) 
inside one individual cell, it is time to change perspective and view the 
findings in the present papers on a larger scale. As mentioned in the 
introduction, there are several obvious differences between the 
cerebrum and the cerebellum, one being the glia to neuron ratio. 
Thus, it is not surprising that this has implications for the neuron glial 
interactions resting on neuron glial compartmentation and the 
extensive exchange of metabolites between the two cell types. One of 
the most studied pathways is the glutamate-glutamine-GABA cycle 
(Berl and Clarke, 1969; van den Berg and Garfinkel, 1971; Berl and 
Clarke, 1983; for review, see Bak et al., 2006). Although the 
glutamine-GABA cycle was first to be described (van den Berg and 
Garfinkel, 1971), it has been believed to be of less importance than 
the glutamate-glutamine cycle due to the fact that a smaller part of 
the neurotransmitter released from GABAergic neurons is taken up by 
surrounding astrocytes than that released from glutamatergic neurons 
(Schousboe et al., 1977; Danbolt, 2001; Schousboe, 2003). The 
glutamate-glutamine cycle was the subject of paper 3, in which it was 
shown that glutamatergic cerebellar neurons rely more on reuptake of 
glutamate than supply of glutamine from astrocytes for glutamate 
homeostasis, and thus it can be proposed that the glutamate-
glutamine cycle is of less importance to the cerebellum than in cortex. 
This reminds us of how highly heterogeneous the brain is and that 
extrapolation of findings from one region of the brain or from one cell 
type to another should be exercised with care.  
 
Future perspectives 
The present studies have been performed using cell cultures. 
This offers a simplified system for metabolic studies. Even though the 
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enzymes involved in glutamate metabolism in these cultures have 
been shown to be similar to those in vivo (Drejer et al., 1985; Larsson 
et al., 1985), it should be taken into consideration that there still are 
many differences between the in vitro and in vivo situations. The main 
weakness is perhaps that the cultures are established using immature 
cells of mainly one type that are taken out of their structural context. 
The importance of testing findings from cell culture work by different 
methods and comparing them to in vivo studies cannot be emphasized 
enough. With this said, the detailed information about metabolic 
fluxes in the intact functioning brain obtained during the last decade 
using new technology like in vivo MRS, would not have been possible 
without the knowledge on metabolic pathways and compartmentation 
obtained using isolated cell types (Hertz, 2004). Perhaps the biggest 
challenge lies in combining the methodical tools to reach a higher 
level of knowledge. It therefore remains to be seen whether the 
findings from the present studies have implications in vivo.  
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6 CONCLUSIONS 
  
The questions addressed in the objectives section can now be 
answered:  
 
Glutamate and glutamine 
 It is known that glutamate and glutamine serve as substrates for 
intermediary metabolism in cerebellar neurons. Is there a 
substrate preference between these two amino acids? 
¾ As shown previously, both glutamate and glutamine were 
shown to be excellent precursors for intermediary metabolism 
in cerebellar neurons (papers 3 and 4), however, in paper 3 it 
was concluded that glutamate is preferred over glutamine. 
 
 Is glutamate and glutamine metabolism in cerebellar neurons 
affected by long-term exposure to KA? 
¾ In paper 1 it was shown that a KA concentration of 50 µM 
present in the culture medium of cerebellar neurons did not 
affect the glutamate metabolism in these cells. However, 
increasing the KA concentration in the medium to 0.50 mM, led 
to a decrease in intermediary metabolism of both glutamate 
and glutamine (paper 4). Thus, KA does affect glutamate and 
glutamine metabolism, at least when present in a high 
concentration (>50 µM)  
 
 The pyruvate recycling pathway has been shown to operate in 
astrocytes. Is it also active in cultured neurons from cerebellum? 
¾ Despite results from previous cell culture studies, which have 
shown pyruvate recycling in astrocytes but not in neurons, this 
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pathway was clearly present in both astrocytic and neuronal 
cultures from cerebellum in experiments presented in paper 5. 
 
GABA   
 Is GABA present in cerebellar neuronal cultures, and if so, how is 
the concentration compared to that in neocortical neuronal 
cultures?  
¾ Yes, GABA was present in both the GABAergic and 
glutamatergic neurons in cerebellar cultures (papers 1 and 2). 
In paper 1, the average content of intracellular GABA was 20 ± 
4 nmol/mg protein in cerebellar and 32 ± 2 nmol/mg protein in 
neocortical cultures. 
 
 If GABA is present in these neurons, how does it get there; is it 
taken up from serum in the medium or is it synthesized by the 
cerebellar neurons (GABAergic and/or glutamatergic)?  
¾ The GABA content in cerebellar neurons cannot be the result of 
uptake from the medium alone, because 13C MRS analyses 
presented in paper 1 showed incorporation of 13C label in GABA 
from [1-13C]glucose, i.e. GABA is actively synthesized in these 
cultures. In paper 2 it was shown that GABA is synthesized by 
the subpopulation of GAD positive neurons present in these 
cultures and distributed to the other cells in the culture. This 
was supported by findings in paper 3, suggesting an active role 
of the GABA shunt in these cultures.  
 
 If it is synthesized, what is the mechanism and time course 
throughout the culturing period for this synthesis? 
¾ GABA in cerebellar neurons is synthesized mainly by 
decarboxylation of glutamate catalyzed by GAD. It seems 
unlikely that the putrescine pathway contributes to the 
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synthesis. Experiments presented in paper 2 showed that the 
amount of GABA in cell extract of cerebellar neuronal cultures 
more than doubled during the first five days in culture. After 
day five the amount decreased slightly until the end of the 
culture period (day 13). 
 Does long-term KA exposure affect GABA synthesis in these 
cultures?  
¾ Treatment with 50 µM KA only marginally affected cellular 
content and labeling from [1-13C]glucose of GABA compared to 
untreated cerebellar neuronal cultures. However, the 
phenotype of the GAD positive neurons seems to be changed 
(paper 1). Exposure to 0.50 mM KA for seven days led to 
differential effects on GABA content in the cells depending on 
medium was changed (paper 4) or not (paper 1) and in the 
presence of glutamate or glutamine in the fresh medium 
(paper 4). In conclusion, there are indications that 50 µM KA 
present in the medium during the culture period does not 
affect metabolism of cerebellar neurons, whereas 0.50 mM has 
complex effects on GABA synthesis in these cultures.  
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Neurochemistry International 48 (2006) 572–578AbstractCultures of dissociated cerebella from 7-day-old mice were maintained in vitro for 1–13 days. GABA biosynthesis and degradation were studied
during development in culture and pharmacological agents were used to identify the enzymes involved. The amount of GABA increased, whereas
that of glutamate was unchanged during the first 5 days and both decreased thereafter. The presence of aminooxyacetic acid (AOAA, 10 mM) which
inhibits transaminases and other pyridoxal phosphate dependent enzymes including GABA-transaminase (GABA-T), in the culture medium
caused an increase in the intracellular amount of GABA and a decrease in glutamate. The GABA content was also increased following exposure to
the specific GABA-T inhibitor g-vinyl GABA. From day 6 in culture (day 4 when cultured in the presence of AOAA) GABA levels in the medium
were increased compared to that in medium from 1-day-old cultures. Synthesis of GABA during the first 3 days was demonstrated by the finding
that incubation with either [1-13C]glucose or [U-13C]glutamine led to formation of labeled GABA. Synthesis of GABA after 1 week in culture,
when the enzymatic machinery is considered to be at a more differentiated level, was shown by labeling from [U-13C]glutamine added on day 7.
Altogether the findings show continuous GABA synthesis and degradation throughout the culture period in the cerebellar neurons. At 10 mM
AOAA, GABA synthesis from [U-13C]glutamine was not affected, indicating that transaminases are not involved in GABA synthesis and thus
excluding the putrescine pathway. At a concentration of 5 mM AOAA GABA labeling was, however, abolished, showing that glutamate
decarboxylase, which is inhibited at this level of AOAA, is responsible for GABA synthesis in the cerebellar cultures. In conclusion, the present
study shows that GABA synthesis is taking place via GAD in a subpopulation of the cerebellar neurons, throughout the culture period.
# 2006 Elsevier Ltd. All rights reserved.
Keywords: Cerebellar granule neurons; GABA-transaminase; Glutamate1. Introduction
Neuronal phenotypes are classically connected to expression
of specific enzymes and other entities such as the vesicular
glutamate transporters for glutamatergic neurons (FremeauAbbreviations: AOAA, aminooxyacetic acid; DIV, days in vitro; GABA, g-
aminobutyric acid; GABA-T, GABA-transaminase; GAD, glutamate decarbox-
ylase; GVG, g-vinyl GABA; MCL, molecular carbon labeling; PAG, phosphate
activated glutaminase; TCA, tricarboxylic acid
* Corresponding author. Tel.: +47 73590492; fax: +47 73598655.
E-mail address: ursula.sonnewald@ntnu.no (U. Sonnewald).
0197-0186/$ – see front matter # 2006 Elsevier Ltd. All rights reserved.
doi:10.1016/j.neuint.2006.01.005et al., 2004). Characteristics of GABAergic neurons are GABA
transporters in vesicles and plasma membranes and glutamate
decarboxylase (GAD), the main GABA synthesizing enzyme
(Saito et al., 1974; Borden, 1996; Chaudhry et al., 1998).
GABA may also be formed via the putrescine pathway;
however, this pathway appears to be operational mostly during
early development (Seiler, 1980). Degradation of GABA takes
place via GABA-transaminase (GABA-T) and succinate
semialdehyde dehydrogenase, which are not only character-
istics of GABAergic neurons, but are ubiquitously present in
neurons and astrocytes throughout the brain (McGeer et al.,
1983).
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neurons with glutamatergic and some with GABAergic
phenotype since both glutamate and GABA are released in a
Ca2+ dependent manner upon depolarization of the cell
membranes (Pearce et al., 1981; Drejer et al., 1982, 1987;
Drejer and Schousboe, 1989). However, the neuronal character-
istics of cerebellar cultures can be influenced by exposure of the
cells to kainic acid (KA). This is reflected by the finding that
vesicular release of GABA can be essentially eliminated by
culturing the cells in the presence of 50 mM KA (Drejer and
Schousboe, 1989; Damgaard et al., 1996). In spite of this it has
been demonstrated that the ability of these cultures to synthesize
GABA is not affected by KA (Sonnewald et al., 2004).
Immunohistochemistry using a GAD67 antibody demonstrated
GAD-like immunostaining in 6% of the cell bodies and
additionally punctate fluorescence was observed in the processes
throughout the cultures grown in the absence of KA. Exposure of
the cerebellar neurons to KA (50 mM) eliminated the punctate
staining but had no effect on the GAD-like immunostaining in
cell bodies. Replacing KAwith a glutamate transport inhibitor to
induce excitotoxicity led to reduced levels of GAD and the
vesicular GABA transporter (Kovacs et al., 2003). Surprisingly,
the cellular content of GABA in 7-day-old cerebellar cultures
was similar to that observed in cultures of cortical neurons of the
same age which contain a dense layer of GAD positive neurons
(Sonnewald et al., 2004).
It is intriguing that GABA synthesis in these cerebellar
cultures after a 7-day culturing period reached a magnitude
comparable to that observed in neocortical neurons, since the
intensity of GAD67 immunofluorescence was considerably
lower in the cerebellar neurons. Little is known about the time
course of GABA synthesis in the latter cultures. Results
presented in this study describe the metabolism of GABA and
glutamate in cerebellar cultures. It has been shown that, during
the course of a week, both cerebellar and cortical neurons in
culture develop an enzymatic machinery analogous to that of
the brain in vivo (Drejer et al., 1985; Larsson et al., 1985).
Hence, most experiments were done on days 3, 5 and 7 in
culture. Cerebellar neurons were cultured in the presence of
50 mM KA and [1-13C]glucose or [U-13C]glutamine to monitor
GABA synthesis. Glutamine may serve as precursor for GABA
involving either GAD or the putrescine pathway. To probe the
involvement of GABA degrading enzymes in the maintenance
of GABA homeostasis, experiments were performed using
10 mM aminooxyacetic acid (AOAA) which inhibits GABA-T,
other transaminases and other pyridoxal phosphate dependent
enzymes or 100 mM g-vinyl GABA (GVG) to selectively
inhibit GABA-T (Schousboe et al., 1974; Lippert et al., 1977).
In order to inhibit GAD completely, a concentration of 5.0 mM
AOAA was used (Wu and Roberts, 1974).
2. Materials and methods
2.1. Materials
Plastic tissue culture dishes were purchased from Nunc A/S (Roskilde,
Denmark), fetal calf serum from Seralab Ltd. (Sussex, UK) and culture mediumfrom GIBCO BRL, Life Technologies A/S (Roskilde, Denmark). 7-day-old
mice (NMRI) were purchased from Møllegaard Breeding Center (Ejby, Den-
mark) or were obtained from the animal facility at the Department of Pharma-
cology, The Danish University of Pharmaceutical Sciences. [1-13C]Glucose and
[U-13C]glutamine (98%+ enriched) were from Cambridge Isotopes Labora-
tories (Woburn, MA, USA). KA was from Sigma Chemical Co. (St. Louis, MO,
USA) or Tocris Cookson Inc. (Ellisville, MO, USA). All other chemicals were
of the purest grade available from regular commercial sources.
2.2. Cerebellar neurons and culture conditions
All animal procedures were conducted according to national regulations.
Cerebellar cells were isolated from cerebella of 7-day-old mice (Schousboe
et al., 1989). The brain tissue was trypsinized followed by trituration in a DNase
solution containing a trypsin inhibitor from soybeans. Cells were suspended
(3  106 cells/ml) in a slightly modified Dulbecco’s minimum essential med-
ium (DMEM) containing 28 mM glucose and 0.45 mM glutamine, 50 mM KA
and 10% (v/v) fetal calf serum and seeded in poly-D-lysine coated culture dishes
or flasks. Six-well plates were used for HPLC and 25 cm2 flasks for liquid
chromatography mass spectrometry (LC–MS) analyses. In some cultures,
[1-13C]glucose (28 mM) or [U-13C]glutamine (0.45 mM) were used instead
of unlabeled substrate. Some cultures were exposed to 10 mM or 0.5 mM
AOAA or 100 mM GVG from day 0. Cytosine arabinoside (20 mM) was added
after 24–48 h to prevent astrocyte proliferation (Schousboe et al., 1989). After
the indicated number of days in vitro (DIV), medium was removed and cells
were washed with 0.9% saline and extracted with 70% (v/v) ethanol, followed
by centrifugation at 3000  g for 5 min. The supernatants were lyophilized and
stored at 20 8C. In some cases media were collected, deproteinized with
ethanol (70% (v/v) final concentration), lyophilized and stored at 20 8C.
Cellular protein in the ethanol pellets was determined after re-dissolving in 1 M
KOH at 37 8C for 30 min, using the Pierce BCA protein assay with bovine
serum albumin as standard.
2.3. Acute exposure to AOAA
In order to investigate the ability of AOAA to inhibit GAD completely,
cultures were treated with 5.0 mM AOAA which was added to the medium on
day 7 in vitro. After 30 min, half (2.5 ml) of the culture medium was removed
and 1 ml fresh serum-free DMEM was added. This medium contained pyruvate
(5.0 mM, final concentration), [U-13C]glutamine (0.5 mM, final concentration)
and AOAA (5.0 mM, final concentration). After 3 h, the cultures received 8 ml
of [U-13C]glutamine (219 mM) to the incubation media (3.5 ml) to preserve an
adequate amount of the labeled precursor in the medium and the incubation was
continued for another 3 h. Control cultures were treated identically except that
AOAA was not added. At the end of the incubation period, the medium was
removed and the cells were washed twice with ice-cold PBS prior to extraction
using 70% (v/v) ethanol. The procedures for centrifugation and protein analysis
were as described above. The cell extracts were analyzed for percent labeling
employing LC–MS.
2.4. HPLC and LC–MS analyses
Glutamate and GABA were quantified in cell extracts and in some cases
GABA was quantified in the culture media by high performance liquid
chromatography (HPLC) analysis using fluorescence detection, after pre-col-
umn derivatization with o-phthaldialdehyde (Geddes and Wood, 1984). All LC–
MS analyses were performed using a Shimadzu LCMS-2010 mass spectrometer
coupled to a Shimadzu 10AVP HPLC system. The Phenomenex EZ:faast amino
acid analysis kit for LC–MS was used for analysis of labeling in glutamate and
GABA.
2.5. Data analysis
Percent 13C (atom percent excess) was determined for M + 1 (the mass of
the parent ion (M) plus 1 unit of molecular weight (Dalton) corresponding to 1
atom of 13C), M + 2, M + 3, M + 4 plus in the case of glutamate M + 5 after
correction for natural abundant 13C as described by Biemann (1962). To obtain a
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Fig. 2. The amount (nmol/well) of glutamate (A) and GABA (B) in cell extracts
of cerebellar neurons. The cells were seeded in 6-well plates and maintained in
medium containing KA (50 mM) in the presence or absence of AOAA (10 mM)
for 13 days as described in Section 2. Results are means  S.D. of 3–6 samples.
Filled squares represent the control cells, and open squares the AOAA treated
cultures. Statistically significant differences between the different days in vitro
(controls) were analyzed using ANOVA followed by the LSD (least significant
difference) post hoc test, and p < 0.05 was considered significant. For the
development in culture of glutamate contents values for DIV 7–13 were
significantly reduced compared to DIV 1–6, and for GABA DIV 3–6 were
significantly higher than DIV 1 and DIV 7–13 significantly lower than DIV 6.
No difference for GABAwas found between DIV 5 and 6. Likewise, differences
between control cultures and AOAA treated cells were assessed using the same
procedure and statistically significant differences ( p < 0.05) are indicated by
asterisks.measure of total incorporation of 13C label, the average percent of labeled
carbon atoms for each metabolite was calculated, i.e. percent molecular carbon
labeling (MCL, for further details see Bak et al. (2006)). The [U-13C] labeling
(percent of total amount) of GABA and glutamate is the atom percent excess for
M + 4 and M + 5, respectively, following subtraction of natural abundances. All
results are presented as means  S.D. Differences between cultures of different
developmental stages or exposed to various pharmacological agents were
analyzed statistically with one-way ANOVA followed by the LSD (least
significant difference) post hoc test for multiple comparison or Student’s t-test
for two groups, and p < 0.05 was considered statistically significant.
3. Results
As a measure of cell growth the amount of protein in the
cultures was shown to almost double over a period of 4 days in
vitro and this level was maintained until day 13 (Fig. 1).
Treatment of the cultures with AOAA (10 mM) had no effect on
the protein content (Fig. 1).
The developmental patterns of the amounts (nmol/well) of
glutamate and GABA in the cerebellar neurons maintained in
the presence or absence of 10 mM AOAA during the culture
period (13 days) are shown in Fig. 2A and B. The amount of
glutamate was constant until day 6 in culture after which it was
decreasing with time until day 10 in culture. In the presence of
AOAA the amount of glutamate was lower than that of age
matched untreated cultures from days 4 to 9. The amount of
GABA more than doubled till day 5 and decreased
subsequently to a level similar to that at the beginning of the
culture period. In the presence of AOAA the GABA levels were
significantly increased compared to the age matched untreated
cultures from day 4 and throughout the culture period.
Fig. 3 shows the amount of protein (mg/well, A) and the
GABA (B) and glutamate (C) contents (nmol/mg protein) in
cerebellar neurons cultured for 3, 5 and 7 days. Culturing the cells
in medium containing GVG (100 mM) had no effect on the
protein content, whereas that of glutamate was slightly higher on
day 5 and lower on day 7 compared to the age matched untreated
cultures. The GABA content was increased in the presence of
GVG at days 5 and 7 in culture compared to age matched
untreated cultures. Culturing in the presence of 0.5 mM AOAAFig. 1. The amount of protein (mg/well) in cerebellar neurons. The cells were
seeded in 6-well plates and maintained in medium containing KA (50 mM) in
the presence or absence of AOAA (10 mM) for 13 days as described in Section
2. Results are means  S.D. of 3–6 samples. Filled squares represent the control
cells, and open squares the AOAA treated cultures. Differences between days 1
or 2 and subsequent days in vitro were analyzed using ANOVA followed by the
LSD (least significant difference) post hoc test, and p < 0.05 was considered
statistically significant. Protein at DIV 3–13 was statistically significantly
different from DIV 1 and 2 regardless of the presence of AOAA.led to decreased amounts of protein and glutamate at all days
investigated and the GABA content was decreased on days 3 and
5 compared to age matched untreated cells.
Fig. 4 shows the GABA concentration (nmol/ml) in media
from neurons cultured in the absence or presence of 10 mM
AOAA for 1, 4 and 6 days. For comparison the GABA
concentration in medium (without cells) kept in the incubator
for 3 and 6 days was determined and the average value is shown
in Fig. 4. It is necessary to determine the GABA concentration
in medium without cells since fetal calf serum contains GABA
and also to evaluate the effect of incubation at 37 8C for several
days. The concentration of GABA in the medium of cells
maintained for 1 and 4 DIV was the same as that in medium
without cells. At 6 DIV the GABA concentration in the medium
was higher than that at 1 and 4 DIV. In the presence of AOAA
the GABA concentration was increased already on day 4
compared to medium from AOAA treated cultures on day 1 and
it was increased further on day 6 reaching a level significantly
higher than that of the age matched untreated cultures.
The MCL (see Section 2) of GABA and glutamate in
cerebellar neurons cultured in media containing either
[1-13C]glucose or [U-13C]glutamine is presented in Table 1.
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Fig. 3. The amount (mg/well) of protein (A), and contents (nmol/mg protein) of
GABA (B) and glutamate (C) in cerebellar neurons cultured in 6-well plates.
Cells were cultured in medium containing KA (50 mM) in the presence or
absence of GVG (100 mM) or AOAA (0.5 mM) as described in Section 2.
Results are means  S.D. of 3–8 samples. Filled bars represent control cells.
Open and hatched bars represent GVG and AOAA treated cultures, respectively.
Statistically significant differences between treated and untreated (control)
cultures as well as between cells cultured for different number of days were
analyzed using ANOVA followed by the LSD (least significant difference) post
hoc test, and p < 0.05 was considered significant. (a) Significantly different
from the untreated cells on the same day, (*) significantly different from the
corresponding cultures on day 3, and (#) significantly different from the
corresponding cultures on day 5.
Fig. 4. The concentration (nmol/ml) of GABA in medium from cerebellar
neurons cultured in 6-well plates and maintained in medium (2 ml) containing
KA (50 mM) in the presence or absence of AOAA (10 mM). Results are corrected
for evaporation and are expressed as means  S.D. of 3–5 samples. Filled bars
represent untreated cultures (control) and open bars AOAA treated cultures. The
hatched bar represents the average of the GABA concentration in media kept in the
incubator for 3 or 6 days. It was possible to use the average since no difference was
found comparing media kept for 3 and 6 days. Statistically significant differences
between AOAA treated and not-treated (control) cultures as well as between cells
cultured for different number of days were analyzed using ANOVA followed by
the LSD (least significant difference) post hoc test, and p < 0.05 was considered
significant. (*) Significantly different from the corresponding cultures at 1 DIV,
(#) significantly different from the corresponding cultures at 4 DIV, (¤) signifi-
cantly different from medium without cells, and (a) significantly different from
control cultures at the same DIV.
Table 1
The MCL (%) of GABA and glutamate from [1-13C]glucose and [U-13C]glu-
tamine in cerebellar neurons cultured for 3 and 7 DIV
Amino acid MCL (%)
[1-13C]Glucose [U-13C]Glutamine
GABA
3 Days
AOAA 19.7  0.2a 12.1  0.4
Control 23.6  0.8 10.9  1.3
7 Days
AOAA 26.1  0.3a,b 4.2  0.2a,b
Control 28.8  0.2b 1.3  0.3b
Glutamate
3 Days
AOAA 23.2  0.1c 7.0  1.3c
Control 23.1  0.8 5.7  1.8c
7 Days
AOAA 28.3  0.4b,c 0.8  0.3b,c
Control 27.9  0.1b,c 1.1  0.5b
Cerebellar neurons were cultured in 25 cm2 flasks in media containing KA
(50 mM) in the presence or absence of AOAA (10 mM) using [1-13C]glucose or
[U-13C]glutamine as described in Section 2. The average labeling of molecular
carbon (MCL) in percent (see Section 2) of GABA and glutamate is
shown  S.D. of four cultures. Statistically significant differences between
experimental conditions and culture ages were analyzed using ANOVA fol-
lowed by the LSD (least significant difference) post hoc test, and p < 0.05 was
considered statistically significant.
a Significantly different from the corresponding control cultures.
b Significantly different from similarly treated cultures at 3 DIV.
c Significantly different from the percent 13C labeling in GABA in cultures
treated identically.When [1-13C]glucose was present in the medium, the MCL of
GABA was increased at 7 compared to 3 DIV, regardless of the
presence of 10 mM AOAA. MCL of GABAwas lower in AOAA
treated compared to untreated cultures kept for 3 or 7 DIV. No
differences were observed in the MCL of glutamate from
[1-13C]glucose between AOAA treated and untreated cultures
maintained for 3 or 7 DIV. However, an increase in the MCL of
glutamate was observed in cerebellar neurons cultured for 7 days
compared to 3 days. Following 3 days in culture in medium
containing [1-13C]glucose and AOAA the MCL of glutamate was
higher than that of GABA whereas in the untreated cultures no
difference was observed. After 7 days in culture in medium
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Fig. 5. The [U-13C] labeling (percent of total amount) of GABA and glutamate
in cerebellar neurons (7 DIV) incubated in medium containing [U-13C]gluta-
mine in the presence or absence of AOAA (5.0 mM) as detailed in Section 2.
Results are means  S.D. of 4 to 5 samples. Filled bars represent the untreated
and open bars the AOAA treated cells. Statistically significant differences
between these were analyzed using the unpaired two tailed Student’s t-test, and
p < 0.05 was considered statistically significant. (a) Significantly different from
the corresponding AOAA treated cultures, (b) significantly different from
[U-13C]GABA in cultures maintained under similar conditions, and n.d. means
not detectable.containing [1-13C]glucose the MCL of glutamate was slightly
higher in AOAA treated than that observed for GABA and the
opposite relationship was observed in untreated cultures. When
[U-13C]glutamine was present in the medium from the beginning
of the culture period, the MCL of both GABA and glutamate was
decreased in cells cultured for 7 compared to 3 DIV. The MCL of
GABA was higher than that of glutamate regardless of the
experimental conditions, except at day 7 in cultures not exposed
to AOAA. Furthermore, the MCL of GABAwas increased in the
AOAA treated cells in 7-day-old cultures but unchanged in 3-
day-old cultures. This is in contrast to cells cultured in the
presence of [1-13C]glucose, in which label was decreased in the
presence of AOAA both at 3 and 7 DIV. However, as shown in
Fig. 5, when AOAA (5 mM) was added to the medium on day 7,
conversion of [U-13C]glutamine to [U-13C]glutamate took place
whereas no [U-13C]GABA was detected. In these cultures
pyruvate was added to the culture medium together with
[U-13C]glutamine to ensure TCA cycle metabolism and cell
survival in the presence of AOAA which prevents a continuous
oxidation of glucose due to the inhibition of the malate aspartate
shuttle (McKenna et al., 2006). Cell viability was checked by
microscopic inspection of the cultures and cell morphology was
not affected by the AOAA treatment (results not shown).
4. Discussion
The present study demonstrates GABA synthesis via GAD
in cerebellar neurons throughout the first week in culture. The
cellular content of GABA in the cerebellar neurons more than
doubled during the first 5 days in culture, whereas that of
glutamate remained unchanged. This was accompanied by an
increase in the amount of protein. It should be noted that the
number of neurons does not increase after the brain tissue isremoved from the animals and subsequently seeded in the
culture dishes. Actually, approximately 50% of the seeded cells
die (Westergaard et al., 1991). Thus, the increase in protein
reflects cell growth and possibly differentiation. The enzymatic
machinery of cerebellar neurons after 1 week in culture is
comparable to that observed in the brain in vivo (Drejer et al.,
1985). After day 5 in culture the amount of GABA and
glutamate inside the cells decreased slightly until the end of the
culture period (day 13). However, GABA content in the
medium increased with time. This indicates that GABA is
released from the cerebellar cells in a non-depolarization
dependent manner, presumably via reversal of transporters and
may reflect its functional importance during differentiation
(Belhage et al., 1985; Waagepetersen et al., 1999). Further-
more, GABA release is a prerequisite for its neurotrophic action
and may also play a role in neuroprotection.
Synthesis of GABA during the first 3 days was demonstrated
by the finding that incubation with either [1-13C]glucose or
[U-13C]glutamine led to formation of labeled GABA. It may be
conceivable that GABA synthesis could be especially prominent
during the first few days in culture since it has been reported that
in hippocampus, GAD67 is expressed in the mossy fibers of the
developing rat brain, whereas in adults, GAD67 was no longer
detectable, unless seizures were induced (Maqueda et al., 2003).
To investigate the possibility that GABA synthesis is not only
taking place during the early phase of the culturing period but
continues also during later stages, [U-13C]glutamine was added
on day 7 in culture and both GABA and glutamate labeling was
pronounced. Furthermore, when [1-13C]glucose was present in
the culture medium for 3 and 7 days, labeling on day 7 was clearly
higher than on day 3. Labeling from [U-13C]glutamine under the
same conditions was less pronounced than that from glucose,
which may reflect that the amount of [U-13C]glutamine available
in the medium was insufficient to sustain neuronal metabolism
for 7 days. That this may be the case is supported by the finding
that when [U-13C]glutamine was added on day 7, GABA labeling
was much higher.
To investigate the enzymatic pathways responsible for
GABA synthesis and degradation, enzyme inhibitors were
added to the culture medium. The enzyme responsible for
degradation of GABA, GABA-T, is inhibited by GVG (Lippert
et al., 1977). As expected (Gram et al., 1988), GVG at a
concentration of 100 mM increased the GABA content of the
cultures. GVG had no effect on the protein content which may
indicate that the GABA concentration even in the absence of
GVG was adequate for maintenance of normal neuronal
growth. This is supported by the finding that GABA at 50 mM, a
value comparable to that observed in the present study, acts as a
trophic factor in the development of cerebellar neuronal
cultures (Hansen et al., 1984). The transaminase inhibitor
AOAA was used at 10 mM, a concentration sufficient to inhibit
mainly GABA-T (Schousboe et al., 1974) but also other
transaminases (Kihara and Kubo, 1989). As expected, the
amount of GABA increased with time even more than in the
absence of AOAA whereas the glutamate concentration
decreased compared to that in untreated cells. The latter
finding may be compatible with the previous demonstration that
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neurons in these cultures is dependent upon the function of the
malate aspartate shuttle which involves transamination
(Palaiologos et al., 1988). Glutamate formed via transamination
seems to be important for GABA labeling from [1-13C]glucose
(for pathway see Brenner et al. (2005)) since such labeling was
decreased in the presence of 10 mM of AOAA. Conversion of
a-ketoglutarate to glutamate is mostly achieved by transamina-
tion, which will be blocked by AOAA. However, glutamate
dehydrogenase is also present in the cerebellar neurons
(Zaganas et al., 2001) and can convert a-ketoglutarate to
glutamate. The efficiency of this process is evident from the
unchanged glutamate labeling in the presence of 10 mM
AOAA. This, together with a decreased GABA labeling, points
towards compartmentation of glutamate metabolism, indicating
GABA synthesis in a different cellular compartment from
where the majority of glutamate synthesis is taking place.
There are two known pathways for conversion of glutamine
to GABA. One is called the putrescine pathway (Seiler, 1980)
which involves transamination and the other conversion of
glutamine to glutamate and subsequent decarboxylation to
GABA which is referred to as the GAD pathway. Labeling of
GABA from [U-13C]glutamine was not affected by 10 mM
AOAA, indicating that transamination is not involved in the
process. Thus, it appears likely that the GAD pathway is
responsible for GABA synthesis from glutamine in the
cerebellar cultures. This, together with the fact that metabolism
of glutamate and GABA seems compartmentalized as
mentioned above, indicates that GABA synthesis takes place
in the 6% GAD positive cells observed by Sonnewald et al.
(2004).
An increase in the AOAA concentration from 10 mM to
0.5 mM led to a pronounced decrease in the GABA and
glutamate content as well as the amount of protein at 3 and 5
DIV. As mentioned above, in the presence of the transaminase
blocker, the decrease in glutamate content was expected. The
large decrease in GABA may to a certain extent be explained by
partial inhibition of GAD in the presence of 0.5 mM AOAA
(Wu and Roberts, 1974) and the decrease in protein content
may to some extent reflect the decrease in the availability of the
neurotrophic agent GABA. However, it is conceivable that an
impaired oxidative metabolism of glucose played a prominent
role in the large decrease of the protein content since this
metabolism is dependent upon the malate aspartate shuttle
which was inhibited by 0.5 mM AOAA (Kauppinen et al.,
1987). An impaired glucose metabolism will affect neurons and
therefore it may indirectly contribute to the decrease in
glutamate as well as GABA contents. Interestingly, on day 7 in
culture, the GABA content was not different from that of age
matched untreated cells, whereas glutamate and the protein
content were lower.
To obtain further information about GABA synthesis,
AOAA was used at a concentration of 5 mM, which is expected
to block both GAD and transaminases completely (Wu and
Roberts, 1974; Kihara and Kubo, 1989). Indeed, GABA
labeling from [U-13C]glutamine was totally abolished even
though glutamate was extensively labeled.In conclusion, the present results show that GABA synthesis
is taking place via GAD in a subpopulation of the cerebellar
neurons, throughout the culture period. Labeling of GABA
occurs from both [1-13C]glucose and [U-13C]glutamine and can
be blocked by AOAA. Moreover, it is confirmed that net
synthesis of glutamate is dependent on the activity of the malate
aspartate shuttle.
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The glutamate–glutamine cycle is thought to be of paramount importance in the mature brain;
however, its significance is likely to vary with regional differences in distance between astrocyte and
synapse. The present study is aimed at evaluating the role of this cycle in cultures of cerebellar
neurons, mainly consisting of glutamatergic granule cells. Cells were incubated in medium
containing [U-13C]glutamate or [U-13C]glutamine in the presence and absence of unlabeled
glutamine and glutamate, respectively. Cell extracts and media were analyzed using high-
performance liquid chromatography (HPLC) and gas chromatography combined with mass
spectrometry (GC/MS). Both [U-13C]glutamate and [U-13C]glutamine were shown to be excellent
precursors for synthesis of neuroactive amino acids and tricarboxylic acid (TCA) cycle
intermediates. Labeling from [U-13C]glutamate was higher than that from [U-13C]glutamine in all
metabolites measured. The presence of [U-13C]glutamate plus unlabeled glutamine in the
experimental medium led to labeling very similar to that from [U-13C]glutamate alone. However,
incubation in medium containing [U-13C]glutamine in the presence of unlabeled glutamate almost
abolished labeling of metabolites. Thus, it could be shown that glutamate is the preferred substrate
for intermediary metabolism in cerebellar neurons. Label distribution indicating TCA cycle activity
showed more prominent cycling from [U-13C]glutamine than from [U-13C]glutamate. Labeling of
succinate was lower than that of the other TCA cycle intermediates, indicating an active role of the
c-amino butyric acid shunt in these cultures. It can be concluded that the cerebellar neurons rely
more on reuptake of glutamate than supply of glutamine from astrocytes for glutamate homeostasis.
Journal of Cerebral Blood Flow & Metabolism advance online publication, 11 October 2006; doi:10.1038/sj.jcbfm.9600400
Keywords: 13C labeling; GABA; glutamate–glutamine cycle; glutamatergic neurons; mass spectrometry;
tricarboxylic acid cycle
Introduction
Glutamate is a multipurpose amino acid in the
mature central nervous system. It is not only the
major excitatory neurotransmitter, in addition it
takes part in transamination and thus nitrogen
homeostasis and is the precursor for other important
molecules, including the main inhibitory neuro-
transmitter, g-amino butyric acid (GABA). Although
glutamate is ubiquitous in all parts of the central
nervous system and present in large amounts in the
brain, it is of critical importance that brain gluta-
mate homeostasis is strictly controlled. The extra-
cellular concentration of glutamate needs to be kept
low, both to increase the signal-to-noise ratio in
binding of transmitter substance in the synaptic cleft
and to prevent excitotoxicity caused by excessive
excitation of glutamate receptors and subsequent
cell injury or death (for references, see Daikhin and
Yudkoff, 2000). Rapid transport of glutamate from
the synaptic cleft is performed through several types
of specific transporter proteins, and uptake into
astrocytes surrounding the synapse is believed to be
more important than reuptake into the presynaptic
neuron (Schousboe et al, 1977; Danbolt, 2001). Thus
neurons experience a net loss of glutamate, which
must be replenished by astrocytes because of the
lack of the anaplerotic enzyme pyruvate carboxylase
in neurons (Shank et al, 1985). This constitutes the
basis for the pathway known as the glutamate–
glutamine cycle (Berl and Clarke, 1983) in which
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neurotransmitter released from neurons is taken up
by surrounding astrocytes, where it is converted to
glutamine by the glial-specific enzyme glutamine
synthetase (Norenberg and Martinez-Hernandez,
1979). Glutamine is not neuroactive and can move
in the extracellular space without interfering with
receptors, and is the most abundant amino acid in
blood and cerebral spinal fluid with a concentration
ofB0.5 mmol/L (Grill et al, 1992; White et al, 2004).
Glutamine uptake into neurons is mediated by
different general amino-acid transporters (Su et al,
1997; Dolinska et al, 2004). In neurons, glutamine
can be converted into glutamate by the enzyme
phosphate activated glutaminase and act as pre-
cursor for restoring the neurotransmitter pool,
completing the glutamate–glutamine cycle. Indeed,
several studies have confirmed the importance of
glutamine as precursor for neurotransmitter gluta-
mate (for a review, see Peng et al, 1993). As
described, the cycle necessitates extensive inter-
action between neurons and astrocytes. This will,
however, vary because of differences in the number
of glial cells per neuron and also in respect to
how closely the astrocytes envelop the synapses.
Thus, it can be expected that the importance of the
glutamate–glutamine cycle varies with location in
the brain.
The present study is aimed at evaluating the role
of the glutamate–glutamine cycle in cultured cere-
bellar neurons. It has been shown that after 7 days in
vitro, these mainly glutamatergic cultures express
glutamate and glutamine metabolizing enzymes
analogous to the brain in vivo (Drejer et al, 1985).
The cells were incubated in medium containing
[U-13C]glutamate or [U-13C]glutamine in the pre-
sence and absence of unlabeled glutamine and
glutamate, respectively. High-performance liquid
chromatography (HPLC) and gas chromatography/
mass spectrometry (GC/MS) analysis of cell extracts
and media revealed that both [U-13C]glutamate and
[U-13C]glutamine were excellent precursors for
synthesis of neuroactive amino acids and tricar-
boxylic acid (TCA) cycle intermediates in these
cultures. However, glutamate was shown to be the
preferred substrate.
Materials and methods
Materials
NMRI mice were obtained from Taconic M&B (Copenha-
gen, Denmark). Plastic tissue culture dishes were pur-
chased from Nunc A/S (Roskilde, Denmark) and fetal calf
serum from Seralab Ltd. (Sussex, UK). Culture medium,
glutamate receptor antagonists DNQX (6,7-dinitroquinoxa-
line-2,3-dione) and D-AP5 (D-2-amino-5-phosphonopenta-
noic acid) were from Sigma Chemical Co. (St Louis, MO,
USA). [U-13C]Glutamate and [U-13C]glutamine were
from Cambridge Isotope Laboratories (Woburn, MA,
USA), and the GC/MS derivatization reagent MTBSTFA
(N-methyl-N-(tert-butyldimethylsilyl)trifluoroacetamide)+ 1%
t-BDMS-Cl (tert-butyldimethylchlorosilane) was purchased
from Regis Technologies, Inc. (Morton Grove, IL, USA).
All other chemicals were of the purest grade available
from regular commercial sources.
Cell Cultures
Cerebellar neurons were isolated and cultured from 7-day-
old mice as described by Schousboe et al (1989). Briefly,
tissue was trypsinized followed by trituration in a DNase
solution containing a trypsin inhibitor from soybeans.
Cells were suspended (2.5 106 cells/ml) in a modified
Dulbecco’s minimum essential medium containing
24.5 mmol/L KCl, 31 mmol/L glucose, 7 mmol/L p-amino-
benzoic acid, 0.05 mmol/L kainic acid, and 10% (v/v) fetal
calf serum, and seeded in poly-D-lysine coated Petri
dishes (2 ml/35 mm). After 48 h in culture, 20 mmol/L
(final concentration) cytosine arabinoside was added to
the medium to prevent astrocytic proliferation.
Experiments Using [U-13C]Glutamate and
[U-13C]Glutamine for Gas Chromatography/Mass
Spectrometry Analysis
The culture medium was removed from 7-day-old cultures
and the cells were incubated for 2 h at 371C in 2 ml serum-
free experimental medium (prepared without glutamine)
containing 3 mmol/L glucose and either no additions (for
HPLC analysis), [U-13C]glutamate (0.25 mmol/L), [U-13C]
glutamine (0.50 mmol/L), [U-13C]glutamate (0.25 mmol/L)
plus unlabelled glutamine (0.50 mmol/L) or [U-13C]
glutamine (0.50 mmol/L) plus unlabelled glutamate
(0.25 mmol/L). To avoid toxic effects of glutamate during
the incubation period, two glutamate receptor antagonists
DNQX (25 mmol/L), a selective antagonist at the a-amino-3-
hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) and
kainate receptor subtypes, and D-AP5 (100 mmol/L), an N-
methyl-D-aspartate (NMDA) antagonist, were also present
in the experimental medium (Frandsen et al, 1989). After
2 h, the experimental medium was collected and the cells
were washed twice with cold phosphate-buffered saline
and extracted with 70% (v/v) ethanol. The cell extracts
were scraped off the dishes and centrifuged at 10,000g for
15 min to separate the metabolites from the insoluble
proteins. The supernatants (cell extracts) were divided
into two parts, one directly analyzed with HPLC and the
other lyophilized for subsequent sample preparation for
GC/MS analysis. Cellular protein in the ethanol pellets
was determined after dissolving in 1 mol/L KOH at 371C
for 60 mins, using the Pierce BCA (Pierce, Rockford, IL,
USA) protein assay with bovine serum albumin as
standard.
High-Performance Liquid Chromatography
Amino acids in cell extracts and experimental media
were quantified by HPLC on a Hewlett Packard 1100
system (Agilent Technologies, Palo Alto, CA, USA).
The amino acids were precolumn derivatized with
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o-phthaldialdehyde (Geddes and Wood, 1984) and subse-
quently separated on a ZORBAX SB-C18 (4.6 250 mm,
5 mm) column from Agilent using a phosphate buffer
(50 mmol/L, pH = 5.9) and a solution of methanol (98.75%)
and tetrahydrofuran (1.25%) as eluents. The separated
amino acids were detected with fluorescence and com-
pared with a standard curve derived from standard
solutions of amino acids run after every 12 samples.
Gas Chromatography/Mass Spectrometry
Lyophilized cell extracts were redissolved in HCL
(10 mmol/L), adjusted to pH < 2 with 6 mol/L HCL, and
dried under atmospheric air. The amino acids were
extracted into an organic phase of ethanol and benzene
and dried again under atmospheric air before derivatiza-
tion with MTBSTFA in the presence of 1% t-BDMS-Cl
(Mawhinney et al, 1986). The samples were analyzed on a
Hewlett Packard 5890 Series II gas chromatograph linked
to a Hewlett Packard 5972 Series mass spectrometer.
Data Analysis
Peaks from MS spectra were integrated, and atom percent
excess (13C) of glutamate, glutamine, GABA, succinate,
malate, aspartate, and citrate was determined after
calibration using unlabeled standard solutions (Biemann,
1962). Results from HPLC quantification of amino acids in
cell extracts were combined with values of atom percent
excess obtained from GC/MS to give nmol/mg protein of
different 13C labeled isotopomers of glutamate, aspartate,
and GABA. Consumption of [U-13C]glutamate and
[U-13C]glutamine was calculated by subtracting the re-
maining amounts of the two amino acids measured in the
experimental medium from the amounts added followed
by correction for the amount of cellular protein in the
culture. Results are presented as means7s.d. Differences
between groups were analyzed statistically using one-way
analysis of variance followed by the least significant
difference post hoc test, and P < 0.05 was considered
statistically significant.
Results
Cerebellar neurons were incubated in medium with
different additions: no addition (control group),
[U-13C]glutamate, [U-13C]glutamine, [U-13C]gluta-
mate plus glutamine, and [U-13C]glutamine plus
glutamate (see Materials and methods). Since HPLC
analysis does not distinguish between isotopomers,
the latter two groups were combined in Table 1,
which shows the cellular content of selected amino
acids in cerebellar neurons and the consumption of
glutamate and glutamine. Compared with control,
adding glutamate to the experimental medium led to
increased intracellular levels of aspartate, gluta-
mate, glutamine, and GABA. Cultures incubated
with glutamine contained increased levels of GABA
corresponding to the increase seen when glutamate
was added. Aspartate and glutamate also increased
as a response to glutamine addition, but not to the
same extent as when glutamate was added. As
expected, intracellular glutamine concentration also
increased when glutamine was added to the med-
ium. When both glutamate and glutamine were
added to the experimental medium, aspartate,
glutamate, and glutamine levels were increased
more than when the two amino acids were added
individually, whereas GABA content was increased
to the same extent as when glutamate and glutamine
were added alone. Quantification of glutamate and
glutamine in the experimental media showed that
glutamate consumption was much higher than
glutamine consumption despite the medium con-
centration of glutamine being twice that of gluta-
mate. Glutamate consumption was unaffected by the
presence of glutamine, whereas the consumption of
glutamine was reduced by nearly 50% when
glutamate was added to the medium.
[U-13C]Glutamate or [U-13C]glutamine from the
experimental medium enters neurons through spe-
cific transporter proteins. Once inside the cells,
[U-13C]glutamine can be converted to [U-13C]gluta-
mate, which can be decarboxylated to uniformly
labeled GABA in GABAergic neurons, or in all cells,
Table 1 Cellular content of selected amino acids (nmol/mg protein) in extracts of cultured cerebellar neurons and consumption of
glutamate and glutamine (mmol/mg protein/2 h) from the experimental medium
Cellular content (nmol/mg protein) Consumption (mmol/mg protein/2 h)
Aspartate Glutamate Glutamine GABA Glutamate Glutamine
Ctr 3171 8873 371 871 — —
Glu 231712a 445716a 2072a 1171a 1.570.1 —
Gln 7676a,b 134710a,b 5776a,b 1072a — 0.770.1
Glu+Gln 278720a,b,c 529731a,b,c 8475a,b,c 1171a 1.670.1 0.470.1c
Cerebellar neurons were incubated for 2 h in medium containing 3 mmol/L glucose, 25 mmol/L DNQX, and 100 mmol/L D-AP5 and either no addition (Ctr
(control), n = 3), 0.25 mmol/L glutamate (Glu, n = 6), 0.50 mmol/L glutamine (Gln, n = 6), or 0.25 mmol/L glutamate plus 0.50 mmol/L glutamine (Glu+Gln,
n = 12), for details see Materials and methods. Results are presented as means7s.d., and P < 0.05 was considered statistically significant.
aDifferent from the Ctr group.
bDifferent from the Glu group.
cDifferent from the Gln group.
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be turned into a-[U-13C]ketoglutarate and be meta-
bolized in the TCA cycle for energy production and
metabolite synthesis. The 13C label from the pre-
cursor’s carbon skeleton will in the latter case be
distributed among the TCA cycle metabolites and
GABA as illustrated in Figure 1.
The labeling of glutamate, GABA, succinate,
malate, aspartate, and citrate as detected by GC/MS
is presented in Figure 2 as atom percent excess (%
labeling). When [U-13C]glutamate is turned into
a-[U-13C]ketoglutarate and enters the TCA cycle,
[1,2,3-13C]glutamate (M + 3) is formed after one turn.
This isotopomer results from condensation of
uniformly labeled oxaloacetate (OAA) with un-
labeled acetyl-CoA forming [3,4,5,6-13C]citrate
(Figure 1), which can be turned into [1,2,3,6-13C]iso-
citrate, a-[1,2,3-13C]ketoglutarate and finally into
[1,2,3-13C]glutamate. After another turn in the TCA
cycle, half of the glutamate formed will be
[1,2-13C]glutamate (M + 2) and half [3-13C]glutamate
(M + 1). After a third turn, 25% of glutamate will be
unlabeled, whereas 75% will be labeled either in the
1, 2, or 3 position (M + 1) (Figure 1).
From [U-13C]glutamate entering the TCA cycle via
a-[U-13C]ketoglutarate, uniformly labeled succinate,
malate, and OAA are formed (Figure 1), and OAA
can be transaminated into aspartate. All of these
compounds have four C atoms, and their [U-13C]
isoforms have the mass M + 4 and are presented in
Figure 2. [U-13C]OAA can, as already mentioned,
condense with unlabeled acetyl-CoA to form
[3,4,5,6-13C]citrate with six carbon atoms, four of
which are 13C (M + 4). Hence, the mass M + 4
represents the first turn in the TCA cycle for all
these compounds. In the next turn, they will all
contain two labeled C atoms and appear as M + 2,
and in the third turn, they will contain one labeled C
atom (M + 1) (Figure 1).
As shown in Figure 2, labeling from [U-13C]gluta-
mate (column A) and [U-13C]glutamine (column B)
was substantial, with glutamate giving the highest
percent labeling in all metabolites analyzed. When
[U-13C]glutamate and unlabeled glutamine were
added to the experimental medium (column C),
percent label decreased only slightly compared with
when [U-13C]glutamate was added alone (column
A). However, when [U-13C]glutamine and unlabeled
glutamate were added to the medium, labeling was
almost abolished for all metabolites (column D).
Figure 2 shows that labeling of glutamate and
malate, aspartate and citrate was high ( > 65% from
[U-13C]glutamate and 40% to 60% from [U-13C]glu-
tamine (in the absence of glutamate)), whereas that
of succinate was much lower ( < 30% labeling from
glutamate and < 10% from glutamine). Although the
percent labeling in succinate was lower, the pattern
was the same as for the other TCA metabolites.
GABA can be formed from glutamate in GABA
ergic neurons, which constitute about 6% of cere-
bellar neuronal cultures (Sonnewald et al, 2004).
GABA formed directly from [U-13C]glutamate is
uniformly labeled (M + 4). From [1,2,3-13C]glutamate
(after one turn in the TCA cycle), [3,4-13C]GABA is
formed (M + 2). Another turn in the TCA cycle for
GLN/GLU/αKG
SUC/FUM/
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Figure 1 Schematic representation of possible isotopomers of various metabolites arising from [U-13C]glutamate or [U-13C]glutamine
via the three first turns in the TCA cycle in neurons: K represents 13C and J represents 12C atoms; GLN: glutamine; GLU:
glutamate; aKG: a-ketoglutarate; SUC: succinate; FUM: fumarate; MAL: malate; OAA: oxaloacetate; ASP: aspartate; CIT: citrate;
GABA: g-amino butyric acid.
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the glutamate carbon skeleton and subsequent
formation of GABA will result in labeling in one C
atom in GABA (M + 1), from both [1,2-13C] and
[3-13C]glutamate, [4-13C] and [3-13C]GABA, respec-
tively. The same two isotopomers are also formed
after three turns in the TCA cycle (Figure 1). Figure 2
shows that the labeling of GABA analyzed by GC/
MS was lower than that of glutamate, malate,
aspartate, and citrate. Total labeling from [U-13C]glu-
tamate was B30% regardless of the presence of
unlabeled glutamine. Significantly less (17%)
GABA was labeled from [U-13C]glutamine alone,
and this was further reduced in the presence of
unlabeled glutamate (6%).
Intracellular amounts of glutamate, aspartate, and
GABA as quantified by HPLC are shown in Figure 3.
The amounts of glutamate and aspartate varied
considerably with addition of glutamate or gluta-
mine in the experimental medium, but followed the
same pattern, whereas GABA concentration was
independent of glutamate and glutamine content in
medium. Results from mass spectrometry provide
information about percent labeling, which com-
bined with information about amounts of metabo-
lites gives quantitative data. Amounts of different
13C labeled isotopomers of glutamate, aspartate, and
GABA from the first two turns in the TCA cycle are
shown in Figure 3. The intracellular amount of
uniformly labeled glutamate was 248 nmol/mg pro-
tein after incubation with [U-13C]glutamate. This
was reduced to 32 and 17 nmol/mg protein when
glutamine was the labeled precursor, in the absence
and presence of unlabeled glutamate, respectively.
When labeled glutamate was added in the presence
of unlabeled glutamine, the amount of intracellular
uniformly labeled glutamate was, however, in-
creased to 279 nmol/mg protein. The same trend
was seen in [U-13C]aspartate, although the amounts
wereB50% of those of [U-13C]glutamate. These two
excitatory amino acids also showed similarities in
the next turn in the TCA cycle. GABA had a much
lower labeling from both labeled precursors than
glutamate and aspartate, labeling from [U-13C]gluta-
mine being lower than that from [U-13C]glutamate.
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Figure 2 Percent labeling in glutamate, GABA, succinate, malate, aspartate and citrate as detected by GC/MS in cell extracts of
cultured cerebellar neurons after incubation with [U-13C]glutamate (column A), [U-13C]glutamine (column B), [U-13C]glutamate plus
unlabeled glutamine (column C) or [U-13C]glutamine plus unlabeled glutamate (column D), for details see Materials and methods.
Results are presented as means + s.d. in atom percent excess, and P < 0.05 was considered statistically significant. *All masses are
different from the corresponding masses in the other groups. #M + 4 is different from the groups incubated with [U-13C]glutamate
with and without glutamine, the other masses are different from all other groups. aDifferent from the corresponding mass in the A
group; bdifferent from the corresponding mass in the B group; cdifferent from the corresponding mass in the C group.
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Discussion
Metabolism of glutamate and glutamine in the
brain is closely connected via the glutamate–
glutamine cycle, in which neurotransmitter
glutamate taken up from the synaptic cleft by
astrocytes is converted to glutamine and trans-
ported back to neurons as a precursor for the
neurotransmitter pool (Berl and Clarke, 1983).
Similar mechanisms operate in the glutamate–
glutamine–GABA cycle (van den Berg and Garfinkel,
1971; Sonnewald et al, 1993b). However, reuptake
into the presynaptic neuron is believed to be
the preferred mechanism for removal of GABA
from the synapse (Schousboe, 2003). To which
extent glutamine and thus this cycle is impor-
tant for cultured cerebellar neurons has been
explored in the present study by comparing
[U-13C]glutamate and [U-13C]glutamine as substrates
for intermediary metabolism. In our model, addition
of glutamine to the neuronal cultures mimics
astrocyte–neuronal interactions in the brain, with
the advantage of isolating neuronal from glial
metabolism and thus making interpretation of
results unambiguous.
[U-13C]Glutamate and [U-13C]Glutamine Metabolism
Glutamine has been shown to be an excellent
precursor for the neurotransmitters glutamate
and GABA, both in cultured cerebellar neurons
(Waagepetersen et al, 2005), cortical neurons
(Westergaard et al, 1995), and in freshly isolated
cortical synaptosomes from rat brain (Yudkoff et al,
1989; Sonnewald and McKenna, 2002). Label
from [U-13C]glutamine was also found in glutamate
and GABA in the present study. Moreover, labeling
of TCA cycle intermediates and aspartate was
detected, showing that the carbon skeleton of
[U-13C]glutamine entered the TCA cycle. The
presence of isotopomers from subsequent turns also
showed that the carbon skeleton stayed in the TCA
cycle. This confirms that the glutamate–glutamine
cycle does not operate in a stochiometric fashion
(McKenna et al, 1993, 1994; Sonnewald et al, 1993a)
and that glutamine is readily oxidized by cerebellar
cultures for energy.
Exogenous glutamate has also been used to label
neuronal metabolites. Westergaard et al (1995)
showed that in cultured cortical neurons, which
are predominantly GABAergic, incubation with
[U-13C]glutamate gave high enrichment in aspartate
in addition to labeling of GABA. Incubating cere-
bellar neurons in medium containing [U-13C]gluta-
mate in the present study led not only to uniformly
labeled intracellular aspartate and glutamate, but to
some extent, the carbon skeleton also stayed in the
TCA cycle for several turns. This is in accordance
with similar studies of cerebellar neurons analyzed
with magnetic resonance spectroscopy (Sonnewald
et al, 1996; Santos et al, 2006). Using the more
sensitive method mass spectrometry, extensive
labeling of TCA cycle intermediates and GABA
was also detected in the present study. Labeling of
GABA in cerebellar cultures has earlier been shown
by Qu et al (2000). The present study confirms that
[U-13C]glutamate serves as an excellent precursor for
intermediary metabolism in cultured cerebellar
neurons.
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Figure 3 The amounts of glutamate, aspartate, and GABA (white bars), the amounts of M + 5 ([U-13C]glutamate), M + 4
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[U-13C]glutamine plus unlabeled glutamate (column D), for details see Materials and methods. Results are presented as means +
s.d. in nmol/mg protein, and P < 0.05 was considered statistically significant. aDifferent from the corresponding metabolite in the A
group; bdifferent from the corresponding metabolite in the B group; cdifferent from the corresponding metabolite in the C group.
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As shown in the previous paragraphs, both
[U-13C]glutamine and [U-13C]glutamate are well
suited as precursors for neurotransmitter formation
and substrates for neuronal intermediary metabo-
lism. However, in the present study [U-13C]gluta-
mate gave a higher percent labeling than
[U-13C]glutamine in all metabolites, including
GABA. Sonnewald and McKenna (2002) found that
[U-13C]glutamate was superior in labeling of aspar-
tate, whereas GABA labeling was only observed
from [U-13C]glutamine, and not from [U-13C]gluta-
mate when unlabeled glutamine was present, in
cortical synaptosomes. Although [U-13C]glutamate
was a better precursor for GABA than [U-13C]gluta-
mine in the present study, glutamine was a rela-
tively better precursor for GABA than for the other
metabolites investigated, indicating that GABA
synthesis occurs in a separate compartment (see
below) consistent with findings in cortical synapto-
somes (Sonnewald and McKenna, 2002). Wester-
gaard et al (1995) showed that in primary cultures
of cortical neurons labeling of aspartate, GABA,
and [1,2,3-13C]glutamate was very similar from
[U-13C]glutamine and [U-13C]glutamate. Thus, not
surprisingly, GABAergic neurons in the cerebellum
appear to have a different substrate preference for
GABA synthesis than GABAergic neurons in cere-
bral cortex. In cultured cortical neurons, TCA cycle
metabolism of the carbon skeleton subsequently
used in formation of GABA was more pronounced
from [U-13C]glutamine than from [U-13C]glutamate
(Westergaard et al, 1995). This was also observed in
the present study in cultured cerebellar neurons.
With [U-13C]glutamate as the precursor, approxi-
mately 60% of the labeled succinate, malate,
aspartate, and citrate was uniformly labeled and
thus derived from the first turn,B20% was from the
second and B10% from the third turn in the TCA
cycle. When [U-13C]glutamine was present in the
experimental medium, these numbers were B40%,
B30%, andB25%, respectively, and similar results
were seen in GABA. Thus, cycling from glutamine
was more prominent than that from glutamate. The
fact that mitochondrial metabolism of the carbon
skeleton of endogenous glutamate derived from
glutamine and glutamate taken up into the cells
differed could be due to differences in the distribu-
tion of the enzyme phosphate activated glutaminase
catalyzing the formation of glutamate from gluta-
mine. This compartmentation could perhaps be
related to intracellular mitochondrial heterogeneity
(Westergaard et al, 1995; Sonnewald et al, 1998).
Interestingly, label distribution indicating TCA
cycling of the carbon skeleton subsequently con-
verted into GABA was similar whether [U-13C]glu-
tamate or [U-13C]glutamine was the precursor
present in the experimental medium, showing
intercellular compartmentation in addition to the
intracellular compartmentation mentioned above.
To evaluate the preference for glutamate and
glutamine as substrates for intermediary metabolism
in cultured brain cells or synaptosomes, both
substrates have to be present in the medium
simultaneously. When Sonnewald and McKenna
(2002) incubated synaptosomes with [U-13C]gluta-
mate in the presence of unlabeled glutamine, the
carbon skeleton from [U-13C]glutamate entered the
TCA cycle and labeled aspartate and [1,2,3-13C]glu-
tamate, but not GABA. However, label from
[U-13C]glutamine in the presence of unlabeled
glutamate was incorporated into GABA, but not
aspartate. This is consistent with what has been
reported in cortex for the two precursors applied
separately (Westergaard et al, 1995), showing that
the compartmentation is maintained under more
physiological conditions with both substrates pre-
sent (Sonnewald and McKenna, 2002). The impor-
tance of glutamine as a precursor and thus the
importance of the glutamate–glutamine–GABA cy-
cle for GABA synthesis is surprising since reuptake
of GABA into the presynapse is believed to be
prominent (Schousboe, 2003). Neurotransmitter
glutamate, however, is thought to be removed from
the synaptic cleft mainly by uptake into astrocytes
(Schousboe et al, 1977; Danbolt, 2001). On the basis
of this, it can be assumed that the importance of
the glutamate–glutamine cycle should be greater for
the synthesis of neurotransmitter glutamate than
for GABA. However, results from the present study
suggest otherwise. Consumption of glutamate in the
cerebellar neurons was twice that of glutamine
when given alone and together with glutamine,
even though the glutamine concentration in the
medium was twice as high as that of glutamate. Most
importantly, glutamine consumption was reduced
by nearly 50% in the presence of glutamate
compared with when glutamate was not present in
the experimental medium. Thus, glutamate could
substitute for glutamine, but the reverse was not the
case. Labeling of intracellular metabolites was only
slightly reduced when neurons were incubated in
medium containing [U-13C]glutamate in the pre-
sence of unlabeled glutamine compared with that
in the absence of glutamine. Surprisingly, when
unlabeled glutamate was present together with
[U-13C]glutamine, labeling was almost abolished
in all metabolites measured. The carbon skeleton
of [U-13C]glutamate and [U-13C]glutamine will, in
the TCA cycle, not only be distributed into the
metabolites mentioned above, but also be converted
to 13CO2, which is not detected by the experimental
setup used in the present study. As mentioned
above, the carbon skeleton of glutamine stayed in
the TCA cycle longer than that of glutamate and
thus it is likely that a higher percentage of glutamine
compared with that of glutamate was converted
to 13CO2.
Considering the results presented, it can be
postulated that the glutamate–glutamine cycle is of
less importance for neurons in the cerebellum than
what has been described for cerebral cortical
neurons. This is further supported by the fact that
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granule neurons are by far the most abundant cells
in the rat cerebellum (265 106) and outnumber glia
(2.2 106) in the granule layer significantly (Korbo
et al, 1993). A similar quantitative neuronal dom-
inance has been reported in human cerebellum
(Andersen et al, 1992). Thus, in the cerebellar
cortex, glial processes do not envelop all synapses.
Indeed, it has been shown that around synapses
between the parallel fibers, the axons of granule
neurons, and interneuron dendrites, astrocyte pro-
cesses are lacking (Danbolt, 2001). Therefore, the
distance from the synapse to the nearest glial cell is
quite large and, in addition, the relative number of
glutamate transporters on these astrocytes is low
(Danbolt, 2001). However, it has been shown that in
the cerebellar granule cell layer, the density of
mRNA for a neuronal glutamate transporter was
very high (Velaz-Faircloth et al, 1996). Considering
the relatively large distance between synaptic
regions of cerebellar granule cells and astrocytes
and the high level of glutamate transporters on these
neurons, it can be argued that reuptake of glutamate
must be important for granule neurons. This has
indeed been shown by Waagepetersen et al (2005),
who reported that the intracellular pool of glutamate
in cerebellar neurons was dependent on reuptake of
extracellular glutamate.
The ‘Partial Tricarboxylic Acid Cycle’
Battaglioli and Martin (1990) showed that in
synaptosomes, aspartate synthesis was strongly
stimulated by glutamate and glutamine, but the
stimulation by glutamate was greatest. Similarly, in
the present study, an increase in intracellular
glutamate concentration was always accompanied
by a corresponding increase in that of aspartate.
The intracellular glutamate concentration was
highest in the cells incubated with both glutamate
and glutamine, followed by those incubated with
glutamate alone, and thereafter cells incubated
with glutamine, which also led to an increase
compared with control. The coupling between
glutamate and aspartate can be explained by the
fact that cerebellar neurons have a high activity of
glutamate dehydrogenase and aspartate amino
transferase (Drejer et al, 1985; Westergaard et al,
1991; Zaganas et al, 2001). Thus, entry of glutamate
via a-ketoglutarate into the TCA cycle and conver-
sion of oxaloacetate to aspartate is very efficient
in the cerebellum and energy is obtained from this
so-called ‘partial TCA cycle’ (Hertz et al, 1991;
Sonnewald and McKenna, 2002).
GABA Shunt in Cerebellar Neurons
The cerebellar neuronal cultures consist primarily
of glutamatergic granule cells with a minor con-
tribution of GABAergic stellate and basket neurons,
that is, GABAergic as well as glutamatergic
characteristics are expressed in these cultures
(Pearce et al, 1981; Hertz et al, 1985; Hertz and
Schousboe, 1987; Drejer and Schousboe, 1989;
Kovacs et al, 2003). Thus, cultures of dissociated
cerebellum constitute an excellent model system for
the in vivo situation, in which the association of
GABAergic with glutamatergic neurons can be
investigated. The major enzyme responsible for
GABA synthesis in brain, glutamate decarboxylase,
was shown to be present in 6% of cultured
cerebellar neurons (Sonnewald et al, 2004) indicat-
ing the presence of two distinct cell types and thus,
at least two cellular compartments. In the present
study, the amount of intracellular GABA in the
cultures was increased to the same extent by all
experimental conditions, compared with control
cultures. This is in contrast to the results obtained
for aspartate, which increased with increasing
glutamate concentration, as mentioned above, show-
ing cellular compartmentation. It has been shown
that the glutamate decarboxylase positive neurons,
which constitute the GABAergic compartment,
produce GABA during the whole culture period
and that GABA is distributed throughout the whole
culture (Sonnewald et al, 2006). In the present
study, no labeled substrates were present in the
medium during the 7-day culture period, thus
GABA produced during this time was unlabeled.
When medium containing [U-13C]glutamate or
[U-13C]glutamine was added to the cultures for the
2-h incubation period, labeled GABA could be
formed only in the small number of GABAergic
cells. Hence, most GABA in the cultures in general,
and in the cerebellar granule neurons in particular,
was unlabeled at the time of culture extraction.
GABA can be catabolized via the GABA shunt, in
which the carbon skeleton of GABA enters the TCA
cycle after conversion to succinate. Interestingly,
percent labeling of succinate was very similar to that
of GABA and much lower than that of the other TCA
cycle intermediates measured. The number of
GABAergic neurons in the cultures is small, and
thus it seems unlikely that the succinate content
in these neurons could account for the dilution of
labeling in the total succinate pool. It can be
assumed that catabolism of GABA and entry of
the carbon skeleton of GABA into the TCA cycle
through the GABA shunt is taking place in the
glutamatergic cells from unlabeled GABA. Hence, a
possible function of GABA in the glutamatergic
neurons is the ability to produce a separate
succinate pool for potential energy production in
the TCA cycle, suggesting a special role for the
GABA shunt in the cerebellum.
Conclusion
Through the results presented, it could be shown
that glutamate is preferred over glutamine as a
substrate for intermediary metabolism in cultured
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cerebellar neurons. It can be concluded that these
neurons rely more on reuptake of glutamate than
supply of glutamine from astrocytes for glutamate
homeostasis.
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Abstract
Glutamate neurotoxicity is implicated in most neurodegenerative diseases, and in the present study the long-term effects of the glutamate
agonist kainic acid (KA) on cerebellar neurons are investigated. Primary cell cultures, mainly consisting of glutamatergic granule neurons, were
cultured in medium containing 0.05 or 0.50 mM KA for 7 days and subsequently incubated in medium containing [U-13C]glutamate or
[U-13C]glutamine. The amount of protein and number of cells were greatly reduced in cultures exposed to 0.50 mMKA compared to those exposed
to 0.05 mMKA. Glutamine consumption was not affected by KA concentration, whereas that of glutamate was decreased by high KA, confirming
reduction in glutamate transport reported earlier. Neurons cultured with 0.50 mM KA and incubated with glutamate contained decreased amounts
of glutamate, aspartate and GABA compared to those cultured with 0.05 mM KA. Incubation of cells exposed to 0.50 mM KAwith glutamine led
to an increased amount of glutamate compared to cells exposed to 0.05 mM KA, whereas the intracellular amounts of aspartate and GABA
remained unaffected by KA concentration. Furthermore, mitochondrial metabolism of a-[U-13C]ketoglutarate derived from [U-13C]glutamate and
[U-13C]glutamine was significantly reduced by 0.50 mM KA. The results presented illustrate differential vulnerability to KA and can only be
understood in terms of inter- and intracellular compartmentation.
# 2006 Elsevier Ltd. All rights reserved.
Keywords: 13C labeling; GABA; Glutamatergic neurons; Kainic acid; Mass spectrometry; Tricarboxylic acid cycle
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Neurodegenerative diseases, characterized principally by
the progressive loss of neurons, can affect various brain regions
and include a number of different diagnoses. Typically, the
pattern of neuronal loss is selective, affecting one or more
groups of neurons, while leaving others intact. Ataxia-
telangiectasia is an example of a degenerative disorder, with
predominantly cerebellar neuronal degeneration with selective
loss of GABAergic Purkinje and glutamatergic granule cells
(Crawford, 1998; De Girolami et al., 1999). Selective
destruction of one or more groups of neurons is also seen
after exposure to different toxic substances. In the cerebellum,* Corresponding author at: Department of Neuroscience, Faculty of Medi-
cine, Olav Kyrres gate 9, N-7489 Trondheim, Norway. Tel.: +47 73590492;
fax: +47 73598655.
E-mail address: ursula.sonnewald@ntnu.no (U. Sonnewald).
0197-0186/$ – see front matter # 2006 Elsevier Ltd. All rights reserved.
doi:10.1016/j.neuint.2006.11.004
Please cite this article in press as: Olstad, E. et al., Long-term kainic a
metabolism in cultured cerebellar neurons, Neurochem. Int. (2006), dogranule neurons are very sensitive to methyl mercury,
thiophene and 2-chloropropionic acid, whereas Purkinje cells
are sensitive to ethanol and diphenylhydantoin (Fonnum and
Lock, 2000; Sonnewald et al., 2002). Glutamate homeostasis
and metabolism is of supreme importance in the brain.
However, the balance between physiological and pathological
signaling is delicate, and thus glutamate neurotoxicity is
implicated in most neurodegenerative diseases. It has been
shown that the glutamate agonist kainic acid (KA) exerts toxic
effects after systemic or intracranial injection in rodents.
Systemic KA injections lead to seizures and subsequent
neuronal cell loss, and has therefore been widely used as an
epilepsy model (Ben-Ari, 1985; Bradford, 1995; Schwarzer and
Sperk, 1995; Mu¨ller et al., 2000; Qu et al., 2003). Injection of
KA directly into cerebella of hamsters and rats has been shown
to selectively damage neurons which receive synaptic input
from granule cells, while the granule cells themselves were
spared (Herndon and Coyle, 1977); leading to the hypothesis
that KA exerts its toxic effects through glutamate receptors. Incid exposure reveals compartmentation of glutamate and glutamine
i:10.1016/j.neuint.2006.11.004
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substantial number of granule cells in mouse cerebellar cortex
with sparing of many Purkinje cells after injection of KA in
mouse cerebellar cortex. In cell culture experiments, KA has
been shown to cause both positive and negative effects on
survival of neurons from this area (Bala´zs et al., 1990;
Frandsen and Schousboe, 1990; Kato et al., 1991; Jensen et al.,
1999; Drian et al., 2001). Furthermore, it has been reported
that KA exposure led to disturbed maturation of GABAA
receptor subunit expression in these neurons (Engblom et al.,
2003).
Although several authors have investigated neurotoxic
effects of short time exposure toKA, little is known about long-
term effects on neuronal metabolism. Thus, the purpose of the
present study was to investigate the effects of long-term
exposure of cerebellar neurons to KAwith respect to glutamate
and glutamine metabolism. Cerebellar neurons were cultured
inmedium containing 0.05 or 0.50 mMKA for thewhole 7-day
culture period, and subsequently incubated for 2 h in medium
containing [U-13C]glutamate or [U-13C]glutamine. High
performance liquid chromatography (HPLC) and gas chro-
matography/mass spectrometry (GC/MS) analyses were
performed on media and cell extracts, and cellular protein
was quantified. The cerebellar neuronal culture model system
is well suited for this kind of metabolic study because after 7
days in vitro, the cultures express glutamate and glutamine
metabolizing enzymes analogous to that of the brain in vivo
(Drejer et al., 1985). Moreover, the cultures show similarities
to the in vivo situation due to expression of both GABAergic as
well as glutamatergic characteristics (Pearce et al., 1981; Hertz
et al., 1985; Hertz and Schousboe, 1987; Drejer and
Schousboe, 1989; Kovacs et al., 2003). The glutamatergic
granule cells dominate quantitatively in the cultures, just as in
the cerebellum in vivo (Drejer and Schousboe, 1989; Andersen
et al., 1992). In addition, the cultures contain about 6%
GABAergic stellate and basket neurons, and a small number of
glial cells (Messer, 1977; Drejer et al., 1985; Damgaard et al.,
1996; Sonnewald et al., 2004). Thus, cellular compartmenta-
tion of metabolism can readily be studied in these cultures.
Furthermore, the blood–brain-barrier, which normally
excludes glutamate and glutamine from entering the brain,
is bypassed in this system.
2. Experimental procedures
2.1. Materials
NMRI mice were obtained from Taconic M&B (Copenhagen, Denmark).
Plastic tissue culture dishes were purchased from Nunc A/S (Roskilde, Den-
mark) and fetal calf serum (FCS) from Seralab Ltd. (Sussex, UK). Culture
medium, kainic acid, glutamate receptor antagonists DNQX (6,7-dinitroqui-
noxaline-2,3-dione) and D-AP5 (D-2-amino-5-phosphonopentanoic acid) were
from Sigma Chemical Co. (St. Louis, MO, USA). [U-13C]Glutamate and
[U-13C]glutamine were from Cambridge Isotope Laboratories (Woburn, MA,
USA), and the GC/MS derivatization reagent MTBSTFA (N-methyl-N-(tert-
butyldimethylsilyl)trifluoroacetamide) + 1% t-BDMS-Cl (tert-butyldimethyl-
chlorosilane) was purchased from Regis Technologies, Inc. (Morton Grove,
IL, USA). All other chemicals were of the purest grade available from regular
commercial sources.Please cite this article in press as: Olstad, E. et al., Long-term kainic a
metabolism in cultured cerebellar neurons, Neurochem. Int. (2006), do2.2. Cell cultures
Cerebellar neurons were isolated and cultured from 7-day-old mice as
described by Schousboe et al. (1989). Briefly, the tissue was trypsinized
followed by trituration in a DNase solution containing a trypsin inhibitor from
soybeans. Cells were suspended (2.75  106 cells/ml) in a modified Dulbecco’s
minimum essential medium (Hertz et al., 1982) containing 24.5 mM KCl,
31 mM glucose, 7 mM p-aminobenzoic acid, 10% (v/v) FCS and either 0.05 or
0.50 mM kainic acid, and seeded in poly-D-lysine coated Petri dishes (2 ml/
35 mm). After 48 h in culture, 20 mM (final concentration) cytosine arabinoside
was added to the medium to prevent astrocytic proliferation.
2.3. Microscopy
Cell morphology was assessed using a Nikon Eclipse TE 2000-S inverted
phase-contrast microscope (Nikon, Inter Instruments AS, Norway). The micro-
scope was equipped with a SPOT RT Digital Camera (SPOT Diagnostic
Instruments, Sterling Heights, MI, USA), and photomicrographs of cells were
taken after 7 days in vitro.
2.4. Experiments using [U-13C]glutamate and [U-13C]glutamine
The culture medium containing 0.05 or 0.5 mM KAwas removed from 7-
day-old cultures and the cells were incubated for 2 h at 37 8C in 2 ml serum free
medium prepared without glutamine, containing 3 mM glucose and either no
additions (control, for HPLC analysis), [U-13C]glutamate (0.25 mM) or
[U-13C]glutamine (0.50 mM). KA was not present in this incubation medium.
In order to avoid the toxicity of glutamate during the incubation, two glutamate
receptor antagonists DNQX (25 mM), an AMPA/kainate-selective antagonist,
and D-AP5 (100 mM), an NMDA antagonist, were also present in the incubation
medium (Frandsen et al., 1989). After the incubation period, medium was
removed for HPLC analysis and the cells were washed twice with cold
phosphate buffered saline and extracted with 70% (v/v) ethanol. The cell
extracts were scraped off the dishes and centrifuged at 10,000  g for
15 min to separate the metabolites from the insoluble proteins. The supernatants
were divided into two parts, one directly analyzed with HPLC; the other
lyophilized for subsequent sample preparation for GC/MS analysis.
2.5. Protein quantification
Cellular protein in the ethanol pellets was determined after dissolving in
1 M KOH at 37 8C for 60 min, using the Pierce BCA (Pierce, Rockford, IL,
USA) protein assay with bovine serum albumin as standard.
2.6. HPLC
Amino acids in cell extracts and medium were quantified by HPLC on a
Hewlett Packard 1100 system (Agilent Technologies, Palo Alto, CA, USA). The
amino acids were pre-column derivatized with o-phthaldialdehyde (Geddes and
Wood, 1984) and subsequently separated on a ZORBAX SB-C18
(4.6 mm  250 mm, 5 mm) column from Agilent using a phosphate buffer
(50 mM, pH 5.9) and a solution of methanol (98.75%) and tetrahydrofurane
(1.25%) as eluents. The separated amino acids were detected with fluorescence
and quantified by comparison to a standard curve derived from standard
solutions of amino acids run after every twelve samples.
2.7. GC/MS
Lyophilized cell extracts were redissolved in HCl (10 mM), adjusted to
pH < 2 with 6 M HCl and dried under atmospheric air. The amino acids were in
multiple steps extracted into an organic phase of ethanol and benzene and dried
again under atmospheric air before derivatization with MTBSTFA in the
presence of 1% t-BDMS-Cl (Mawhinney et al., 1986). The samples were
analyzed on a Hewlett Packard 5890 Series II gas chromatograph linked to a
Hewlett Packard 5972 Series mass spectrometer. Atom percent excess (13C) of
glutamate, glutamine, GABA and aspartate was determined after calibration
using unlabeled standard solutions (Biemann, 1962).cid exposure reveals compartmentation of glutamate and glutamine
i:10.1016/j.neuint.2006.11.004
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Incubating cerebellar neurons in medium containing [U-13C]glutamate or
[U-13C]glutamine and subsequent analysis of cell extracts bymass spectrometry
can provide useful information about the metabolism in these cells. In order to
interpret the mass spectrometry data, it is necessary to know the metabolic fate
of the two labeled precursors. [U-13C]Glutamate or [U-13C]glutamine from the
incubation medium enters the neurons through transporter proteins. Once inside
the cells, [U-13C]glutamine can be converted to [U-13C]glutamate. The latter
can be decarboxylated into uniformly labeled GABA in GABAergic neurons, or
it can be converted into a-[U-13C]ketoglutarate and be metabolized in the
tricarboxylic acid (TCA) cycle for energy production and metabolite synthesis.
The 13C label from the precursor’s carbon skeleton will in the latter case be
distributed among the TCA cycle metabolites as illustrated in Fig. 1. From the
first turn in the TCA cycle, all metabolites will be uniformly labeled to the
oxaloacetate (OAA) step. [U-13C]OAA can be transaminated to [U-13C]aspar-
tate and leave the TCA cycle, or continue cycling by condensing with unlabeled
acetyl-CoA to form [3,4,5,6-13C]citrate. In the TCA cycle, [3,4,5,6-13C]citrate
is converted into [1,2,3,6-13C]isocitrate and a-[1,2,3-13C]ketoglutarate as one
turn in the TCA cycle is completed. From a-[1,2,3-13C]ketoglutarate leaving
the TCA cycle, [1,2,3-13C]glutamate and [3,4-13C]GABA can be derived. If a-
[1,2,3-13C]ketoglutarate stays in the cycle (Fig. 1), [1,2-13C]succinyl-CoA is
formed. From [1,2-13C]succinyl-CoA, two possible isotopomers of succinate,
[1,2-13C]- or [3,4-13C]succinate arises due to the symmetrical nature of this
molecule. Fumarate, malate, OAA and aspartate formed from [1,2-13C]- or
[3,4-13C]succinate will all be present in both isoforms. After introduction of
another unlabeled acetyl-CoA into the TCA cycle and subsequent exit ofFig. 1. Schematic representation of possible isotopomers of metabolites arising from
via three turns in the TCA cycle: (*) 13C and (*) 12C atoms. The labeling of fumarat
the same as that of citrate, although the numbering of the C atoms differs. GLU: gluta
fumarate; MAL: malate; OAA: oxaloacetate; CIT: citrate; ISOCIT: isocitrate.
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isotopomers [1,2-13C]- and [3-13C]glutamate, and [3-13C]- and [4-13C]GABA
can be derived. Further oxidative metabolism of labeled a-ketoglutarate in the
cycle results in isotopomers labeled in either one of the four C positions for
succinate, fumarate, malate, OAA and aspartate (Fig. 1). The third turn in the
TCA cycle is concluded by the formation of a-ketoglutarate singly labeled in C-
1, C-2 or C-3 position with the possibility to form [1-13C]-, [2-13C]- and
[3-13C]glutamate or [3-13C]- and [4-13C]GABA.
2.9. Data analysis
Peaks from mass spectra were integrated, and atom percent excess values
were calculated for glutamate, aspartate and GABA by comparison with
unlabeled standard solutions. Atom percent excess values for masses larger
thanM (i.e.M + 1,M + 2, etc.) were added to give percent 13C enrichment of the
different compounds (Table 1). Results from HPLC quantification of the above
mentioned amino acids in cell extracts were combined with values of atom
percent excess obtained from MS to give nmol/mg protein of the uniformly
labeled compounds and of the isotopomers from the first, second and third turn
of the TCA cycle (Table 2). Setting the percent enrichment presented in Table 1
to 100% made it possible to compare the groups incubated with [U-13C]glu-
tamate or [U-13C]glutamine directly with respect to which extent of glutamate
and GABAwas derived without TCA cycle activity and from precursors from
consecutive turns of the TCA cycle, the latter also including aspartate. Con-
sumption of [U-13C]glutamate and [U-13C]glutamine was calculated by sub-
tracting the amounts of the two amino acids measured in the incubation media
after 2 h from the amounts added. Results are presented as mean  standard[U-13C]glutamate or [U-13C]glutamine (after conversion to [U-13C]glutamate)
e, malate and OAA is the same as that of succinate, whereas isocitrate labeling is
mate; aKG: a-ketoglutarate; SUC-CoA: succinyl-CoA; SUC: succinate; FUM:
cid exposure reveals compartmentation of glutamate and glutamine
i:10.1016/j.neuint.2006.11.004
Table 1
Percent 13C enrichment in glutamate, aspartate and GABA in cell extracts of
cerebellar neurons cultured in medium containing 0.05 or 0.50 mM kainic acid
(KA)
Glutamate (% 13C) Aspartate (% 13C) GABA (% 13C)
glu
0.05 mM KA 90.6  0.5 85.4  0.4 29.2  0.8
0.50 mM KA 92.1  0.4a 86.3  0.7a 28.7  3.1
gln
0.05 mM KA 58.8  1.2 48.5  1.0 17.2  1.2
0.50 mM KA 64.7  1.4a 52.9  1.8a 20.7  1.7a
On day 7 in vitro, the culture mediumwas removed and the cells were incubated
for 2 h in medium containing 0.25 mM [U-13C]glutamate (glu, n = 6) or
0.50 mM [U-13C]glutamine (gln, n = 6), for details see Section 2. Results
are presented as mean %  S.D., and p < 0.05 was considered significant after
analysis using Student’s t-test.
a Different from the corresponding cells cultured in medium containing
0.05 mM KA.
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statistically using one-way analysis of variance (ANOVA) followed by the LSD
(least significant difference) post hoc test, and between two groups using
Student’s t-test, p < 0.05 was considered significant.
3. Results
3.1. Neuronal survival and cell morphology
Cerebellar neurons were cultured with medium containing
0.05 or 0.50 mM KA for 7 days before incubation in fresh
medium containing either no additions (control group),
[U-13C]glutamate or [U-13C]glutamine (see Section 2). The
amount of protein in the cultures was not affected by different
incubation conditions (results not shown); however, protein
amount in cultures exposed to medium with 0.50 mM KA for
the whole 7-day culture period was significantly decreased
compared to cultures exposed to medium with 0.05 mMKA, as
shown in Fig. 2A. The number of cells per culture dish was
visibly reduced, whereas the morphology of single cells as
assessed by microscopy was unaffected by KA concentration
(Fig. 2B).Table 2
Cellular content of labeled glutamate, aspartate and GABA (nmol/mg protein) derive
containing 0.05 or 0.50 mM kainic acid (KA)
Glutamate (nmol/mg protein) Aspartate (nmol/m
Total
label
Uniformly First
turn
Second
turn
Total
label
First
turn
glu
0.05 mM KA 404  16 248  13 85  4 47  3 198  10 118
0.50 mM KA 300  34a 211  22a 50  7a 23  3a 107  16a 71
gln
0.05 mM KA 79  6 32  3 22  1 18  1 37  3 14
0.50 mM KA 103  9a 45  5a 28  2a 20  2a 42  4a 17
The amounts of differently labeled isotopomers of glutamate, aspartate and GAB
[U-13C]glutamate (glu, n = 6) or 0.50 mM [U-13C]glutamine (gln, n = 6) for 2 h, for
and p < 0.05 was considered statistically significant.
a Different from the corresponding cells cultured in medium containing 0.05 mM
Please cite this article in press as: Olstad, E. et al., Long-term kainic a
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amino acids
The cellular content of selected amino acids in cultured
cerebellar neurons is presented in Fig. 3. Compared to control,
intracellular concentrations of glutamate and aspartate were
increased after incubation in medium with [U-13C]glutamate
and to a lesser extent after incubation in medium with
[U-13C]glutamine in cultures exposed to either 0.05 or
0.50 mM KA compared to cells incubated in plain medium
(control group). Cells exposed to the high KA concentration,
had a lower glutamate and aspartate content after incubation in
control medium and medium containing [U-13C]glutamate
compared to cultures exposed to low KA. On the other hand,
after incubation with medium containing [U-13C]glutamine,
high KA led to an increase in glutamate content compared
to the low KA group, whereas the intracellular aspartate
concentration after incubation with medium containing
[U-13C]glutamine remained unaffected by KA concentration.
The intracellular concentration of aspartate followed that of
glutamate, and was approximately 50% of that of glutamate
under all conditions. Incubating neurons with medium
containing [U-13C]glutamate or [U-13C]glutamine increased
cellular content of glutamine in both KA groups compared to
control. Incubation in medium with [U-13C]glutamine gave a
higher intracellular glutamine level than incubation in the
presence of [U-13C]glutamate. Cultures incubated in control
medium had the same glutamine content whether cultured with
0.05 or 0.50 mM KA, whereas culturing cells in medium with
the high KA concentration led to decreased glutamine content
after incubation in the presence of [U-13C]glutamate and
increased glutamine content after incubation in medium with
[U-13C]glutamine compared to low KA. The amount of GABA
in cells cultured in the presence of 0.05 mM KA and incubated
with [U-13C]glutamate or [U-13C]glutamine was increased to
the same extent compared to control. Culturing cells in the
presence of 0.50 mM KA led to increased intracellular
concentration of GABA after incubation in plain medium
(control group), whereas incubation in medium with
[U-13C]glutamate led to reduced intracellular GABA contentd from different turns in the TCA cycle in cerebellar neurons cultured in medium
g protein) GABA (nmol/mg protein)
Second
turn
Third
turn
Total
label
Uniformly First
turn
Second/
third turn
 6 45  3 22  2 3.2  0.3 1.5  0.1 0.9  0.1 0.6  0.1
 11a 20  3a 8  1a 2.3  0.2a 1.2  0.1a 0.6  0.1a 0.3  0.1a
 1 11  1 10  1 1.7  0.3 0.8  0.1 0.6  0.1 0.3  0.1
 2a 12  1 11  1 1.7  0.3 0.8  0.1 0.5  0.1 0.3  0.1
A in cell extracts of cerebellar neurons incubated in medium with 0.25 mM
details see Section 2. Results are presented as mean  S.D. in nmol/mg protein,
KA.
cid exposure reveals compartmentation of glutamate and glutamine
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Fig. 2. The amount of protein in cultures (A) and photomicrographs (B) of cerebellar neurons cultured in medium containing 0.05 or 0.50 mM kainic acid (KA) in
35 mm Petri dishes. On day 7 in vitro, the culture medium was removed, and the cells were incubated for 2 h in medium containing either no additions, 0.25 mM
[U-13C]glutamate or 0.50 mM [U-13C]glutamine, for details see Section 2. The protein amount was not affected by different incubation conditions, thus cultures from
different incubation conditions are presented together. Results are mean  S.D. in mg protein per culture (n = 12 in each group), and p < 0.05 was considered
statistically significant. Bars in photomicrographs represent 0.100 mm. *Different from the group cultured in medium containing 0.05 mM KA.
Fig. 3. Cellular content of glutamate, aspartate, glutamine and GABA detected by HPLC in extracts of cultured cerebellar neurons. Cells were cultured in medium
containing either 0.05 or 0.50 mMkainic acid (KA). On day 7 in vitro, the culture mediumwas removed, and the cells were incubated for 2 h in mediumwith either no
additions (ctr, n = 3), 0.25 mM [U-13C]glutamate (glu, n = 6), 0.50 mM [U-13C]glutamine (gln, n = 6), for details see Section 2. Results are presented as mean  S.D.
in nmol/mg protein, and p < 0.05 was considered statistically significant. aDifferent from the ctr group; bDifferent from the glu group; *Different from the
corresponding group cultured in medium containing 0.05 mM KA.
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Fig. 4. Distribution of 13C label in glutamate, aspartate and GABA detected by mass spectrometry analysis of cell extracts of cultured cerebellar neurons after
incubation with 0.25 mM [U-13C]glutamate (A, n = 6) or 0.50 mM [U-13C]glutamine (B, n = 6). Cells were cultured in medium containing either 0.05 mM or
0.50 mM kainic acid (KA), for details see Section 2. Note that uniformly labeled glutamate and GABA is presented, and that GABA from the second and third turn is
presented together due to the fact that the same isotopomers arise from both turns. Results are presented as mean  S.D. in percent of the total labeled compound, and
p < 0.05 was considered statistically significant. *Different from the corresponding group cultured in medium containing 0.05 mM KA.
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Incubation in medium with [U-13C]glutamine led to similar
intracellular GABA concentrations regardless of KA exposure
during the culture period.
The cells’ consumption of [U-13C]glutamate or [U-13C]glu-
tamine was determined by quantifying the amounts of the two
precursors in the incubation media and subtracting these from
the amounts added. Cultures exposed to 0.50 mM KA and
incubated in medium containing [U-13C]glutamate, consumed
approximately half of the amount of glutamate compared to
cultures exposed to 0.05 mM KA, 734  184 nmol/mg protein
versus 1537  55 nmol/mg protein during the 2 h incubation,
respectively. In contrast, glutamine consumption by neurons
incubated in medium containing [U-13C]glutamine was not
affected by KA concentration. The consumption of glutamine
was 719  59 nmol/mg protein in the low KA group and
627  162 nmol/mg protein per 2 h in the high KA group.
3.3. 13C labeling of metabolites
In Table 1, percent 13C enrichment in glutamate, aspartate
and GABA in cell extracts after incubation in medium with
[U-13C]glutamate or [U-13C]glutamine is presented. In general,Please cite this article in press as: Olstad, E. et al., Long-term kainic a
metabolism in cultured cerebellar neurons, Neurochem. Int. (2006), doin glutamate and aspartate, percent enrichment after incubation
in the presence of [U-13C]glutamate was very high (>85%),
and higher than after incubation in medium with [U-13C]glu-
tamine (approximately 45–65%). In GABA, percent enrich-
ment was much lower, but also in this metabolite, the
enrichment was higher after incubation in medium with
[U-13C]glutamate than with [U-13C]glutamine, 30% and
20%, respectively. Cells cultured in the presence of 0.50 mM
KA and incubated in medium containing [U-13C]glutamate had
a higher percent enrichment in glutamate and aspartate, but not
in GABA, compared to cells cultured in the presence of
0.05 mMKA and incubated in medium with [U-13C]glutamate.
On the other hand, cells exposed to 0.50 mMKA and incubated
in the presence of [U-13C]glutamine, had a higher percent
enrichment in all metabolites than cells cultured in medium
containing 0.05 mM KA and incubated in medium with
[U-13C]glutamine.
In order to investigate the effect of KA on metabolism, 13C
labeling from [U-13C]glutamate and [U-13C]glutamine arising
from different turns in the TCA cycle was calculated. In Fig. 4
percent labeling from [U-13C]glutamate and [U-13C]glutamine
in uniformly labeled glutamate and GABA and also glutamate,
aspartate and GABA from precursors derived from the threecid exposure reveals compartmentation of glutamate and glutamine
i:10.1016/j.neuint.2006.11.004
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presence of 0.05 mM KA and incubated in medium with
[U-13C]glutamate contained 60% uniformly labeled gluta-
mate, i.e. un-metabolized precursor. Approximately 20% was
[1,2,3-13C]glutamate derived from a-[1,2,3-13C]ketoglutarate
formed after one turn in the TCA cycle, and 10% was
[1,2-13C] or [3-13C]glutamate from labeled a-ketoglutarate
formed after two TCA cycle turns (see Fig. 1). Less than 1% of
the labeled glutamatewas formed from labelled a-ketoglutarate
which had been through three full turns in the TCA cycle.
Culturing cells in medium containing 0.50 mM KA before
incubation with [U-13C]glutamate, led to a different distribu-
tion of intracellular labeled glutamate. In this case, approxi-
mately 70% was un-metabolized [U-13C]glutamate, whereas
17% and 8% was from labelled a-ketoglutarate after one
and two TCA cycle turns, respectively. Only 0.1% of the
labeled glutamate was formed after three full turns in the TCA
cycle. A larger percentage of the labeled glutamate in the cells
was un-metabolized, and thus a smaller percentage was derived
from the different TCA cycle turns, in neurons cultured in
medium with a high KA concentration compared to neurons
cultured in medium with a low KA concentration. Cells
cultured in medium containing 0.05 mM KA and incubated
with [U-13C]glutamine, showed a more even label distribution
in glutamate derived from intermediates from different turns in
the TCA cycle. In this case, uniformly labeled glutamate
constituted 40% of the labeled glutamate in the cells, and
30%, 20% and 10% was formed after one, two and three
TCA turns, respectively, indicating more prominent TCA
cycling of a-ketoglutarate derived from glutamine than of that
derived from glutamate. The metabolic effect of culturing
neurons in high KA followed by incubation in medium with
[U-13C]glutamine was similar to that seen in cells incubated in
the presence of [U-13C]glutamate, but less pronounced. The
distribution of label in aspartate formed from [U-13C]glutamate
and [U-13C]glutamine was similar to that in glutamate.
Moreover, the effect of KA on aspartate labeling was similar
in the glutamate and glutamine groups. However, distribution of
label in GABA after culturing cells in medium containing
0.05 mM KA and incubation in the presence of [U-13C]glu-
tamate or [U-13C]glutamine was similar to that from
[U-13C]glutamine in glutamate and aspartate. Neurons cultured
in the presence of 0.50 mM KA and incubated in medium with
[U-13C]glutamate showed similar KA effects in GABA as in
glutamate and aspartate. However, neurons incubated with
[U-13C]glutamine showed no differences in labeling distribu-
tion of GABA whether the cells were cultured in medium
containing 0.05 or 0.50 mM KA.
In Table 2, the effects of kainic acid on intracellular content of
glutamate, aspartate andGABAand the effects onmetabolism as
detected in label distribution representing different TCA cycle
turns, are combined (see Section 2). Cells cultured in medium
containing 0.05 mM KA and subsequently incubated with
[U-13C]glutamate had a higher amount of labeled glutamate,
aspartate and GABA than cells cultured with the same KA
concentration, but incubated with [U-13C]glutamine. Culturing
neurons in medium with a high KA concentration led to aPlease cite this article in press as: Olstad, E. et al., Long-term kainic a
metabolism in cultured cerebellar neurons, Neurochem. Int. (2006), doreduction of total label and uniformly labeled glutamate,
aspartate and GABA, as well as that derived from precursors
from all TCA cycle turns, after incubation with [U-13C]gluta-
mate compared to neurons cultured in medium with a low KA
concentration. In contrast, neurons cultured in the presence of
high KA and subsequently incubated with [U-13C]glutamine,
contained higher levels of total label and uniformly labeled
glutamate and that derived from precursors from all TCA cycle
turns compared to neurons culturedwith lowKA.The amounts of
total labeled and uniformly labeled aspartate were increased in
the high KA compared to the low KA group, whereas labeling
from the second and third turn of the TCA cycle was unaffected
by KA. Labeling of GABA from [U-13C]glutamine also
remained unaffected by KA concentration during the culture
period.
4. Discussion
The present study was conducted to elucidate the long-term
effects of KA with special emphasis on glutamate and
glutamine metabolism in cultured cerebellar neurons. As
discussed below, KA exerted neurotoxic effects and decreased
intermediary metabolism in these cells.
4.1. KA neurotoxicity
It has been shown in several studies that KA can act as a
neurotoxic agent (Seil et al., 1979; Ben-Ari, 1985; Bala´zs et al.,
1990; Schwarzer and Sperk, 1995). However, positive effects of
KA has also been reported. In order to illustrate the complexity
of KA effects on cells, it can be pointed out that exposure to low
KA concentrations enhances survival of cerebellar neurons in
culture with a maximal positive effect at 0.05 mM KA,
whereas high concentrations (>0.20 mM) are toxic to these
cells (Bala´zs et al., 1990). In the present study, we chose to
expose the cells in the control group to 0.05 mM KA, since this
has been shown to enhance cell survival (Bala´zs et al., 1990)
and give the purest glutamatergic preparation (Drejer and
Schousboe, 1989; Sonnewald et al., 2004). Even though
Engblom et al. (2003) reported disturbed maturation of GABAA
receptor subunit expression in cerebellar neuronal cultures after
exposure to 0.05 mM KA, glucose metabolism remained
unaltered by this treatment (Sonnewald et al., 2004). In addition
to the KA effects on cell survival mentioned above, KA is a
potent agonist at the kainate and AMPA subclasses of
ionotropic glutamate receptors (Lerma, 1998). Hence, admin-
istration of KA causes an acute excitatory response by direct
receptor activation (Ben-Ari, 1985; Sperk, 1994; Bradford,
1995; Qu et al., 2003). In the present study, cell protein was
reduced by approximately 25% in the cultures exposed to
0.50 mM KA compared to those cultured with 0.05 mM KA,
confirming a neurotoxic effect of high KA concentrations. In
cerebellar cultures, selective KA toxicity has been used as a tool
to obtain pure cerebellar granule cell cultures (Drejer and
Schousboe, 1989). Drejer and Schousboe added 0.05 mM KA
to the cultures from day 5 in vitro, and showed that evoked
[3H]GABA release from the cultures was abolished, whereascid exposure reveals compartmentation of glutamate and glutamine
i:10.1016/j.neuint.2006.11.004
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However, other studies have shown that GABAergic neurons in
these cultures are not eliminated by long-term exposure to
0.05 mM KA from day 0 in vitro (Sonnewald et al., 2004,
2006). The present study confirmed previous findings that
GABA is produced in the cultures despite the presence of a high
KA concentration in the culture medium. In fact, GABA
content in the control cultures (incubated without [U-13C]glu-
tamate or [U-13C]glutamine) increased after exposure to
0.50 mM KA compared to 0.05 mM KA (see below).
4.2. KA effect on amino acids metabolism
Culturing cerebellar neurons with 0.50 mM KA for the
whole culture period had profound effects on cellular content of
amino acids in the present study. These effects were
exacerbated when [U-13C]glutamate was present in the
incubation medium. The decrease in cellular content of all
amino acids detected in cells cultured with 0.50 mM KA
compared to those cultured with 0.05 mM KA could have been
caused by a decrease in uptake of [U-13C]glutamate into the
neurons. This theory was supported by the 50% reduction of
glutamate consumption in the high KA compared to the lowKA
group. In fact, KA has been shown to be a selective inhibitor of
the high-affinity sodium dependent glutamate transporter
EAAT2 (GLT) (Koch et al., 1999; Danbolt, 2001; Bridges
and Esslinger, 2005). When cultures in the present study were
incubated with [U-13C]glutamine, the situation was very
different than after incubation with [U-13C]glutamate. In this
case, exposure to a high KA concentration during the culture
period led to an increase in cellular content of glutamine and
glutamate compared to cells exposed to a low KA concentra-
tion, whereas the consumption of glutamine from the medium
was not affected by KA concentration. Thus, glutamine uptake
in these cells was not impaired as a response to KA exposure.
An increased cellular content of glutamine and glutamate can
reflect both increased uptake of the precursors and decreased
metabolism. Indeed, turnover in the TCA cycle of the carbon
skeleton from [U-13C]glutamate and [U-13C]glutamine was
decreased in the neurons exposed to 0.50 mM KA compared to
those exposed to 0.05 mM, as discussed in the following.
In the previous paragraph, it was mentioned that the high KA
concentration reduced glutamate uptake by the cerebellar
neurons in culture by approximately 50% compared to the low
KA concentration. The intracellular glutamate concentration
was, however, only reduced by 25%. It can be assumed that
this discrepancy is due to decreased metabolism of intracellular
glutamate or a shift in metabolism resulting in an increased
production of endogenous glutamate. There are few studies on
the effect of KA on metabolism in cultured neurons. However,
several groups have used KA to probe mitochondrial viability.
Boje and Skolnick (1992) exposed cultured rat cerebellar
neurons to various amounts of KAwhich was added 12 h after
culture start, and assessed mitochondrial viability after 8 days
in vitro. Compared to cells cultured without KA, exposure to
0.05 mM KA led to a decrease in mitochondrial viability of
approximately 25%, and exposure to 0.50 mM KA led to aPlease cite this article in press as: Olstad, E. et al., Long-term kainic a
metabolism in cultured cerebellar neurons, Neurochem. Int. (2006), dofurther 25% reduction in mitochondrial viability. This is in
agreement with the present study which suggests that a high KA
concentration leads to an impairment of mitochondrial
function, shown by the presence of more un-metabolized
[U-13C]glutamate or [U-13C]glutamine in cells cultured in
medium containing 0.50 mM KA compared to 0.05 mM KA,
and also by the labeling pattern indicating reduced TCA cycle
activity.
4.3. GABA in cerebellar neuronal cultures
As mentioned earlier, the presence of GABA in cultured
cerebellar neurons has been confirmed by the present study.
Sonnewald et al. (2006) reported that this GABA is produced by
the6%GABAergic neurons in the culture and is distributed to
the other neurons, hence the glutamatergic neurons in these
cultures contain GABA. Olstad et al. (2006) proposed that a
possible function of GABA in these cells is energy production
through the GABA shunt, where the carbon skeleton of GABA
enters the TCA cycle as succinate. Interestingly, it has been
shown that KA injections in rodents can induce GABA
formation by glutamatergic neurons in the hippocampus
(Schwarzer and Sperk, 1995). It was suggested that the cells
were enabled to produce GABA for protection against
excessive excitation. In the present study, similar results were
obtained. Culturing the predominantly glutamatergic neurons
in the presence of a high KA concentration, and subsequently
incubating them in fresh medium without [U-13C]glutamate or
[U-13C]glutamine present (the control group), led to an increase
in intracellular GABA concentration compared to neurons
exposed to a low KA concentration. Whether this increase was
due to increased GABA production in GABAergic neurons,
decreased GABA catabolism or synthesis of GABA in
glutamatergic cells remains to be determined.
4.4. Compartmentation of glutamate and glutamine
metabolism
It is well established that glutamine serves the role as
precursor for neurotransmitter glutamate and GABA, and also
as energy substrate for intermediary metabolism in neurons
(Westergaard et al., 1995; Sonnewald and McKenna, 2002;
Waagepetersen et al., 2005; Olstad et al., 2006). In order to
fulfill this task, glutamine has to be converted to glutamate.
Thus, it could be assumed that providing cultured neurons with
[U-13C]glutamine or [U-13C]glutamate as precursors would
result in similar labeling patterns in metabolites. Several studies
have shown that this, however, is not the case (Westergaard
et al., 1995; Olstad et al., 2006). In a monoculture consisting
of one type of neurons, this is evidence for intracellular
compartmentation or mitochondrial heterogeneity. As men-
tioned, dissociated cell cultures from postnatal rodent
cerebellum consist of glutamatergic granule neurons, with a
small contribution of GABAergic stellate and basket neurons.
Despite adding an anti-mitotic agent (cytosine arabinoside) to
the cultures, a small number of glial cells are also present in the
culture. Thus, the fact that more than one cell type are present incid exposure reveals compartmentation of glutamate and glutamine
i:10.1016/j.neuint.2006.11.004
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Since only the GABAergic neurons have been shown to be
capable of producing GABA (Sonnewald et al., 2004, 2006)
and the astrocytes glutamine (Norenberg and Martinez-
Hernandez, 1979), it is possible to differentiate between
intercellular and intracellular compartmentation in cultures of
cerebellar neurons. Indeed, results from the present study
illustrate both inter- and intracellular compartmentation.
Intracellular compartmentation has previously been reported
in cultured cortical neurons, where TCA cycle metabolism of
the carbon skeleton subsequently used in formation of GABA
was higher from [U-13C]glutamine than from [U-13C]glutamate
(Westergaard et al., 1995). Also in the present study
intracellular compartmentation was seen since TCA cycling
of the carbon skeleton from [U-13C]glutamine was more
pronounced than that from [U-13C]glutamate in all metabolites
except GABA. In the latter, cycling from the two labeled
precursors was similar, indicating that in the GABAergic
compartment, the carbon skeleton from [U-13C]glutamate has a
higher turnover than in the glutamatergic compartment.
Although the cycling from [U-13C]glutamate and [U-13C]glu-
tamine was similar in the GABAergic compartment, results
from the present study suggest compartmentation inside the
GABAergic compartment. This is evident from the fact that
cycling of the carbon skeleton from [U-13C]glutamate
subsequently used to form GABA was affected by KA,
whereas cycling of the carbon skeleton from [U-13C]glutamine
was not. Since the cerebellar cultures consist of two types of
GABAergic neurons, stellate and basket neurons, it is not
surprising that the GABAergic compartment shows further
compartmentation.
5. Conclusion
Long-term exposure of cells to 0.50 mM KA led to a
profound loss of cerebellar neurons, i.e. a neurotoxic effect of
KA was seen in this study. Decreased glutamate consumption
caused by culturing cells in a medium containing a high KA
concentration was consistent with earlier reports of KA being a
glutamate transport inhibitor, whereas glutamine uptake
remained unaffected by KA concentration during the culture
period. Furthermore, mitochondrial metabolism of the carbon
skeleton from both [U-13C]glutamate and [U-13C]glutamine
was significantly reduced after long-term exposure to 0.50 mM
KA compared to exposure to 0.05 mM KA. The results
presented can only be understood in terms of inter- and
intracellular compartmentation of metabolism, since TCA
cycling of the carbon skeleton from [U-13C]glutamine was
more pronounced than that from [U-13C]glutamate, and since
the carbon skeleton from [U-13C]glutamate had a higher
turnover in the GABAergic than in the glutamatergic
compartment which constitute these cultures.
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Pyruvate recycling is a pathway for complete oxidation of
glutamate and cellular location, and the physiological sig-
nificance of such recycling has been debated during the
last decade. The present study was aimed at elucidating
whether recycling takes place in neuron-enriched cultures
of dissociated cerebella, consisting mainly of glutamater-
gic granule cells, some GABAergic neurons, and few
astrocytes. These cultures and cultures of astrocytes
from cerebellum were incubated in medium containing
[U-13C]glutamate, and cell extracts were analyzed by gas
chromatography and mass spectrometry. Additionally, in
the case of the neurons, a magnetic resonance (MR)
spectrum was obtained. It could be shown that the atom
percentage excess of the isotopomer representing pyru-
vate recycling in glutamate (M + 4) was similar for astro-
cytes and neuron-enriched cultures. However, the latter
showed more recycling in glutamine (synthesized in the
small fraction of astrocytes) than the pure astrocyte cul-
tures, whereas the reverse was the case for aspartate. In
fact, the atom percentage excess of the isotopomer rep-
resenting pyruvate recycling in glutamine was slightly but
significantly higher than that in glutamate in the neuron-
enriched cultures. It can be concluded that pyruvate recy-
cling is clearly present in neurons, and this was verified
by MR spectroscopy. VC 2007Wiley-Liss, Inc.
Key words: astrocytes; glutamatergic neurons; mass
spectrometry; metabolism; tricarboxylic acid cycle
Pyruvate carboxylase located in astrocytes is thought
to be the enzyme responsible for anaplerosis in brain
(Patel, 1974), and carboxylation of pyruvate has been
demonstrated in rat, mouse, and human brain (Lapidot
and Gopher, 1994; Hassel et al., 1995; O¨z et al., 2004;
Patel et al., 2005; Melø et al., 2006). Previous experiments
and results from cell cultures incubated in the presence of
[U-13C]glucose and 3-nitropropionic acid confirmed that
pyruvate carboxylation takes place in astrocytes but not
neurons (Yu et al., 1983; Shank et al., 1985; Waagepe-
tersen et al., 2001; Qu et al., 2001). During development
anaplerosis (filling up) is necessary, because concentrations
of glutamate and glutamine in brain increase (Tka´e` et al.,
2003), whereas in adults anaplerosis is not self-evident. It is
generally accepted that the adult brain has to replenish the
tricarboxylic acid (TCA) cycle when a four (or more) car-
bon unit such as glutamine or a lactate molecule derived
from TCA cycle intermediates (malate or oxaloacetate)
leaves the brain. Glutamine is indeed released from the
brain (Grill et al., 1992), but it has not been shown that
lactate from brain is TCA cycle derived. Another possibil-
ity is that a four (or more) carbon unit is degraded in the
brain. Pyruvate recycling is such a pathway in which com-
pounds such as glutamate, glutamine, or aspartate, which
are originally derived from pyruvate carboxylation, can be
degraded to pyruvate and reenter the TCA cycle as acetyl
CoA (see Fig. F11). Previous studies have shown that pyru-
vate recycling takes place in rat brain, and initially the cel-
lular location was thought to be neurons (Cerdan et al.,
1990). However, cell culture studies pointed toward astro-
cytes as the site for recycling (Sonnewald et al., 1996a;
Bakken et al., 1997a,b, 1998a; Ha˚berg et al., 1998; Alves
et al., 2000; Waagepetersen et al., 2002).
The present study was undertaken to reinvestigate
the cellular location of pyruvate recycling. By using 13C la-
beled compounds and 13C magnetic resonance spectros-
copy (MRS), it is possible to monitor cellular metabolism
and astrocyte–neuron interactions. Various 13C-labeled
substrates have been used to unravel different aspects of
cerebral metabolism. We incubated cerebellar neurons and
astrocytes with medium containing [U-13C]glutamate.
Analysis of neuronal cell extracts by MRS and the more
sensitive method gas chromatography/mass spectrometry
(GC/MS) revealed that pyruvate recycling takes place in
neurons as well as in astrocytes.
MATERIALS AND METHODS
Materials
NMRI mice were obtained from Taconic M&B (Co-
penhagen, Denmark). Plastic tissue culture dishes were pur-
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chased from Nunc A/S (Roskilde, Denmark) and fetal calf se-
rum (FCS) from Seralab Ltd. (Sussex, United Kingdom).
Culture medium and glutamate receptor antagonists DNQX
(6,7-dinitroquinoxaline-2,3-dione) and D-AP5 (D-2-amino-
5-phosphonopentanoic acid) were from Sigma (St. Louis,
MO). [U-13C]glutamate (98%+ enriched) and 99.9% D2O
were from Cambridge Isotope Laboratories (Woburn, MA);
ethylene glycol was from Merck (Darmstadt, Germany), and
the GC/MS derivatization reagent MTBSTFA (N-methyl-N-
(tert-butyldimethylsilyl)-trifluoroacetamide) + 1% t-BDMS-Cl
(tert-butyldimethylchlorosilane) was purchased from Regis
Technologies, Inc. (Morton Grove, IL). All other chemicals
were of the purest grade available from regular commercial
sources.
Cell Cultures
Neuron-enriched cerebellar cultures were isolated and
cultured from 7-day-old mice as described by Schousboe et al.
(1989). Briefly, the tissue was trypsinized, followed by tritura-
tion in a DNase solution containing a trypsin inhibitor from
soybeans. Cells were suspended (2.75 3 106 cells/ml) in a
modified Dulbecco’s minimum essential medium (DMEM;
Hertz et al., 1982), containing 24.5 mM KCl, 31 mM glu-
cose, 7 lM p-aminobenzoic acid, 0.05 mM kainic acid, and
10% (v/v) fetal calf serum (FCS) and seeded in poly-D-lysine-
coated Petri dishes (2 ml/35 mm). After 48 hr in culture,
20 lM (final concentration) cytosine arabinoside was added to
the medium to prevent astrocytic proliferation. Experiments
were performed on 7-day-old cultures.
Cerebellar astrocytes were cultured as described by
Hertz et al. (1989). Briefly, cerebellum was taken from 7-day-
old mice and passed through Nitex nylon netting (80-lm
pore size) into DMEM containing 20% (v/v) FCS. Medium
was changed 2 days after plating and subsequently twice per
week, gradually changing to 10% FCS. From the third week,
dibutyryl-cAMP was added to the medium to promote mor-
phological differentiation of the astrocytes. Experiments were
performed on 3-week-old cultures.
Experiments Using [U-13C]Glutamate for MRS and
GC/MS Analysis
The culture medium was removed, and the cells were
incubated for 2 hr at 378C in serum-free DMEM (prepared
without glutamine) containing 3 mM glucose and [U-13 C]
glutamate (neurons, 0.25 mM; astrocytes 0.5 mM). To avoid
the toxicity of glutamate to neurons during the incubation,
two glutamate receptor antagonists, DNQX (25 lM), an a-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA)/kainate-selective antagonist, and D-AP5 (100 lM),
an N-methyl-D-aspartate (NMDA) antagonist, were also
present in the incubation medium of neurons (Frandsen
et al., 1989). After the incubation period, the cells were
washed twice with cold phosphate-buffered saline and
extracted with 70% (v/v) ethanol. The cell extracts were
scraped off the dishes and centrifuged at 10,000g for 15 min
to separate the metabolites from the insoluble proteins. The
supernatants (cell extracts) were divided into two parts; one
was lyophilized for subsequent sample preparation for GC/
MS analyses (six samples), and the remaining halves were
pooled and lyophilized (one sample) for MR spectroscopy
(neurons).
GC/MS
Lyophilized cell extracts were redissolved in HCl (10 mM),
adjusted to pH <2 with 6 M HCl, and dried under atmos-
pheric air. The amino acids were extracted into an organic
phase of ethanol and benzene and dried again under atmos-
pheric air before derivatization with MTBSTFA in the pres-
ence of 1% t-BDMS-Cl (Mawhinney et al., 1986). The sam-
ples were analyzed on a Hewlett Packard 5890 Series II gas
chromatograph linked to a Hewlett Packard 5972 Series mass
spectrometer.
MR Spectroscopy
The lyophilized sample consisting of six pooled cell
extracts of neuron-enriched cultures was redissolved in D2O.
A proton decoupled 150.92-MHz 13C MR spectrum was
obtained on a Bruker 600 spectrometer using a Bruker Bio-
Spin CryoProbe (Bruker Analytik GmbH, Rheinstetten, Ger-
many). The spectrum was accumulated using a 308 pulse
angle, an acquisition time of 1.08 sec, and a 0.5-sec relaxation
delay. The number of scans was 129,024.
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Fig. 1. Schematic presentation of pyruvate recycling from glutamate,
which can be amidated to glutamine or enter the TCA cycle as a-
ketoglutarate and be converted to uniformly labeled succinate and af-
ter several steps malate (MAL) and oxaloacetate (OAA). The latter
can further be transaminated into aspartate. If pyruvate recycling is
active, malate via malic enzyme or oxaloacetate via phosphoenolpyr-
uvate carboxykinase plus pyruvate kinase can be converted to pyru-
vate, which can enter the TCA cycle via acetyl CoA and give rise to
unique labeling patterns in glutamate and aspartate.
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Data Analysis
Atom percentage excess (13C) of glutamate, glutamine,
and aspartate was determined after calibration with unlabeled
standard solutions (Biemann, 1962). In the following, the
sums of M + 1, M + 2, and M + 3 in glutamate or glutamine
and that of M + 1, M + 2, and M + 4 in aspartate are used
to describe TCA cycle activity, because these isotopomers are
derived from the TCA cycle using unlabeled acetyl CoA. To
describe pyruvate recycling, which is also part of TCA cycle
activity, M + 4 in glutamate or glutamine and M + 3 in
aspartate are used. It should be noted that this is a simplifica-
tion in which the pyruvate recycling pathway is underesti-
mated and the TCA cycle involving unlabeled acetyl CoA is
overestimated (see Figs.F2,F3 2, 3). The pyruvate recycling over
TCA cycle activity (PR/TCA) ratio was calculated by divid-
ing atom percentage excess for glutamate or glutamine M + 4
(aspartate, M + 3) by the sum of TCA cycle derived iso-
topomers M + 1, M + 2, and M + 3 (aspartate, the sum of
M + 1, M + 2, and M + 4). Results are presented as means
6 SD. Differences between astrocytes and neurons were ana-
lyzed statistically by Student’s t-test and differences in atom
percentage excess of the corresponding isotopomers between
glutamate, glutamine, and aspartate with one-way ANOVA
followed by the LSD (least significant difference) post hoc
test. P < 0.05 was considered statistically significant.
RESULTS
[U-13C]glutamate present in the incubation me-
dium can enter cells through specific transporter pro-
teins. Once inside the cells, [U-13C]glutamate has several
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Fig. 2. Schematic representation of possible isotopomers of glutamate and glutamine arising from
[U-13C]glutamate via the first turn in the TCA cycle (top) and pyruvate recycling (bottom): solid
ovals represent 13C, and open ovals represent 12C atoms. The masses (M, M + 1, M + 2, etc.) of
the different isotopomers are indicated, and the M + 4 isotopomers, which can only result from
pyruvate recycling, are shown in boldface.
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metabolic fates. Of interest for pyruvate recycling is the
conversion into a-[U-13C]ketoglutarate, which can enter
the TCA cycle to be converted to uniformly labeled
succinate and after several steps malate and oxaloacetate
(OAA). The latter can also be transaminated to aspartate
(Fig. 1). [U-13C]oxaloacetate can stay in the cycle and
condense with acetyl CoA to give rise, after several
steps, to particular labeling patterns in glutamate and glu-
tamine (Fig. 2) and aspartate (Fig. 3). However, if pyru-
vate recycling is active, malate via malic enzyme or
OAA via phosphoenolpyruvate carboxykinase plus pyru-
vate kinase can be converted to pyruvate, which can
enter the TCA cycle via acetyl CoA (Fig. 1) and give rise
to unique labeling patterns in glutamate (Fig. 2, bottom)
and aspartate (Fig. 3, bottom). It should be noted that uni-
formly labeled glutamate is formed when [U-13C]OAA
condenses with [1,2-13C]acetyl CoA, and this isotopomer
cannot be distinguished from the [U-13C]glutamate added
to the medium.
With GC/MS, information about the percentage
distribution of isotopomers with different masses (M, M +
1, M + 2, etc.) of each metabolite is obtained. However,
the position of the 13C atoms in the isotopomers is not
readily available. From Figures 2 and 3, it can be seen that
M + 4 in glutamate and glutamine and M + 3 in aspartate
are the only isotopomer masses resulting from pyruvate
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Fig. 3. Schematic representation of possible isotopomers of aspartate arising from [U-13C]glutamate
via the first turn in the TCA cycle (top) and pyruvate recycling (bottom): solid ovals represent
13C, and open ovals represent 12C atoms. The masses (M, M + 1, M + 2, etc.) of the different
isotopomers are indicated, and the M + 3 isotopomers, which can only result from pyruvate recy-
cling, are shown in boldface.
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recycling that can be distinguished from those from TCA
cycling by GC/MS. By using this method, 13C labeling
was detected in glutamate, glutamine, GABA, aspartate,
succinate, fumarate, malate, and citrate in neurons and
astrocytes. For simplicity, only glutamate, glutamine, and
aspartate labelings are shown, because they illustrate the
point of this paper clearly. Glutamine (synthesized in
astrocytes only) was detected both in the astrocytes and in
the neuron-enriched cultures. In TableT1 I, the percentage
uniformly labeled glutamate and glutamine in neurons and
astrocytes is presented. The fraction of uniformly labeled
glutamate was higher in astrocytes than in neurons,
whereas the opposite was the case for glutamine. Further-
more, the isotopomers derived from the TCA cycle using
unlabeled acetyl CoA and those derived from pyruvate
recycling in glutamate, aspartate, and glutamine are pre-
sented in Table I. It should be noted that some isotopom-
ers from pyruvate recycling will also appear with the same
number of 13C atoms as those derived from the TCA cycle
(see Figs. 2, 3). In addition, uniformly labeled isotopomers
can also result from recycling. Therefore, the extent of py-
ruvate recycling is underestimated in Table I, insofar as
this pathway is represented only by the M + 4 isotopomer
in glutamate and glutamine and by M + 3 in aspartate.
From Table I it is clear that atom percentage excess of the
isotopomer from the TCA cycle is higher in neurons than
astrocytes for all three amino acids, whereas pyruvate recy-
cling in astrocytes and neuron-enriched cultures were sim-
ilar in glutamate but not in glutamine and aspartate. The
neuron-enriched cultures showed more atom percentage
excess in the isotopomer derived from recycling in gluta-
mine (synthesized in the small fraction of astrocytes) than
in pure astrocyte cultures, whereas the reverse was the case
for aspartate. In fact, the percentage isotopomer from recy-
cling in glutamine was slightly but significantly higher
than that in glutamate in the neuron-enriched cultures and
lower in the astrocytes.
To visualize pyruvate recycling in a representative
way, the ratio of M + 4 (PR) over the sum of M + 1,
M + 2, and M + 3 (TCA) for glutamate and glutamine
was calculated and is presented in parentheses in Table I.
For aspartate, the uniformly labeled isotopomer resulting
from the first TCA cycle turn (Fig. 3) is included in this
ratio [(M + 3)/S(M + 1, M + 2 and M + 4)]. Approxi-
mately half of the aspartate in the cells (49% 6 9% astro-
cytes; 51% 6 1% neurons) was uniformly labeled. In
evaluating the extent to which glutamate, glutamine,
and aspartate were derived from pyruvate recycling com-
pared with the extent to which isotopomers were
derived from TCA cycle activity (PR/TCA ratio), it is
clear that pyruvate recycling was more prominent in
glutamate in astrocytes than in neurons (Table I). As
mentioned, uniformly labeled aspartate was included in
the calculation of PR/TCA in Table I, and this makes it
evident that pyruvate recycling was much smaller than
TCA cycle activity in this metabolite. Furthermore, the
PR/TCA ratio for aspartate was much lower than the
ratios for glutamate and glutamine in neurons, and lower
than the ratio of glutamate in astrocytes (Table I). The
PR/TCA ratio for glutamine was similar to that of glu-
tamate in the astrocytes and similar in pure astrocyte cul-
tures and in astrocytes present in neuron-enriched cul-
tures.
With 13C MR spectroscopy, it is possible to detect
the position in which a particular compound is 13C labeled
in contrast to GC/MS, where only the extent of labeling
is detectable under the conditions used in the present
study. 13C-labeled glutamate and aspartate were observed
in the MR spectrum of extracts from neurons incubated
with medium containing [U-13C]glutamate (Fig. F44). To
show enough detail, only the parts of the spectrum that
contain glutamate C-4 and aspartate C-3 are shown.
Looking at the glutamate C-4 frequency range presented
in Figure 4A, peaks showing 13C labeling in the C-4 posi-
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TABLE I. Percentage of Uniformly Labeled Isotopomers ([U-13C], Glutamate, and Glutamine), Isotopomers Derived From the TCA
Cycle Using Unlabeled Acetyl CoA (TCA) and From the TCA Cycle Involving Pyruvate Recycling (PR)*
Glutamate Aspartate Glutamine
[U-13C] (%) TCA (%) PR (%) TCA (%) PR (%) [U-13C] (%) TCA (%) PR (%)
Neurons 55.7 6 1.5 30.4 6 1.1 4.6 6 0.1 79.8 6 0.4b 5.5 6 0.1b 59.6 6 1.1b 19.0 6 0.9b,c 5.1 6 0.5b,c
(0.15 6 0.01) (0.07 6 0.001b) (0.27 6 0.03b,c)
Astrocytes 62.9 6 6.8a 18.2 6 4.6a 5.8 6 1.7 68.0 6 2.1a,b 11.3 6 2.5a,b 46.1 6 6.1a,b 9.7 6 3.7a,b,c 2.5 6 0.7a,b,c
(0.33 6 0.13a) (0.17 6 0.04ab) (0.31 6 0.20)
*In parenthesis, the ratio of isotopomers derived from pyruvate recycling over those derived from TCA using unlabeled acetyl CoA is calculated for
glutamate, aspartate, and glutamine in cultured neurons and astrocytes from cerebellum. Neuron-enriched and astrocyte cultures from cerebellum were
incubated for 2 hr in medium containing 3 mM glucose, 25 lM DNQX, and 100 lM D-AP5 and 0.25 mM [U-13C]glutamate (neurons, n ¼ 6) or
0.5 mM (astrocytes, n ¼ 6) [U-13C]glutamate; for details, see Materials and Methods. The results are from GC/MS analyses, where [U-13C] is repre-
sented by M + 5 (glutamate and glutamine), isotopomers derived from the TCA cycle using unlabeled acetyl CoA (TCA) by S(M + 1, M + 2 and
M + 3) for glutamate and glutamine and S(M + 1, M + 2 and M + 4) for aspartate, and finally isotopomers from the TCA cycle involving pyruvate
recycling are represented by M + 4 (glutamate and glutamine) and M + 3 (aspartate). Results are presented as means 6 SD, and P < 0.05 was consid-
ered statistically significant.
aDifferent from the corresponding group in neurons.
bDifferent from atom percent excess of the corresponding glutamate isotopomers in the same cell type.
cDifferent from atom percent excess of the corresponding aspartate isotopomers in the same cell type.
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tion also give information about neighboring positions C-
3 and C-5, but not about the C-1 and C-2 positions. The
peaks consist of a doublet of doublets (indicated by arrows)
representing [3,4,5-13C]glutamate, one doublet with 52 Hz
splitting from [4,5-13C]glutamate, another doublet with
34 Hz splitting from [3,4-13C]glutamate, and finally a sin-
glet representing [4-13C]glutamate. Both doublets and the
singlet arise from pyruvate recycling and are indicated by
asterisks. The aspartate C-3 peaks (Fig. 4B) show a similar
pattern with a doublet of doublets (arrows) representing
[2,3,4-13C]aspartate, one doublet with 51 Hz splitting
representing [3,4-13C]aspartate arising from TCA cycling
(number sign), another doublet with 36 Hz splitting from
[2,3-13C]aspartate derived from pyruvate recycling (aster-
isks), and finally the [3-13C]aspartate singlet from TCA
cycling (number sign). [3,4,5-13C]glutamate seen in the
spectrum can be part of the precursor, [U-13C]glutamate,
whereas [2,3,4-13C]aspartate can also be included in
[U-13C]aspartate derived from [U-13C]glutamate via the
first turn of the TCA cycle (Fig. 3). [3,4-13C]aspartate
and [3-13C]aspartate are derived from the second and
third turns of the TCA cycle, respectively (Fig. 3).
[4,5-13C]-, [3,4-13C]-, and [4-13C]glutamate are all
derived from pyruvate recycling (Fig. 2). MR spectra of
astrocyte extracts were not obtained; they have been pub-
lished previously and showed recycling in glutamate and
aspartate (Ha˚berg et al., 1998).
DISCUSSION
Pyruvate recycling is a well-known metabolic path-
way in the liver, but it was first detected in brain by
Cerdan et al. (1990). In a later study by the same authors,
the metabolism of [1,2-13C]glucose and [U-13C]-3-
hydroxybutyrate was investigated in rat brain via ex vivo
13C MR spectroscopy, taking advantage, in particular, of
homonuclear 13C-13C spin coupling patterns. A quantita-
tive analysis of the 13C spectra demonstrated a cerebral
pyruvate recycling system contributing maximally 17% of
the pyruvate metabolism through the pyruvate dehydro-
genase in brain (Ku¨nnecke et al., 1993). This recycling
was believed to take place in neurons and not astrocytes,
because it was apparent in glutamate but not in gluta-
mine. In 1995, Hassel and Sonnewald reported partial
pyruvate recycling in mouse brain astrocytes, because lac-
tate formation from the TCA cycle was detected from
[2-13C]acetate but not [1-13C]glucose. The enrichment
of total brain lactate from [2-13C]acetate reached approxi-
mately 1% in both the C-2 and the C-3 positions in
fasted mice. It was calculated that this could account for
20% of the lactate formed in the glial compartment
(Hassel and Sonnewald, 1995). Pyruvate recycling in
brain was also studied in fasted rats receiving either an in-
traperitoneal or a subcutaneous injection of [1,2-13C]ace-
tate (Ha˚berg et al., 1998). MR spectroscopic analysis of
plasma showed larger amounts of [1, 2-13C]acetate in the
intraperitoneal group compared with the subcutaneous
group, and this was coupled to more pyruvate recycling
detected in the former group in glutamate and GABA.
However, Lapidot and Gopher (1994) were not able to
detect such recycling in rabbit brain.
Pyruvate recycling is a pathway for complete oxi-
dation of glutamate in the TCA cycle. In cultured corti-
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Fig. 4. Parts of the MR spectrum showing glutamate C-4 (A) and
aspartate C-3 (B) and the isotopomers responsible for the configura-
tion of the peaks: solid ovals represent 13C, and open ovals represent
12C atoms. Both peaks consist of a doublet of doublets (indicated by
arrows) representing [3,4,5-13C]glutamate and [2,3,4-13C]aspartate,
one doublet with approximately 50 Hz splitting from [4,5-13C]gluta-
mate (recycling, *) and [3,4-13C]aspartate (TCA cycling, #), another
doublet with approximately 35 Hz splitting from [3,4-13C]glutamate
(recycling, *) and [2,3-13C]aspartate (recycling, *), and finally a sin-
glet representing [4-13C]glutamate (recycling, *) and [3-13C]aspartate
(TCA cycling, #). No information can be obtained about labeling in
the C-1 and C-2 positions for glutamate and the C-1 position for
aspartate indicated by dashed ovals.
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cal astrocytes, pyruvate formed from [U-13C]glutamate
was shown to reenter the TCA cycle after conversion to
acetyl CoA, as demonstrated by the labeling patterns in
aspartate C-2 and C-3, lactate C-2, and glutamate C-4,
which provided evidence for pyruvate recycling in astro-
cytes (Ha˚berg et al., 1998). Also, in neuron-enriched
cultures from cerebellum, labeling of lactate was detected
from [U-13C]glutamate and [U-13C]aspartate, but 13C
label was not shown to reenter the TCA cycle through
acetyl CoA in these cells (Sonnewald et al., 1996b;
Bakken et al., 1998a). Incubating cortical astrocyte cul-
tures with [U-13C]glutamine in the presence of gluta-
mate or [U-13C]aspartate also led to a small amount of
pyruvate recycling in glutamate (Sonnewald et al.,
1996a; Bakken et al., 1997b, 1998a). Recycling was also
demonstrated in astrocytes using [3-13C]glutamate but
could not be shown in cortical GABAergic neurons
(Waagepetersen et al., 2002). Hypoglycemia, a condition
in which acetyl CoA production is reduced, could possi-
bly lead to increased pyruvate recycling. However, recy-
cling was abolished in astrocytes under this condition
(Bakken et al., 1998b). It was hypothesized that cocul-
tures of astrocytes and neurons could possibly have
increased pyruvate recycling compared with astrocytes
because of transfer of lactate produced by astrocytic mi-
tochondria to neurons for glutamate synthesis. Surpris-
ingly, experiments with [3-13C]glutamate and neocorti-
cal cocultures did not show signs of pyruvate recycling
even though astrocytes were present (Waagepetersen
et al., 2002). However, recycling could be shown when
cerebellar cocultures were superfused with medium
containing [U-13C]lactate or [U-13C]glucose (Bak et al.,
2006).
In the present study, cerebellar astrocytes were
incubated with [U-13C]glutamate, and cell extracts were
analyzed by GC/MS. As expected, pyruvate recycling
was detected in glutamate and aspartate. Recycling in
aspartate was about twice as high as that evident in glu-
tamate. This is due to the fact that [U-13C]glutamate
was added to the medium and constituted 63% of all
glutamate in the astrocytes. The sum of the isotopomers
from the TCA cycle and recycling was 24% of total glu-
tamate (Table I). This was the case for 79% (Table I) of
aspartate. Glutamine labeling via pyruvate recycling in
astrocytes was much lower than that observed in gluta-
mate. This was, however, due not to a lower ratio for
pyruvate recycling/cycling in the TCA cycle but to the
fact that, under the chosen incubation conditions, only
12% of glutamine was derived from mitochondrial me-
tabolism compared with 24% of glutamate. The small
percentage of glutamine derived from TCA cycle activ-
ity in astrocytes could explain why Cerdan et al. (1990)
suggested that recycling took place in neurons, not astro-
cytes.
Neuron-enriched cultures from cerebellum are an
excellent model for studying cerebellar metabolism,
because they consist of a majority of glutamatergic with
about 5% GABAergic neurons, mimicking the distribu-
tion in brain (Sonnewald et al., 2004a, 2006; Olstad
et al., 2006), and also astrocytes are present, though only
very few. When these cultures were incubated in me-
dium containing [U-13C]glutamate, GC/MS analysis
clearly showed pyruvate recycling in glutamate, aspartate,
and glutamine. Furthermore, atom percentage excess of
the isotopomer derived from pyruvate recycling in gluta-
mate in astrocytes and neuron-enriched cultures was
similar, thereby ruling out that the few astrocytes present
in the neuron-enriched cultures were responsible for the
recycling. When evaluating the extent to which gluta-
mate was derived from pyruvate recycling compared
with the extent to which isotopomers were derived
from TCA cycle activity using unlabeled acetyl CoA, it
is clear that pyruvate recycling was more prominent in
glutamate in astrocytes than in neurons. However, this is
due to the fact that in astrocytes less glutamate is derived
from the TCA cycle than in neurons, whereas the per-
centage excess 13C labeling for glutamate derived from
pyruvate recycling (M + 4) was similar in astrocytes and
neurons.
Aspartate showed a very low pyruvate recycling
over TCA cycle activity ratio when all TCA-cycle-
derived isotopomers, including uniformly labeled aspar-
tate, were considered. However, comparing the atom
percentage excess of the aspartate isotopomer derived
from recycling and that of glutamate and glutamine,
aspartate recycling was highest in both cell types.
The pyruvate recycling over TCA cycle activity
ratio in glutamine (which is only synthesized in astro-
cytes) was similar to that in glutamate in the astrocytes
and similar in pure astrocyte cultures and in neuron-
enriched cultures containing some astrocytes. How-
ever, labeling from TCA cycle activity using unlabeled
acetyl CoA was more pronounced in glutamine
observed in neuron-enriched than in pure astrocyte
cultures. Thus, there was more pyruvate recycling in
glutamine from neuron-enriched than from astrocytic
cultures. In fact, the atom percentage excess of the iso-
topomer derived from recycling in glutamine in the
neuron-enriched cultures was slightly but significantly
higher than that in glutamate in the same cell type.
This could indicate that glutamate metabolism was
compartmentalized in these neurons, as previously
shown in various cell types (Waagepetersen et al.,
1999; Qu et al., 1999, 2005; Eloqayli et al., 2002;
Sonnewald et al., 2004b), and that glutamate derived
from recycling was preferentially released from neurons
in the neuron-enriched cultures to be converted to
glutamine in the astrocytes. Alternatively, astrocytes
might have a different metabolism in the presence of
neurons than in a monoculture.
To verify pyruvate recycling in neurons, an MR
spectrum was obtained of cell extracts, and recycling was
clearly detectable in glutamate and aspartate. The reason
why such recycling in neurons has not been detected
earlier could be the enhanced sensitivity of the cryo-
MR probe used in the present experiment. Taken to-
gether, these results clearly show significant pyruvate
recycling in cerebellar neurons.
J_ID: Z3P Customer A_ID: 21208 Cadmus Art: JNR21208 Date: 24-JANUARY-07 Stage: I Page: 7
ID: 40459 Date: 24/1/07 Time: 17:30 Path: {Production}JNR#/Vol00000/070019/3B2/C2JNR#070019
Pyruvate Recycling in Neurons 7
Journal of Neuroscience Research DOI 10.1002/jnr
ACKNOWLEDGMENTS
The excellent technical assistance of Bente Urfjell
and Lars Evje is greatly appreciated.
REFERENCES
Alves PM, Nunes R, Zhang C, Maycock CD, Sonnewald U, Carrondo
MJ, Santos H. 2000. Metabolism of [3-13C]malate in primary cultures
of mouse astrocytes. Dev Neurosci 22:456–462.
Bak LK, Waagepetersen HS, Melø TM, Schousboe A, Sonnewald U.
2006. Complex glutamate labeling from [U-13C]glucose or [U-13C]lac-
tate in co-cultures of cerebellar neurons and astrocytes. Neurochem
Res (in press).
Bakken IJ, Sonnewald U, Clark JB, Bates TE. 1997a. [U-13C]glutamate
metabolism in rat brain mitochondria reveals malic enzyme activity.
Neuroreport 8:1567–1570.
Bakken IJ, White LR, Aasly J, Unsga˚rd G, Sonnewald U. 1997b. Lactate
formation from [U-13C]aspartate in cultured astrocytes: compartmenta-
tion of pyruvate metabolism. Neurosci Lett 237:117–120.
Bakken IJ, White LR, Aasly J, Unsga˚rd G, Sonnewald U. 1998a.
[U-13C] aspartate metabolism in cultured cortical astrocytes and cerebellar
granule neurons studied by NMR spectroscopy. Glia 23:271–277.
Bakken IJ, White LR, Unsga˚rd G, Aasly J, Sonnewald U. 1998b.
[U-13C]glutamate metabolism in astrocytes during hypoglycemia and
hypoxia. J Neurosci Res 51:636–645.
Biemann K. 1962. The mass spectra of isotopically labeled molecules, C.
Calculation of analysis. In: Mass spectrometry: organic chemistry appli-
cations. New York: McGraw Hill. p 223–227.
Cerdan S, Ku¨nnecke B, Seelig J. 1990. Cerebral metabolism of
[1,2-13C2]acetate as detected by in vivo and in vitro
13C NMR. J Biol
Chem 265:12916–12926.
Eloqayli H, Qu H, Unsga˚rd G, Sletvold O, Hadidi H, Sonnewald U. 2002.
Effects of pentylenetetrazole and glutamate on metabolism of [U-13C]glu-
cose in cultured cerebellar granule neurons. Neurochem Int 40:181–187.
Frandsen A, Drejer J, Schousboe A. 1989. Direct evidence that excito-
toxicity in cultured neurons is mediated via N-methyl-D-aspartate
(NMDA) as well as non-NMDA receptors. J Neurochem 53:297–299.
Grill V, Bjorkman O, Gutniak M, Lindqvist M. 1992. Brain uptake and
release of amino acids in nondiabetic and insulin-dependent diabetic
subjects: important role of glutamine release for nitrogen balance.
Metabolism 41:28–32.
Ha˚berg A, Qu H, Bakken IJ, Sande LM, White LR, Haraldseth O,
Unsga˚rd G, Aasly J, Sonnewald U. 1998. In vitro and ex vivo 13C-NMR spec-
troscopy studies of pyruvate recycling in brain. Dev Neurosci 20:389–398.
Hassel B, Sonnewald U. 1995. Glial formation of pyruvate and lactate
from TCA cycle intermediates: implications for the inactivation of
transmitter amino acids? J Neurochem 65:2227–2234.
Hassel B, Sonnewald U, Fonnum F. 1995. Glial–neuronal interactions as
studied by cerebral metabolism of [2-13C]acetate and [1-13C]glucose: an
ex vivo 13C NMR spectroscopic study. J Neurochem 64:2773–2782.
Hertz L, Juurlink BHJ, Fosmark H, Schousboe A. 1982. Astrocytes in
primary cultures. In: Pfeiffer SE, editor. Neuroscience approached
through cell culture. Boca Raton, FL: CRC Press. p 175–186.
Hertz L, Juurlink BHJ, Hertz E, Fosmark H, Schousboe A. 1989. Prepa-
ration of primary cultures of mouse (rat) astrocytes. In: Shahar A, de
Vellis J, Vernadakis A, Haber B, editors. A dissection and tissue culture
manual for the nervous system. New York: Alan R Liss. p 105–108.
Ku¨nnecke B, Cerdan S, Seelig J. 1993. Cerebral metabolism of
[1,2-13C2]glucose and [U-
13C4]3-hydroxybutyrate in rat brain as
detected by 13C NMR spectroscopy. NMR Biomed 6:264–277.
Lapidot A, Gopher A. 1994. Cerebral metabolic compartmentation. Esti-
mation of glucose flux via pyruvate carboxylase/pyruvate dehydrogen-
ase by 13C NMR isotopomer analysis of D-[U-13C]glucose metabolites.
J Biol Chem 269:27198–27208.
Mawhinney TP, Robinett RS, Atalay A, Madson MA. 1986. Analysis of
amino acids as their tert.-butyldimethylsilyl derivatives by gas-liquid
chromatography and mass spectrometry. J Chromatogr 358:231–242.
Melø TM, Nehlig A, Sonnewald U. 2006. Neuronal–glial interactions in
rats fed a ketogenic diet. Neurochem Int 48:498–507.
Olstad E, Qu H, Sonnewald U. 2006. Glutamate is preferred over gluta-
mine for intermediary metabolism in cultured cerebellar neurons.
J Cereb Blood Flow Metab (in press).
O¨z G, Berkich DA, Henry PG, Xu Y, LaNoue K, Hutson SM, Gruetter
R. 2004. Neuroglial metabolism in the awake rat brain: CO2 fixation
increases with brain activity. J Neurosci 24:11273–11279.
Patel AB, Chowdhury GM, de Graaf RA, Rothman DL, Shulman RG,
Behar KL. 2005. Cerebral pyruvate carboxylase flux is unaltered during
bicuculline-seizures. J Neurosci Res 79:128–138.
Patel MS. 1974. The relative significance of CO2-fixing enzymes in the
metabolism of rat brain. J Neurochem 22:717–724.
Qu H, Færø E, Jørgensen P, Dale O, Gisvold SE, Unsga˚rd G, Sonne-
wald U. 1999. Decreased glutamate metabolism in cultured astrocytes
in the presence of thiopental. Biochem Pharmacol 58:1075–1080.
Qu H, Eloqayli H, Unsga˚rd G, Sonnewald U. 2001. Glutamate decreases
pyruvate carboxylase activity and spares glucose as energy substrate in
cultured cerebellar astrocytes. J Neurosci Res 66:1127–1132.
Qu H, Eloqayli H, Sonnewald U. 2005. Pentylenetetrazole affects metab-
olism of astrocytes in culture. J Neurosci Res 79:48–54.
Schousboe A, Meier E, Drejer J, Hertz L. 1989. Preparation of primary
cultures of mouse (rat) cerebellar granule cells. In: Shahar A, de Vellis J,
Vernadakis A, Haber B, editors. A dissection and tissue culture manual
of the nervous system. New York: Liss. p 203–206.
Shank RP, Bennett GS, Freytag SO, Campbell GL. 1985. Pyruvate car-
boxylase: an astrocyte-specific enzyme implicated in the replenishment
of amino acid neurotransmitter pools. Brain Res 329:364–367.
Sonnewald U, Westergaard N, Jones P, Taylor A, Bachelard HS, Schous-
boe A. 1996a. Metabolism of [U-13C5] glutamine in cultured astrocytes
studied by NMR spectroscopy: first evidence of astrocytic pyruvate
recycling. J Neurochem 67:2566–2572.
Sonnewald U, White LR, Ødega˚rd E, Westergaard N, Bakken IJ, Aasly
J, Unsga˚rd G, Schousboe A. 1996b. MRS study of glutamate metabo-
lism in cultured neurons/glia. Neurochem Res 21:987–993.
Sonnewald U, Olstad E, Qu H, Babot Z, Cristofol R, Sun˜ol C, Schous-
boe A, Waagepetersen H. 2004a. First direct demonstration of extensive
GABA synthesis in mouse cerebellar neuronal cultures. J Neurochem
91:796–803.
Sonnewald U, Schousboe A, Qu H, Waagepetersen HS. 2004b. Intracel-
lular metabolic compartmentation assessed by 13C magnetic resonance
spectroscopy. Neurochem Int 45:305–310.
Sonnewald U, Kortner TM, Qu H, Olstad E, Sun˜ol C, Bak LK, Schous-
boe A, Waagepetersen HS. 2006. Demonstration of extensive GABA
synthesis in the small population of GAD positive neurons in cerebellar
cultures by the use of pharmacological tools. Neurochem Int 48:572–
578.
Tka´e` I, Rao R, Georgieff MK, Gruetter R. 2003. Developmental and
regional changes in the neurochemical profile of the rat brain deter-
mined by in vivo 1H NMR spectroscopy. Magn Reson Med 50:24–32.
Waagepetersen HS, Sonnewald U, Qu H, Schousboe A. 1999. Mito-
chondrial compartmentation at the cellular level: astrocytes and neu-
rons. Ann N Y Acad Sci 893:421–425.
Waagepetersen HS, Qu H, Schousboe A, Sonnewald U. 2001. Elucida-
tion of the quantitative significance of pyruvate carboxylation in cul-
tured cerebellar neurons and astrocytes. J Neurosci Res 66:763–770.
Waagepetersen HS, Qu H, Hertz L, Sonnewald U, Schousboe A. 2002.
Demonstration of pyruvate recycling in primary cultures of neocortical
astrocytes but not in neurons. Neurochem Res 27:1431–1437.
Yu AC, Drejer J, Hertz L, Schousboe A. 1983. Pyruvate carboxylase ac-
tivity in primary cultures of astrocytes and neurons. J Neurochem
41:1484–1487.
J_ID: Z3P Customer A_ID: 21208 Cadmus Art: JNR21208 Date: 24-JANUARY-07 Stage: I Page: 8
ID: 40459 Date: 24/1/07 Time: 17:30 Path: {Production}JNR#/Vol00000/070019/3B2/C2JNR#070019
8 Olstad et al.
Journal of Neuroscience Research DOI 10.1002/jnr
 
 
Dissertations at the Faculty of Medicine, NTNU 
 
1977 
1. Knut Joachim Berg: EFFECT OF ACETYLSALICYLIC ACID ON RENAL FUNCTION 
2. Karl Erik Viken and Arne Ødegaard: STUDIES ON HUMAN MONOCYTES CULTURED IN  
VITRO 
1978 
3. Karel Bjørn Cyvin: CONGENITAL DISLOCATION OF THE HIP JOINT. 
4. Alf O. Brubakk: METHODS FOR STUDYING FLOW DYNAMICS IN THE LEFT 
VENTRICLE AND THE AORTA IN MAN. 
1979 
5. Geirmund Unsgaard: CYTOSTATIC AND IMMUNOREGULATORY ABILITIES OF HUMAN    
BLOOD MONOCYTES CULTURED IN VITRO 
1980 
6. Størker Jørstad: URAEMIC TOXINS 
7. Arne Olav Jenssen: SOME RHEOLOGICAL, CHEMICAL AND STRUCTURAL PROPERTIES    
OF MUCOID SPUTUM FROM PATIENTS WITH CHRONIC OBSTRUCTIVE BRONCHITIS 
1981 
8. Jens Hammerstrøm: CYTOSTATIC AND CYTOLYTIC ACTIVITY OF HUMAN 
MONOCYTES AND EFFUSION MACROPHAGES AGAINST TUMOR CELLS IN VITRO 
1983 
9. Tore Syversen: EFFECTS OF METHYLMERCURY ON RAT BRAIN PROTEIN. 
10. Torbjørn Iversen: SQUAMOUS CELL CARCINOMA OF THE VULVA. 
1984 
11. Tor-Erik Widerøe: ASPECTS OF CONTINUOUS AMBULATORY PERITONEAL DIALYSIS. 
12. Anton Hole: ALTERATIONS OF MONOCYTE AND LYMPHOCYTE FUNCTIONS IN 
REALTION TO SURGERY UNDER EPIDURAL OR GENERAL ANAESTHESIA. 
13. Terje Terjesen: FRACTURE HEALING AN STRESS-PROTECTION AFTER METAL PLATE 
FIXATION AND EXTERNAL FIXATION. 
14. Carsten Saunte: CLUSTER HEADACHE SYNDROME. 
15. Inggard Lereim: TRAFFIC ACCIDENTS AND THEIR CONSEQUENCES. 
16. Bjørn Magne Eggen: STUDIES IN CYTOTOXICITY IN HUMAN ADHERENT 
MONONUCLEAR BLOOD CELLS. 
17. Trond Haug: FACTORS REGULATING BEHAVIORAL EFFECTS OG DRUGS. 
1985 
18. Sven Erik Gisvold: RESUSCITATION AFTER COMPLETE GLOBAL BRAIN ISCHEMIA. 
19. Terje Espevik: THE CYTOSKELETON OF HUMAN MONOCYTES. 
20. Lars Bevanger: STUDIES OF THE Ibc (c) PROTEIN ANTIGENS OF GROUP B 
STREPTOCOCCI. 
21. Ole-Jan Iversen: RETROVIRUS-LIKE PARTICLES IN THE PATHOGENESIS OF PSORIASIS. 
22. Lasse Eriksen: EVALUATION AND TREATMENT OF ALCOHOL DEPENDENT 
BEHAVIOUR. 
23. Per I. Lundmo: ANDROGEN METABOLISM IN THE PROSTATE. 
1986 
24. Dagfinn Berntzen: ANALYSIS AND MANAGEMENT OF EXPERIMENTAL AND CLINICAL 
PAIN. 
25. Odd Arnold Kildahl-Andersen: PRODUCTION AND CHARACTERIZATION OF 
MONOCYTE-DERIVED CYTOTOXIN AND ITS ROLE IN MONOCYTE-MEDIATED 
CYTOTOXICITY. 
26. Ola Dale: VOLATILE ANAESTHETICS. 
1987 
27. Per Martin Kleveland: STUDIES ON GASTRIN. 
28. Audun N. Øksendal: THE CALCIUM PARADOX AND THE HEART. 
29. Vilhjalmur R. Finsen: HIP FRACTURES 
1988 
30. Rigmor Austgulen: TUMOR NECROSIS FACTOR: A MONOCYTE-DERIVED REGULATOR 
OF CELLULAR GROWTH. 
31. Tom-Harald Edna: HEAD INJURIES ADMITTED TO HOSPITAL. 
32. Joseph D. Borsi: NEW ASPECTS OF THE CLINICAL PHARMACOKINETICS OF 
METHOTREXATE. 
33. Olav F. M. Sellevold: GLUCOCORTICOIDS IN MYOCARDIAL PROTECTION. 
34. Terje Skjærpe: NONINVASIVE QUANTITATION OF GLOBAL PARAMETERS ON LEFT 
VENTRICULAR FUNCTION: THE SYSTOLIC PULMONARY ARTERY PRESSURE AND 
CARDIAC OUTPUT. 
35. Eyvind Rødahl: STUDIES OF IMMUNE COMPLEXES AND RETROVIRUS-LIKE ANTIGENS 
IN PATIENTS WITH ANKYLOSING SPONDYLITIS. 
36. Ketil Thorstensen: STUDIES ON THE MECHANISMS OF CELLULAR UPTAKE OF IRON 
FROM TRANSFERRIN. 
37. Anna Midelfart: STUDIES OF THE MECHANISMS OF ION AND FLUID TRANSPORT IN 
THE BOVINE CORNEA. 
38. Eirik Helseth: GROWTH AND PLASMINOGEN ACTIVATOR ACTIVITY OF HUMAN 
GLIOMAS AND BRAIN METASTASES - WITH SPECIAL REFERENCE TO 
TRANSFORMING GROWTH FACTOR BETA AND THE EPIDERMAL GROWTH FACTOR 
RECEPTOR. 
39. Petter C. Borchgrevink: MAGNESIUM AND THE ISCHEMIC HEART. 
40. Kjell-Arne Rein: THE EFFECT OF EXTRACORPOREAL CIRCULATION ON 
SUBCUTANEOUS TRANSCAPILLARY FLUID BALANCE. 
41. Arne Kristian Sandvik: RAT GASTRIC HISTAMINE. 
42. Carl Bredo Dahl: ANIMAL MODELS IN PSYCHIATRY. 
1989 
43. Torbjørn A. Fredriksen: CERVICOGENIC HEADACHE. 
44. Rolf A. Walstad: CEFTAZIDIME. 
45. Rolf Salvesen: THE PUPIL IN CLUSTER HEADACHE. 
46. Nils Petter Jørgensen: DRUG EXPOSURE IN EARLY PREGNANCY. 
47. Johan C. Ræder: PREMEDICATION AND GENERAL ANAESTHESIA IN OUTPATIENT 
GYNECOLOGICAL SURGERY. 
48. M. R. Shalaby: IMMUNOREGULATORY PROPERTIES OF TNF-α AND THE RELATED 
CYTOKINES. 
49. Anders Waage: THE COMPLEX PATTERN OF CYTOKINES IN SEPTIC SHOCK. 
50. Bjarne Christian Eriksen: ELECTROSTIMULATION OF THE PELVIC FLOOR IN FEMALE 
URINARY INCONTINENCE. 
51. Tore B. Halvorsen: PROGNOSTIC FACTORS IN COLORECTAL CANCER. 
1990 
52. Asbjørn Nordby: CELLULAR TOXICITY OF ROENTGEN CONTRAST MEDIA. 
53. Kåre E. Tvedt: X-RAY MICROANALYSIS OF BIOLOGICAL MATERIAL. 
54. Tore C. Stiles: COGNITIVE VULNERABILITY FACTORS IN THE DEVELOPMENT AND 
MAINTENANCE OF DEPRESSION. 
55. Eva Hofsli: TUMOR NECROSIS FACTOR AND MULTIDRUG RESISTANCE. 
56. Helge S. Haarstad: TROPHIC EFFECTS OF CHOLECYSTOKININ AND SECRETIN ON THE 
RAT PANCREAS. 
57. Lars Engebretsen: TREATMENT OF ACUTE ANTERIOR CRUCIATE LIGAMENT INJURIES. 
58. Tarjei Rygnestad: DELIBERATE SELF-POISONING IN TRONDHEIM. 
59. Arne Z. Henriksen: STUDIES ON CONSERVED ANTIGENIC DOMAINS ON MAJOR OUTER 
MEMBRANE PROTEINS FROM ENTEROBACTERIA. 
60. Steinar Westin: UNEMPLOYMENT AND HEALTH: Medical and social consequences of a 
factory closure in a ten-year controlled follow-up study. 
61. Ylva Sahlin: INJURY REGISTRATION, a tool for accident preventive work. 
62. Helge Bjørnstad Pettersen: BIOSYNTHESIS OF COMPLEMENT BY HUMAN ALVEOLAR 
MACROPHAGES WITH SPECIAL REFERENCE TO SARCOIDOSIS. 
63. Berit Schei: TRAPPED IN PAINFUL LOVE. 
64. Lars J. Vatten: PROSPECTIVE STUDIES OF THE RISK OF BREAST CANCER IN A 
COHORT OF NORWEGIAN WOMAN. 
1991 
65. Kåre Bergh: APPLICATIONS OF ANTI-C5a SPECIFIC MONOCLONAL ANTIBODIES FOR 
THE ASSESSMENT OF COMPLEMENT ACTIVATION. 
66. Svein Svenningsen: THE CLINICAL SIGNIFICANCE OF INCREASED FEMORAL 
ANTEVERSION. 
67. Olbjørn Klepp: NONSEMINOMATOUS GERM CELL TESTIS CANCER: THERAPEUTIC 
OUTCOME AND PROGNOSTIC FACTORS. 
68. Trond Sand: THE EFFECTS OF CLICK POLARITY ON BRAINSTEM AUDITORY EVOKED 
POTENTIALS AMPLITUDE, DISPERSION, AND LATENCY VARIABLES. 
69. Kjetil B. Åsbakk: STUDIES OF A PROTEIN FROM PSORIATIC SCALE, PSO P27, WITH 
RESPECT TO ITS POTENTIAL ROLE IN IMMUNE REACTIONS IN PSORIASIS. 
70. Arnulf Hestnes: STUDIES ON DOWN´S SYNDROME. 
71. Randi Nygaard: LONG-TERM SURVIVAL IN CHILDHOOD LEUKEMIA. 
72. Bjørn Hagen: THIO-TEPA. 
73. Svein Anda: EVALUATION OF THE HIP JOINT BY COMPUTED TOMOGRAMPHY AND 
ULTRASONOGRAPHY. 
1992 
74. Martin Svartberg: AN INVESTIGATION OF PROCESS AND OUTCOME OF SHORT-TERM 
PSYCHODYNAMIC PSYCHOTHERAPY. 
75. Stig Arild Slørdahl: AORTIC REGURGITATION. 
76. Harold C Sexton: STUDIES RELATING TO THE TREATMENT OF SYMPTOMATIC NON-
PSYCHOTIC PATIENTS. 
77. Maurice B. Vincent: VASOACTIVE PEPTIDES IN THE OCULAR/FOREHEAD AREA. 
78. Terje Johannessen: CONTROLLED TRIALS IN SINGLE SUBJECTS. 
79. Turid Nilsen: PYROPHOSPHATE IN HEPATOCYTE IRON METABOLISM. 
80. Olav Haraldseth: NMR SPECTROSCOPY OF CEREBRAL ISCHEMIA AND REPERFUSION 
IN RAT. 
81. Eiliv Brenna: REGULATION OF FUNCTION AND GROWTH OF THE OXYNTIC MUCOSA. 
1993 
82. Gunnar Bovim: CERVICOGENIC HEADACHE. 
83. Jarl Arne Kahn: ASSISTED PROCREATION. 
84. Bjørn Naume: IMMUNOREGULATORY EFFECTS OF CYTOKINES ON NK CELLS. 
85. Rune Wiseth: AORTIC VALVE REPLACEMENT. 
86. Jie Ming Shen: BLOOD FLOW VELOCITY AND RESPIRATORY STUDIES. 
87. Piotr Kruszewski: SUNCT SYNDROME WITH SPECIAL REFERENCE TO THE 
AUTONOMIC NERVOUS SYSTEM. 
88. Mette Haase Moen: ENDOMETRIOSIS. 
89. Anne Vik: VASCULAR GAS EMBOLISM DURING AIR INFUSION AND AFTER 
DECOMPRESSION IN PIGS. 
90. Lars Jacob Stovner: THE CHIARI TYPE I MALFORMATION. 
91. Kjell Å. Salvesen: ROUTINE ULTRASONOGRAPHY IN UTERO AND DEVELOPMENT IN 
CHILDHOOD. 
1994 
92. Nina-Beate Liabakk: DEVELOPMENT OF IMMUNOASSAYS FOR TNF AND ITS SOLUBLE 
RECEPTORS. 
93. Sverre Helge Torp: erbB ONCOGENES IN HUMAN GLIOMAS AND MENINGIOMAS. 
94. Olav M. Linaker: MENTAL RETARDATION AND PSYCHIATRY. Past and present. 
95. Per Oscar Feet: INCREASED ANTIDEPRESSANT AND ANTIPANIC EFFECT IN 
COMBINED TREATMENT WITH DIXYRAZINE AND TRICYCLIC ANTIDEPRESSANTS. 
96. Stein Olav Samstad: CROSS SECTIONAL FLOW VELOCITY PROFILES FROM TWO-
DIMENSIONAL DOPPLER ULTRASOUND: Studies on early mitral blood flow. 
97. Bjørn Backe: STUDIES IN ANTENATAL CARE. 
98. Gerd Inger Ringdal: QUALITY OF LIFE IN CANCER PATIENTS. 
99. Torvid Kiserud: THE DUCTUS VENOSUS IN THE HUMAN FETUS. 
100. Hans E. Fjøsne: HORMONAL REGULATION OF PROSTATIC METABOLISM. 
101. Eylert Brodtkorb: CLINICAL ASPECTS OF EPILEPSY IN THE MENTALLY RETARDED. 
102. Roar Juul: PEPTIDERGIC MECHANISMS IN HUMAN SUBARACHNOID HEMORRHAGE. 
103. Unni Syversen: CHROMOGRANIN A. Phsysiological and Clinical Role. 
1995 
104. Odd Gunnar Brakstad: THERMOSTABLE NUCLEASE AND THE nuc GENE IN THE 
DIAGNOSIS OF Staphylococcus aureus INFECTIONS. 
105. Terje Engan: NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY OF PLASMA 
IN MALIGNANT DISEASE. 
106. Kirsten Rasmussen: VIOLENCE IN THE MENTALLY DISORDERED. 
107. Finn Egil Skjeldestad: INDUCED ABORTION: Timetrends and Determinants. 
108. Roar Stenseth: THORACIC EPIDURAL ANALGESIA IN AORTOCORONARY BYPASS 
SURGERY. 
109. Arild Faxvaag: STUDIES OF IMMUNE CELL FUNCTION in mice infected with MURINE 
RETROVIRUS. 
1996 
110. Svend Aakhus: NONINVASIVE COMPUTERIZED ASSESSMENT OF LEFT VENTRICULAR 
FUNCTION AND SYSTEMIC ARTERIAL PROPERTIES. Methodology and some clinical 
applications. 
111. Klaus-Dieter Bolz: INTRAVASCULAR ULTRASONOGRAPHY. 
112. Petter Aadahl: CARDIOVASCULAR EFFECTS OF THORACIC AORTIC CROSS-
CLAMPING. 
113. Sigurd Steinshamn: CYTOKINE MEDIATORS DURING GRANULOCYTOPENIC 
INFECTIONS. 
114. Hans Stifoss-Hanssen: SEEKING MEANING OR HAPPINESS? 
115. Anne Kvikstad: LIFE CHANGE EVENTS AND MARITAL STATUS IN RELATION TO RISK 
AND PROGNOSIS OF CANSER. 
116. Torbjørn Grøntvedt: TREATMENT OF ACUTE AND CHRONIC ANTERIOR CRUCIATE 
LIGAMENT INJURIES. A clinical and biomechanical study. 
117. Sigrid Hørven Wigers: CLINICAL STUDIES OF FIBROMYALGIA WITH FOCUS ON 
ETIOLOGY, TREATMENT AND OUTCOME. 
118. Jan Schjøtt: MYOCARDIAL PROTECTION: Functional and Metabolic Characteristics of Two 
Endogenous Protective Principles. 
119. Marit Martinussen: STUDIES OF INTESTINAL BLOOD FLOW AND ITS RELATION TO 
TRANSITIONAL CIRCULATORY ADAPATION IN NEWBORN INFANTS. 
120. Tomm B. Müller: MAGNETIC RESONANCE IMAGING IN FOCAL CEREBRAL ISCHEMIA. 
121. Rune Haaverstad: OEDEMA FORMATION OF THE LOWER EXTREMITIES. 
122. Magne Børset: THE ROLE OF CYTOKINES IN MULTIPLE MYELOMA, WITH SPECIAL 
REFERENCE TO HEPATOCYTE GROWTH FACTOR. 
123. Geir Smedslund: A THEORETICAL AND EMPIRICAL INVESTIGATION OF SMOKING, 
STRESS AND DISEASE: RESULTS FROM A POPULATION SURVEY. 
1997 
124. Torstein Vik: GROWTH, MORBIDITY, AND PSYCHOMOTOR DEVELOPMENT IN 
INFANTS WHO WERE GROWTH RETARDED IN UTERO. 
125. Siri Forsmo: ASPECTS AND CONSEQUENCES OF OPPORTUNISTIC SCREENING FOR 
CERVICAL CANCER. Results based on data from three Norwegian counties. 
126. Jon S. Skranes: CEREBRAL MRI AND NEURODEVELOPMENTAL OUTCOME IN VERY 
LOW BIRTH WEIGHT (VLBW) CHILDREN. A follow-up study of a geographically based year 
cohort of VLBW children at ages one and six years. 
127. Knut Bjørnstad: COMPUTERIZED ECHOCARDIOGRAPHY FOR EVALUTION OF 
CORONARY ARTERY DISEASE. 
128. Grethe Elisabeth Borchgrevink: DIAGNOSIS AND TREATMENT OF WHIPLASH/NECK 
SPRAIN INJURIES CAUSED BY CAR ACCIDENTS. 
129. Tor Elsås: NEUROPEPTIDES AND NITRIC OXIDE SYNTHASE IN OCULAR AUTONOMIC 
AND SENSORY NERVES. 
130. Rolf W. Gråwe: EPIDEMIOLOGICAL AND NEUROPSYCHOLOGICAL PERSPECTIVES ON 
SCHIZOPHRENIA. 
131. Tonje Strømholm: CEREBRAL HAEMODYNAMICS DURING THORACIC AORTIC 
CROSSCLAMPING. An experimental study in pigs. 
1998 
132. Martinus Bråten: STUDIES ON SOME PROBLEMS REALTED TO INTRAMEDULLARY 
NAILING OF FEMORAL FRACTURES. 
133. Ståle Nordgård: PROLIFERATIVE ACTIVITY AND DNA CONTENT AS PROGNOSTIC 
INDICATORS IN ADENOID CYSTIC CARCINOMA OF THE HEAD AND NECK. 
134. Egil Lien: SOLUBLE RECEPTORS FOR TNF AND LPS: RELEASE PATTERN AND 
POSSIBLE SIGNIFICANCE IN DISEASE. 
135. Marit Bjørgaas: HYPOGLYCAEMIA IN CHILDREN WITH DIABETES MELLITUS 
136. Frank Skorpen: GENETIC AND FUNCTIONAL ANALYSES OF DNA REPAIR IN HUMAN 
CELLS. 
137. Juan A. Pareja: SUNCT SYNDROME. ON THE CLINICAL PICTURE. ITS DISTINCTION 
FROM OTHER, SIMILAR HEADACHES. 
138. Anders Angelsen: NEUROENDOCRINE CELLS IN HUMAN PROSTATIC CARCINOMAS 
AND THE PROSTATIC COMPLEX OF RAT, GUINEA PIG, CAT AND DOG. 
139. Fabio Antonaci: CHRONIC PAROXYSMAL HEMICRANIA AND HEMICRANIA 
CONTINUA: TWO DIFFERENT ENTITIES? 
140. Sven M. Carlsen: ENDOCRINE AND METABOLIC EFFECTS OF METFORMIN WITH 
SPECIAL EMPHASIS ON CARDIOVASCULAR RISK FACTORES. 
1999 
141. Terje A. Murberg: DEPRESSIVE SYMPTOMS AND COPING AMONG PATIENTS WITH 
CONGESTIVE HEART FAILURE. 
142. Harm-Gerd Karl Blaas: THE EMBRYONIC EXAMINATION. Ultrasound studies on the 
development of the human embryo. 
143. Noèmi Becser Andersen:THE CEPHALIC SENSORY NERVES IN UNILATERAL 
HEADACHES. Anatomical background and neurophysiological evaluation. 
144. Eli-Janne Fiskerstrand: LASER TREATMENT OF PORT WINE STAINS. A study of the efficacy 
and limitations of the pulsed dye laser. Clinical and morfological analyses aimed at improving the 
therapeutic outcome. 
145. Bård Kulseng: A STUDY OF ALGINATE CAPSULE PROPERTIES AND CYTOKINES IN 
RELATION TO INSULIN DEPENDENT DIABETES MELLITUS. 
146. Terje Haug: STRUCTURE AND REGULATION OF THE HUMAN UNG GENE ENCODING 
URACIL-DNA GLYCOSYLASE. 
147. Heidi Brurok: MANGANESE AND THE HEART. A Magic Metal with Diagnostic and 
Therapeutic Possibilites. 
148. Agnes Kathrine Lie: DIAGNOSIS AND PREVALENCE OF HUMAN PAPILLOMAVIRUS 
INFECTION IN CERVICAL INTRAEPITELIAL NEOPLASIA. Relationship to Cell Cycle 
Regulatory Proteins and HLA DQBI Genes. 
149. Ronald Mårvik: PHARMACOLOGICAL, PHYSIOLOGICAL AND PATHOPHYSIOLOGICAL 
STUDIES ON ISOLATED STOMACS. 
150. Ketil Jarl Holen: THE ROLE OF ULTRASONOGRAPHY IN THE DIAGNOSIS AND 
TREATMENT OF HIP DYSPLASIA IN NEWBORNS. 
151. Irene Hetlevik:  THE ROLE OF CLINICAL GUIDELINES IN CARDIOVASCULAR RISK 
INTERVENTION IN GENERAL PRACTICE. 
152. Katarina Tunòn: ULTRASOUND AND PREDICTION OF GESTATIONAL AGE. 
153. Johannes Soma: INTERACTION BETWEEN THE LEFT VENTRICLE AND THE SYSTEMIC 
ARTERIES. 
154. Arild Aamodt: DEVELOPMENT AND PRE-CLINICAL EVALUATION OF A CUSTOM-
MADE FEMORAL STEM. 
155. Agnar Tegnander: DIAGNOSIS AND FOLLOW-UP OF CHILDREN WITH SUSPECTED OR 
KNOWN HIP DYSPLASIA. 
156. Bent Indredavik: STROKE UNIT TREATMENT: SHORT AND LONG-TERM EFFECTS 
157. Jolanta Vanagaite Vingen: PHOTOPHOBIA AND PHONOPHOBIA IN PRIMARY 
HEADACHES 
2000 
158. Ola Dalsegg Sæther: PATHOPHYSIOLOGY DURING PROXIMAL AORTIC CROSS-
CLAMPING CLINICAL AND EXPERIMENTAL STUDIES 
159. xxxxxxxxx (blind number) 
160. Christina Vogt Isaksen: PRENATAL ULTRASOUND AND POSTMORTEM FINDINGS – A 
TEN YEAR CORRELATIVE STUDY OF FETUSES AND INFANTS WITH 
DEVELOPMENTAL ANOMALIES. 
161. Holger Seidel: HIGH-DOSE METHOTREXATE THERAPY IN CHILDREN WITH ACUTE 
LYMPHOCYTIC LEUKEMIA: DOSE, CONCENTRATION, AND EFFECT 
CONSIDERATIONS. 
162. Stein Hallan: IMPLEMENTATION OF MODERN MEDICAL DECISION ANALYSIS INTO 
CLINICAL DIAGNOSIS AND TREATMENT. 
163. Malcolm Sue-Chu: INVASIVE AND NON-INVASIVE STUDIES IN CROSS-COUNTRY 
SKIERS WITH ASTHMA-LIKE SYMPTOMS. 
164. Ole-Lars Brekke: EFFECTS OF ANTIOXIDANTS AND FATTY ACIDS ON TUMOR 
NECROSIS FACTOR-INDUCED CYTOTOXICITY. 
165. Jan Lundbom: AORTOCORONARY BYPASS SURGERY: CLINICAL ASPECTS, COST 
CONSIDERATIONS AND WORKING ABILITY. 
166. John-Anker Zwart: LUMBAR NERVE ROOT COMPRESSION, BIOCHEMICAL AND 
NEUROPHYSIOLOGICAL ASPECTS. 
167. Geir Falck: HYPEROSMOLALITY AND THE HEART. 
168. Eirik Skogvoll: CARDIAC ARREST Incidence, Intervention and Outcome. 
169. Dalius Bansevicius: SHOULDER-NECK REGION IN CERTAIN HEADACHES AND 
CHRONIC PAIN SYNDROMES. 
170. Bettina Kinge: REFRACTIVE ERRORS AND BIOMETRIC CHANGES AMONG 
UNIVERSITY STUDENTS IN NORWAY. 
171. Gunnar Qvigstad: CONSEQUENCES OF HYPERGASTRINEMIA IN MAN 
172. Hanne Ellekjær: EPIDEMIOLOGICAL STUDIES OF STROKE IN A NORWEGIAN 
POPULATION. INCIDENCE, RISK FACTORS AND PROGNOSIS 
173. Hilde Grimstad: VIOLENCE AGAINST WOMEN AND PREGNANCY OUTCOME. 
174. Astrid Hjelde: SURFACE TENSION AND COMPLEMENT ACTIVATION: Factors influencing 
bubble formation and bubble effects after decompression. 
175. Kjell A. Kvistad: MR IN BREAST CANCER – A CLINICAL STUDY. 
176. Ivar Rossvoll: ELECTIVE ORTHOPAEDIC SURGERY IN A DEFINED POPULATION. Studies 
on demand, waiting time for treatment and incapacity for work. 
177. Carina Seidel: PROGNOSTIC VALUE AND BIOLOGICAL EFFECTS OF HEPATOCYTE 
GROWTH FACTOR AND SYNDECAN-1 IN MULTIPLE MYELOMA. 
2001 
178. Alexander Wahba: THE INFLUENCE OF CARDIOPULMONARY BYPASS ON PLATELET 
FUNCTION AND BLOOD COAGULATION – DETERMINANTS AND CLINICAL 
CONSEQUENSES 
179. Marcus Schmitt-Egenolf: THE RELEVANCE OF THE MAJOR hISTOCOMPATIBILITY 
COMPLEX FOR THE GENETICS OF PSORIASIS 
180. Odrun Arna Gederaas: BIOLOGICAL MECHANISMS INVOLVED IN 5-AMINOLEVULINIC 
ACID BASED PHOTODYNAMIC THERAPY 
181. Pål Richard Romundstad: CANCER INCIDENCE AMONG NORWEGIAN ALUMINIUM 
WORKERS 
182. Henrik Hjorth-Hansen: NOVEL CYTOKINES IN GROWTH CONTROL AND BONE DISEASE 
OF MULTIPLE MYELOMA 
183. Gunnar Morken: SEASONAL VARIATION OF HUMAN MOOD AND BEHAVIOUR 
184. Bjørn Olav Haugen: MEASUREMENT OF CARDIAC OUTPUT AND STUDIES OF 
VELOCITY PROFILES IN AORTIC AND MITRAL FLOW USING TWO- AND THREE-
DIMENSIONAL COLOUR FLOW IMAGING 
185. Geir Bråthen: THE CLASSIFICATION AND CLINICAL DIAGNOSIS OF ALCOHOL-
RELATED SEIZURES 
186. Knut Ivar Aasarød: RENAL INVOLVEMENT IN INFLAMMATORY RHEUMATIC DISEASE. 
A Study of Renal Disease in Wegener’s Granulomatosis and in Primary Sjögren’s Syndrome  
187. Trude Helen Flo: RESEPTORS INVOLVED IN CELL ACTIVATION BY DEFINED URONIC 
ACID POLYMERS AND BACTERIAL COMPONENTS 
188. Bodil Kavli: HUMAN URACIL-DNA GLYCOSYLASES FROM THE UNG GENE: 
STRUCTRUAL BASIS FOR SUBSTRATE SPECIFICITY AND REPAIR 
189. Liv Thommesen: MOLECULAR MECHANISMS INVOLVED IN TNF- AND GASTRIN-
MEDIATED GENE REGULATION 
190. Turid Lingaas Holmen: SMOKING AND HEALTH IN ADOLESCENCE; THE NORD-
TRØNDELAG HEALTH STUDY, 1995-97 
191. Øyvind Hjertner: MULTIPLE MYELOMA: INTERACTIONS BETWEEN MALIGNANT 
PLASMA CELLS AND THE BONE MICROENVIRONMENT 
192. Asbjørn Støylen: STRAIN RATE IMAGING OF THE LEFT VENTRICLE BY ULTRASOUND. 
FEASIBILITY, CLINICAL VALIDATION AND PHYSIOLOGICAL ASPECTS 
193. Kristian Midthjell: DIABETES IN ADULTS IN NORD-TRØNDELAG. PUBLIC HEALTH 
ASPECTS OF DIABETES MELLITUS IN A LARGE, NON-SELECTED NORWEGIAN 
POPULATION. 
194. Guanglin Cui: FUNCTIONAL ASPECTS OF THE ECL CELL IN RODENTS 
195. Ulrik Wisløff: CARDIAC EFFECTS OF AEROBIC ENDURANCE TRAINING: 
HYPERTROPHY, CONTRACTILITY AND CALCUIM HANDLING IN NORMAL AND 
FAILING HEART 
196. Øyvind Halaas: MECHANISMS OF IMMUNOMODULATION AND CELL-MEDIATED 
CYTOTOXICITY INDUCED BY BACTERIAL PRODUCTS 
197. Tore Amundsen: PERFUSION MR IMAGING IN THE DIAGNOSIS OF PULMONARY 
EMBOLISM 
198. Nanna Kurtze: THE SIGNIFICANCE OF ANXIETY AND DEPRESSION IN FATIQUE AND 
PATTERNS OF PAIN AMONG INDIVIDUALS DIAGNOSED WITH FIBROMYALGIA: 
RELATIONS WITH QUALITY OF LIFE, FUNCTIONAL DISABILITY, LIFESTYLE, 
EMPLOYMENT STATUS, CO-MORBIDITY AND GENDER 
199. Tom Ivar Lund Nilsen: PROSPECTIVE STUDIES OF CANCER RISK IN NORD-
TRØNDELAG: THE HUNT STUDY. Associations with anthropometric, socioeconomic, and 
lifestyle risk factors 
200. Asta Kristine Håberg: A NEW APPROACH TO THE STUDY OF MIDDLE CEREBRAL 
ARTERY OCCLUSION IN THE RAT USING MAGNETIC RESONANCE TECHNIQUES 
2002 
201. Knut Jørgen Arntzen: PREGNANCY AND CYTOKINES 
202. Henrik Døllner: INFLAMMATORY MEDIATORS IN PERINATAL INFECTIONS 
203. Asta Bye: LOW FAT, LOW LACTOSE DIET USED AS PROPHYLACTIC TREATMENT OF 
ACUTE INTESTINAL REACTIONS DURING PELVIC RADIOTHERAPY. A PROSPECTIVE 
RANDOMISED STUDY. 
204. Sylvester Moyo: STUDIES ON STREPTOCOCCUS AGALACTIAE  (GROUP B 
STREPTOCOCCUS) SURFACE-ANCHORED MARKERS WITH EMPHASIS ON STRAINS 
AND HUMAN SERA FROM ZIMBABWE. 
205. Knut Hagen: HEAD-HUNT: THE EPIDEMIOLOGY OF HEADACHE IN NORD-TRØNDELAG 
206. Li Lixin: ON THE REGULATION AND ROLE OF UNCOUPLING PROTEIN-2 IN INSULIN 
PRODUCING ß-CELLS 
207. Anne Hildur Henriksen: SYMPTOMS OF ALLERGY AND ASTHMA VERSUS MARKERS OF 
LOWER AIRWAY INFLAMMATION AMONG ADOLESCENTS 
208. Egil Andreas Fors: NON-MALIGNANT PAIN IN RELATION TO PSYCHOLOGICAL AND 
ENVIRONTENTAL FACTORS. EXPERIENTAL AND CLINICAL STUDES OF PAIN WITH 
FOCUS ON FIBROMYALGIA 
209. Pål Klepstad:  MORPHINE FOR CANCER PAIN 
210. Ingunn Bakke: MECHANISMS AND CONSEQUENCES OF PEROXISOME PROLIFERATOR-
INDUCED HYPERFUNCTION OF THE RAT GASTRIN PRODUCING CELL 
211. Ingrid Susann Gribbestad: MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY OF 
BREAST CANCER 
212. Rønnaug Astri Ødegård: PREECLAMPSIA – MATERNAL RISK FACTORS AND FETAL 
GROWTH 
213. Johan Haux: STUDIES ON CYTOTOXICITY INDUCED BY HUMAN NATURAL KILLER 
CELLS AND DIGITOXIN 
214. Turid Suzanne Berg-Nielsen: PARENTING PRACTICES AND MENTALLY DISORDERED 
ADOLESCENTS 
215. Astrid Rydning: BLOOD FLOW AS A PROTECTIVE FACTOR FOR THE STOMACH 
MUCOSA. AN EXPERIMENTAL STUDY ON THE ROLE OF MAST CELLS AND SENSORY 
AFFERENT NEURONS 
2003 
216. Jan Pål Loennechen: HEART FAILURE AFTER MYOCARDIAL INFARCTION. Regional 
Differences, Myocyte Function, Gene Expression, and Response to Cariporide, Losartan, and 
Exercise Training. 
217. Elisabeth Qvigstad: EFFECTS OF FATTY ACIDS AND OVER-STIMULATION ON INSULIN 
SECRETION IN MAN 
218. Arne Åsberg: EPIDEMIOLOGICAL STUDIES IN HEREDITARY HEMOCHROMATOSIS: 
PREVALENCE, MORBIDITY AND BENEFIT OF SCREENING. 
219. Johan Fredrik Skomsvoll: REPRODUCTIVE OUTCOME IN WOMEN WITH RHEUMATIC 
DISEASE. A population registry based study of the effects of inflammatory rheumatic disease and 
connective tissue disease on reproductive outcome in Norwegian women in 1967-1995. 
220. Siv Mørkved: URINARY INCONTINENCE DURING PREGNANCY AND AFTER  
DELIVERY: EFFECT OF PELVIC FLOOR MUSCLE TRAINING IN PREVENTION AND 
TREATMENT 
221. Marit S. Jordhøy: THE IMPACT OF COMPREHENSIVE PALLIATIVE CARE 
222. Tom Christian Martinsen: HYPERGASTRINEMIA AND HYPOACIDITY IN RODENTS – 
CAUSES AND CONSEQUENCES  
223. Solveig Tingulstad: CENTRALIZATION OF PRIMARY SURGERY FOR OVARAIN CANCER. 
FEASIBILITY AND IMPACT ON SURVIVAL  
224. Haytham Eloqayli: METABOLIC CHANGES IN THE BRAIN CAUSED BY EPILEPTIC 
SEIZURES 
225. Torunn Bruland: STUDIES OF EARLY RETROVIRUS-HOST INTERACTIONS – VIRAL 
DETERMINANTS FOR PATHOGENESIS AND THE INFLUENCE OF SEX ON THE 
SUSCEPTIBILITY TO FRIEND MURINE LEUKAEMIA VIRUS INFECTION 
226. Torstein Hole: DOPPLER ECHOCARDIOGRAPHIC EVALUATION OF LEFT 
VENTRICULAR FUNCTION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION 
227. Vibeke Nossum: THE EFFECT OF VASCULAR BUBBLES ON ENDOTHELIAL FUNCTION 
228. Sigurd Fasting: ROUTINE BASED RECORDING OF ADVERSE EVENTS DURING 
ANAESTHESIA – APPLICATION IN QUALITY IMPROVEMENT AND SAFETY 
229. Solfrid Romundstad: EPIDEMIOLOGICAL STUDIES OF MICROALBUMINURIA. THE 
NORD-TRØNDELAG HEALTH STUDY 1995-97 (HUNT 2) 
230. Geir Torheim: PROCESSING OF DYNAMIC DATA SETS IN MAGNETIC RESONANCE 
IMAGING 
231. Catrine Ahlén: SKIN INFECTIONS IN OCCUPATIONAL SATURATION DIVERS IN THE 
NORTH SEA AND THE IMPACT OF THE ENVIRONMENT 
232. Arnulf Langhammer: RESPIRATORY SYMPTOMS, LUNG FUNCTION AND BONE 
MINERAL DENSITY IN A COMPREHENSIVE POPULATION SURVEY. THE NORD-
TRØNDELAG HEALTH STUDY 1995-97. THE BRONCHIAL OBSTRUCTION IN NORD-
TRØNDELAG STUDY 
233. Einar Kjelsås: EATING DISORDERS AND PHYSICAL ACTIVITY IN NON-CLINICAL 
SAMPLES 
234. Arne Wibe: RECTAL CANCER TREATMENT IN NORWAY – STANDARDISATION OF 
SURGERY AND QUALITY ASSURANCE 
2004 
235. Eivind Witsø: BONE GRAFT AS AN ANTIBIOTIC CARRIER 
236. Anne Mari Sund: DEVELOPMENT OF DEPRESSIVE SYMPTOMS IN EARLY 
ADOLESCENCE   
237. Hallvard Lærum: EVALUATION OF ELECTRONIC MEDICAL RECORDS – A CLINICAL 
TASK PERSPECTIVE  
238. Gustav Mikkelsen: ACCESSIBILITY OF INFORMATION IN ELECTRONIC PATIENT 
RECORDS; AN EVALUATION OF THE ROLE OF DATA QUALITY 
239. Steinar Krokstad: SOCIOECONOMIC INEQUALITIES IN HEALTH AND DISABILITY. 
SOCIAL EPIDEMIOLOGY IN THE NORD-TRØNDELAG HEALTH STUDY (HUNT), 
NORWAY 
240. Arne Kristian Myhre: NORMAL VARIATION IN ANOGENITAL ANATOMY AND 
MICROBIOLOGY IN NON-ABUSED PRESCHOOL CHILDREN 
241. Ingunn Dybedal: NEGATIVE REGULATORS OF HEMATOPOIETEC STEM AND 
PROGENITOR CELLS 
242. Beate Sitter: TISSUE CHARACTERIZATION BY HIGH RESOLUTION MAGIC ANGLE 
SPINNING MR SPECTROSCOPY 
243. Per Arne Aas: MACROMOLECULAR MAINTENANCE IN HUMAN CELLS – REPAIR OF 
URACIL IN DNA AND METHYLATIONS IN DNA AND RNA 
244. Anna Bofin:  FINE NEEDLE ASPIRATION CYTOLOGY IN THE PRIMARY 
INVESTIGATION OF BREAST TUMOURS AND IN THE DETERMINATION OF 
TREATMENT STRATEGIES 
245. Jim Aage Nøttestad: DEINSTITUTIONALIZATION AND MENTAL HEALTH CHANGES 
AMONG PEOPLE WITH MENTAL RETARDATION 
246. Reidar Fossmark:  GASTRIC CANCER IN JAPANESE COTTON RATS 
247. Wibeke Nordhøy:  MANGANESE AND THE HEART, INTRACELLULAR MR RELAXATION 
AND WATER EXCHANGE ACROSS THE CARDIAC CELL MEMBRANE 
2005 
248. Sturla Molden:  QUANTITATIVE ANALYSES OF SINGLE UNITS RECORDED FROM THE 
HIPPOCAMPUS AND ENTORHINAL CORTEX OF BEHAVING RATS 
249. Wenche Brenne Drøyvold:  EPIDEMIOLOGICAL STUDIES ON WEIGHT CHANGE AND 
HEALTH IN A LARGE POPULATION.  THE NORD-TRØNDELAG HEALTH STUDY 
(HUNT) 
250. Ragnhild Støen:  ENDOTHELIUM-DEPENDENT VASODILATION IN THE FEMORAL 
ARTERY OF DEVELOPING PIGLETS 
251. Aslak Steinsbekk:  HOMEOPATHY IN THE PREVENTION OF UPPER RESPIRATORY 
TRACT INFECTIONS IN CHILDREN 
252. Hill-Aina Steffenach:  MEMORY IN HIPPOCAMPAL AND CORTICO-HIPPOCAMPAL 
CIRCUITS 
253. Eystein Stordal:  ASPECTS OF THE EPIDEMIOLOGY OF DEPRESSIONS BASED ON SELF-
RATING IN A LARGE GENERAL HEALTH STUDY (THE HUNT-2 STUDY) 
254. Viggo Pettersen:  FROM MUSCLES TO SINGING:  THE ACTIVITY OF ACCESSORY 
BREATHING MUSCLES AND THORAX  MOVEMENT IN CLASSICAL SINGING 
255. Marianne Fyhn:  SPATIAL MAPS IN THE HIPPOCAMPUS AND ENTORHINAL CORTEX 
256. Robert Valderhaug:  OBSESSIVE-COMPULSIVE DISORDER AMONG CHILDREN AND 
ADOLESCENTS:  CHARACTERISTICS AND PSYCHOLOGICAL MANAGEMENT OF 
PATIENTS IN OUTPATIENT PSYCHIATRIC CLINICS 
257. Erik Skaaheim Haug:  INFRARENAL ABDOMINAL  AORTIC ANEURYSMS – 
COMORBIDITY AND RESULTS FOLLOWING OPEN SURGERY 
258. Daniel Kondziella: GLIAL-NEURONAL INTERACTIONS IN EXPERIMENTAL BRAIN 
DISORDERS 
259. Vegard Heimly Brun:  ROUTES TO SPATIAL MEMORY IN HIPPOCAMPAL PLACE CELLS 
260. Kenneth McMillan:  PHYSIOLOGICAL ASSESSMENT AND TRAINING OF ENDURANCE 
AND STRENGTH IN PROFESSIONAL YOUTH SOCCER PLAYERS 
261. Marit Sæbø Indredavik:  MENTAL HEALTH AND CEREBRAL MAGNETIC RESONANCE 
IMAGING IN ADOLESCENTS WITH LOW BIRTH WEIGHT 
262. Ole Johan Kemi:  ON THE CELLULAR BASIS OF AEROBIC FITNESS, INTENSITY-
DEPENDENCE AND TIME-COURSE OF CARDIOMYOCYTE AND ENDOTHELIAL 
ADAPTATIONS TO EXERCISE TRAINING 
263. Eszter Vanky: POLYCYSTIC OVARY SYNDROME – METFORMIN TREATMENT IN 
PREGNANCY 
264. Hild Fjærtoft:  EXTENDED STROKE UNIT SERVICE AND EARLY SUPPORTED 
DISCHARGE.  SHORT AND LONG-TERM EFFECTS   
265. Grete Dyb:  POSTTRAUMATIC STRESS REACTIONS IN CHILDREN AND ADOLESCENTS 
266. Vidar Fykse: SOMATOSTATIN AND THE STOMACH 
267. Kirsti Berg: OXIDATIVE STRESS AND THE ISCHEMIC HEART:  A STUDY IN PATIENTS 
UNDERGOING CORONARY REVASCULARIZATION  
268. Björn Inge Gustafsson:  THE SEROTONIN PRODUCING ENTEROCHROMAFFIN CELL, 
AND EFFECTS OF HYPERSEROTONINEMIA ON HEART AND BONE 
2006 
269. Torstein Baade Rø:  EFFECTS OF BONE MORPHOGENETIC PROTEINS, HEPATOCYTE 
GROWTH FACTOR AND INTERLEUKIN-21 IN MULTIPLE MYELOMA 
270. May-Britt Tessem:  METABOLIC EFFECTS OF ULTRAVIOLET RADIATION ON THE 
ANTERIOR PART OF THE EYE 
271. Anne-Sofie Helvik:  COPING AND EVERYDAY LIFE IN A POPULATION OF ADULTS 
WITH HEARING IMPAIRMENT 
272. Therese Standal:  MULTIPLE MYELOMA:  THE INTERPLAY BETWEEN MALIGNANT 
PLASMA CELLS AND THE BONE MARROW MICROENVIRONMENT 
273. Ingvild Saltvedt:  TREATMENT OF ACUTELY SICK, FRAIL ELDERLY PATIENTS IN A 
GERIATRIC EVALUATION AND MANAGEMENT UNIT – RESULTS FROM A 
PROSPECTIVE RANDOMISED TRIAL 
274. Birger Henning Endreseth:  STRATEGIES IN RECTAL CANCER TREATMENT – FOCUS ON 
EARLY RECTAL CANCER AND THE INFLUENCE OF AGE ON PROGNOSIS 
275. Anne Mari Aukan Rokstad:  ALGINATE CAPSULES AS BIOREACTORS FOR CELL 
THERAPY 
276. Mansour Akbari: HUMAN BASE EXCISION REPAIR FOR PRESERVATION OF GENOMIC 
STABILITY 
277. Stein Sundstrøm:  IMPROVING TREATMENT IN PATIENTS WITH LUNG CANCER – 
RESULTS FROM TWO MULITCENTRE RANDOMISED STUDIES 
278. Hilde Pleym: BLEEDING AFTER CORONARY ARTERY BYPASS SURGERY -  STUDIES 
ON HEMOSTATIC MECHANISMS, PROPHYLACTIC DRUG TREATMENT AND EFFECTS 
OF AUTOTRANSFUSION 
279. Line Merethe Oldervoll:  PHYSICAL ACTIVITY AND EXERCISE INTERVENTIONS IN 
CANCER PATIENTS 
280. Boye Welde:  THE SIGNIFICANCE OF ENDURANCE TRAINING, RESISTANCE TRAINING 
AND MOTIVATIONAL STYLES IN ATHLETIC PERFORMANCE AMONG ELITE JUNIOR 
CROSS-COUNTRY SKIERS 
281. Per Olav Vandvik:  IRRITABLE BOWEL SYNDROME IN NORWAY,  STUDIES OF 
PREVALENCE, DIAGNOSIS AND CHARACTERISTICS IN GENERAL PRACTICE AND IN 
THE POPULATION 
282. Idar Kirkeby-Garstad:  CLINICAL PHYSIOLOGY OF EARLY MOBILIZATION AFTER 
CARDIAC SURGERY 
283. Linn Getz: SUSTAINABLE AND RESPONSIBLE PREVENTIVE MEDICINE.  
CONCEPTUALISING ETHICAL DILEMMAS ARISING FROM CLINICAL 
IMPLEMENTATION OF ADVANCING MEDICAL TECHNOLOGY  
284. Eva Tegnander: DETECTION OF CONGENITAL HEART DEFECTS  IN A NON-SELECTED 
POPULATION OF 42,381 FETUSES 
285. Kristin Gabestad Nørsett:  GENE EXPRESSION STUDIES IN GASTROINTESTINAL 
PATHOPHYSIOLOGY AND NEOPLASIA 
286. Per Magnus Haram:  GENETIC VS. AQUIRED FITNESS:  METABOLIC, VASCULAR AND 
CARDIOMYOCYTE  ADAPTATIONS 
287. Agneta Johansson:  GENERAL RISK FACTORS FOR GAMBLING PROBLEMS AND THE 
PREVALENCE OG PATHOLOGICAL GAMBLING IN NORWAY  
288. Svein Artur Jensen:  THE PREVALENCE OF SYMPTOMATIC ARTERIAL DISEASE OF THE 
LOWER LIMB 
289. Charlotte Björk Ingul:  QUANITIFICATION OF REGIONAL MYOCARDIAL FUNCTION BY 
STRAIN RATE AND STRAIN FOR EVALUATION OF CORONARY ARTERY DISEASE.  
AUTOMATED VERSUS MANUAL ANALYSIS DURING ACUTE MYOCARDIAL 
INFARCTION AND DOBUTAMINE STRESS ECHOCARDIOGRAPHY 
290. Jakob Nakling:  RESULTS AND CONSEQUENCES OF ROUTINE ULTRASOUND 
SCREENING IN PREGNANCY – A GEOGRAPHIC BASED POPULATION STUDY 
291. Anne Engum:  DEPRESSION AND ANXIETY – THEIR RELATIONS TO THYROID 
DYSFUNCTION AND DIABETES IN A LARGE EPIDEMIOLOGICAL STUDY 
292. Ottar Bjerkeset: ANXIETY AND DEPRESSION IN THE GENERAL POPULATION:  RISK 
FACTORS, INTERVENTION AND OUTCOME – THE NORD-TRØNDELAG HEALTH 
STUDY (HUNT) 
293. Jon Olav Drogset:  RESULTS AFTER SURGICAL TREATMENT OF ANTERIOR CRUCIATE 
LIGAMENT INJURIES – A CLINICAL STUDY  
294. Lars Fosse: MECHANICAL BEHAVIOUR OF COMPACTED MORSELLISED BONE – AN 
EXPERIMENTAL IN VITRO STUDY 
295. Gunilla Klensmeden Fosse: MENTAL HEALTH OF PSYCHIATRIC OUTPATIENTS BULLIED 
IN CHILDHOOD 
296. Paul Jarle Mork:  MUSCLE ACTIVITY IN WORK  AND LEISURE AND ITS ASSOCIATION 
TO MUSCULOSKELETAL PAIN 
297. Björn Stenström:  LESSONS FROM RODENTS:  I: MECHANISMS OF OBESITY SURGERY – 
ROLE OF STOMACH.  II: CARCINOGENIC EFFECTS OF HELICOBACTER PYLORI AND 
SNUS IN THE STOMACH 
298. Haakon R. Skogseth:  INVASIVE PROPERTIES OF CANCER – A TREATMENT TARGET?  
IN VITRO STUDIES IN HUMAN PROSTATE CANCER CELL LINES 
299. Janniche Hammer:  GLUTAMATE METABOLISM AND CYCLING IN MESIAL TEMPORAL 
LOBE EPILEPSY 
300. May Britt Drugli:  YOUNG CHILDREN TREATED BECAUSE OF ODD/CD:  CONDUCT 
PROBLEMS AND SOCIAL COMPETENCIES IN DAY-CARE AND SCHOOL SETTINGS 
301. Arne Skjold:  MAGNETIC RESONANCE KINETICS OF MANGANESE DIPYRIDOXYL 
DIPHOSPHATE (MnDPDP) IN HUMAN MYOCARDIUM.  STUDIES IN HEALTHY 
VOLUNTEERS AND IN PATIENTS WITH RECENT MYOCARDIAL INFARCTION 
302. Siri Malm:  LEFT VENTRICULAR SYSTOLIC FUNCTION AND MYOCARDIAL 
PERFUSION ASSESSED BY CONTRAST ECHOCARDIOGRAPHY 
303. Valentina Maria do Rosario Cabral Iversen:  MENTAL HEALTH AND PSYCHOLOGICAL 
ADAPTATION OF CLINICAL AND NON-CLINICAL MIGRANT GROUPS 
304. Lasse Løvstakken:  SIGNAL PROCESSING IN DIAGNOSTIC ULTRASOUND:  
ALGORITHMS FOR REAL-TIME ESTIMATION AND VISUALIZATION OF BLOOD FLOW 
VELOCITY 
305. Elisabeth Olstad:  GLUTAMATE AND GABA:  MAJOR PLAYERS IN NEURONAL 
METABOLISM  
306. Lilian Leistad:  THE ROLE OF CYTOKINES AND PHOSPHOLIPASE A2s  IN ARTICULAR 
CARTILAGE CHONDROCYTES IN RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS 
307. Arne Vaaler:  EFFECTS OF PSYCHIATRIC INTENSIVE CARE UNIT IN AN ACUTE 
PSYCIATHRIC WARD 
 
 
